The effect of gender on Helicobacter pylori and gastric cancer by Sheh, Alexander
1 
 
The effect of gender on Helicobacter pylori and gastric cancer 
by  
Alexander Sheh 
B.S., Biological Engineering (2003) 
Cornell University 
 
Submitted to the Department of Biological Engineering  
in Partial Fulfillment of the Requirements for the Degree of 
 
Doctor of Philosophy Degree in Biological Engineering 
 
at the  
 
Massachusetts Institute of Technology 
June 2011 
© 2011 Massachusetts Institute of Technology 
All rights reserved 
 
Signature of Author _____________________________________________________________ 
Department of Biological Engineering 
Division of Comparative Medicine 
April 11, 2011 
 
 
 
Certified by ___________________________________________________________________ 
James G. Fox 
Professor, Department of Biological Engineering 
Director, Division of Comparative Medicine 
Thesis Co-supervisor 
 
 
 
Accepted by ___________________________________________________________________ 
Forest M. White 
Co-chairman, Department Committee on Graduate Students 
Associate Professor of Biological Engineering 
  
2 
 
A thesis advisory committee consisting of the following members has examined this doctoral 
thesis: 
 
David B. Schauer 
Professor, Department of Biological Engineering and Division of Comparative Medicine 
Thesis Co-supervisor 
 
 
Leona D. Samson 
Director, Center for Environmental Health Sciences 
Professor of Toxicology, and Biological Engineering 
American Cancer Society Research Professor 
Committee Chair 
 
 
Andrew Camilli 
Investigator, Howard Hughes Medical Institute 
Professor of Molecular Biology and Microbiology at Tufts University School of Medicine 
 
 
Jacquin C. Niles 
Pfizer-Laubach Career Development Assistant Professor of Biological Engineering 
  
3 
 
The effect of gender on Helicobacter pylori and gastric cancer 
By Alexander Sheh 
 
Submitted to the Department of Biological Engineering on 
April 11, 2011, in Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy Degree in Biological Engineering 
 
ABSTRACT 
Gastric cancer is the 2nd leading cause of cancer death worldwide and the 4th most 
commonly diagnosed cancer worldwide.  Helicobacter pylori infection is the major risk factor of 
gastric cancer, and as such, this bacterium has been classified as a type 1, or definite, carcinogen 
by the International Agency for Research on Cancer.  H. pylori infects the gastric mucosa of more 
than half of the world's population and promotes gastric carcinogenesis by inducing chronic 
inflammation.  Over decades of persistent H. pylori infection and chronic inflammation, the 
stomach goes through a well characterized pathological progression involving chronic gastritis, 
atrophy, intestinal metaplasia, dysplasia, and ultimately cancer.  Interestingly, there are strong 
gender differences in the development of gastric cancer, as men are twice as likely to develop 
the disease than women.  Given the importance of H. pylori and chronic inflammation in gastric 
carcinogenesis, this thesis investigated the role of gender in modulating host immune responses 
to H. pylori.  The aims of this thesis explored 1) the effect of gender on H. pylori’s ability to 
induce mutations and 2) the effect of estrogen and the anti-estrogen, Tamoxifen, on H. pylori-
induced gastric cancer.  For the first aim, the gpt delta mouse model, a murine mutational 
analysis model, was used to study chronic infection with H. pylori.  Increased frequency of point 
mutations was observed in infected female mice at 12 months post infection.  These mutations 
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were not observed in infected male mice.  Further analysis revealed that H. pylori induced a 
greater immune response in female mice in this model, as measured by increased severity of 
gastric lesions, decreased bacterial counts and the higher levels of Th1 antibodies for H. pylori.  
The spectra of mutations pointed towards oxidative damage as the underlying cause of 
induction.  This study revealed that gender differences in mutagenesis were mediated by the 
severity and duration of the immune response.   
In the second aim, 17β-estradiol prevented the formation of gastric cancer in the INS-
GAS mouse model, which develops gastric cancer in a male-predominant manner.  
Unexpectedly, this study led to the discovery that Tamoxifen may act as an agonist in this model 
of gastric cancer, as it was able to prevent gastric cancer using mechanisms similar to 17β-
estradiol.  Both compounds downregulated pathways associated with cellular movement and 
cancer.  CXCL1, a murine homolog of IL-8, was downregulated by treatment at both local and 
systemic levels, which led to a decreased neutrophilic infiltrate.  17β-estradiol and Tamoxifen 
mediated the disruption of a positive feedback loop coupling CXCL1 secretion with neutrophil 
recruitment, which dampened the activation of proinflammatory and oncogenic pathways, 
leading to protection against gastric cancer.  In conclusion, these studies provide further insight 
into the role of gender modulation of host immune response in H. pylori-induced mutagenesis 
and carcinogenesis.  
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Chapter 1: Introduction 
1.1 Gastric cancer 
Overview. Cancer is the leading cause of deaths worldwide, accounting for 7.6 million deaths 
worldwide  (13% of all deaths) in 20081.  In 2008, there were 989,000 cases of gastric cancer 
diagnosed and 738,000 gastric cancer associated deaths, making gastric cancer the fourth most 
common cancer and the second leading cause of cancer death1. The high mortality to incidence 
ratio (0.75) is due in part to the lack of clinical symptoms in most cases of early gastric cancer, 
which makes screening and treatment difficult.  At diagnosis, gastric cancer is usually at an 
advanced stage, making prognosis poor and the overall 5-year survival rate less than 25%2. 
Up until 1985, gastric cancer was the number one cause of cancer deaths worldwide3.  
At the time, the causes and pathogenesis of stomach cancer were not well understood, but for 
reasons unknown, a gradual decline in the incidence of gastric cancer had been observed over 
the last several decades.  Improvements in sanitation and nutrition are believed to have 
contributed by increasing the amount of fresh fruits and vegetables available and by decreasing 
dietary salt intake.  In the field of medicine, the development of endoscopies allowed for better 
management of precancerous lesions.  However, it was the discovery in 1982 of a curved 
bacillus in the stomachs of patients with gastritis and peptic ulcers that revolutionized our 
understanding of the etiology and pathogenesis of gastric cancers4.  This bacillus named, 
Helicobacter pylori, was recognized in 1994 by the International Agency for Research on Cancer 
(IARC) as a class I, or definite, carcinogen, for its role in the development of gastric cancer5.  H. 
pylori was one of the first infectious agents recognized as a potential carcinogen.  For their 
seminal discovery, Robin Warren and Barry Marshall were awarded the Nobel Prize in Medicine 
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in 2005.  The decline in H. pylori infection, resulting from increased sanitation, improved 
nutrition, the common usage of antibiotics and changes in family structures due to modern life, 
is thought to be one of the main reasons for the decreased incidence of gastric cancer6. 
Nevertheless, despite falling incidence rates, the total number of new gastric cancer cases and 
deaths continues to increase worldwide due to overall population growth and aging in high-risk 
areas. 
Epidemiology. Marked differences in gastric cancer incidence are observed based on 
geographical location, ethnicity and gender.  Over 70% of cases occur in developing nations.  
50% of cases worldwide occur in Eastern Asia, with a majority of them in China, Japan and 
South Korea.  Western industrialized nations like the United States have relatively low gastric 
cancer incidence rates.  In the United States, gastric cancer-related incidence and mortality have 
been reduced approximately 50% since 19751,7.  Not surprisingly, in 2008, Eastern Asia, 
including Japan, China, Korea and Mongolia, has the highest mortality rates (28.1 per 100,000 
men and 13.0 per 100,000 women), while North America, including Canada and the United 
States, has the lowest (2.8 and 1.5 per 100,000 men and women, respectively)1.  Other gastric 
cancer "hot spots" include Central and Eastern Europe, as well as Central and South America.   
In contrast, Australia, Africa, Southern Asia, Western Europe and North America are areas of low 
risk (Figure 1.1).  Interestingly, country of birth is a better predictor of gastric cancer risk than 
country of current residence.  Immigrants from regions with high gastric cancer risk to regions 
with lower gastric cancer risk have an intermediate risk of gastric cancer but have higher risk 
compared to second-generation immigrants8-9.  
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Despite the aforementioned influence of location, gastric cancer incidence and mortality 
differed significantly among different ethnic groups.  In the United States between 2003-2007, 
the highest annual incidence rates were observed among Asian/Pacific Islanders (17.5 per 
100,000 men and 10.0 per 100,000 women), followed by blacks (16.7 per 100,000 men and 8.6 
per 100,000 women), Hispanics (14.8 per 100,000 men and 9.1 per 100,000 women), American 
Indians and Alaska Natives (15.5 per 100,000 men and 7.3 per 100,000 women), and whites (9.6 
per 100,000 men and 4.7 per 100,000 women)10. Gastric cancer mortality rates, in the United 
States during the same period, mostly paralleled the trends observed for gastric cancer 
incidence with rates being highest among black Americans  (10.7 per 100,000 men and 5.0 per 
100,000 women), followed by Asian/Pacific Islanders (9.4 per 100,000 men and 5.6 per 100,000 
women), American Indian/Alaska native (9.2 per 100,000 men and 4.2 per 100,000 women), 
Hispanic (8.0 per 100,000 men and 4.6 per 100,000 women), and white Americans (4.6 per 
100,000 men and 2.4 per 100,000 women)10. 
However, irrespective of location and ethnicity, men are twice as likely as women to 
develop gastric cancer with age-standardized incidence rates ranging from 3.9 in Northern 
Africa to 42.4 in Eastern Asia for men and from 2.2 in Southern Africa to 18.3 in Eastern Asia for 
women10-11.  The pattern of the M/F incidence of gastric cancer is a global phenomenon, equally 
seen in populations with high and low risk for gastric cancer (Figure 1.2).  This remains one of 
the unresolved epidemiological questions as this sexual dimorphism has not been explained by 
putative risk factors such as smoking, alcohol and obesity12.  However, epidemiological evidence 
points to the protective role of female hormones13 and we are just starting to study this using in 
vivo models14-15. The question of gender is central to the work of this thesis and will be 
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examined in the context of mutagenesis in Chapter 2 and carcinogenesis in Chapter 3. 
Pathology. Approximately 90% of gastric cancers are adenocarcinomas, malignant epithelial 
tumors that arise from the gastric glandular epithelium16.  Adenocarcinomas, referred to as 
gastric cancer in this work, can be further subdivided by anatomical site and histologic type.  
Anatomically, gastric cancers are categorized as cardia and non-cardia.  Cardia 
adenocarcinomas are more similar pathologically and epidemiologically to esophageal 
adenocarcinomas, and are not the focus of this work, as their development may be associated 
with the absence of H. pylori6.  Most non-cardia gastric cancers originate in the antrum, exhibit 
a male-predominant pattern and are associated with chronic H. pylori infections.  Histologically, 
gastric cancers are classified as either diffuse- or intestinal-type adenocarcinomas17.   Diffuse-
type gastric cancer is present in younger populations and is prevalent in both men and women, 
while the intestinal-type gastric cancer is most commonly associated with high risk populations 
and elderly men.  Diffuse-type adenocarcinomas are characterized by poorly-differentiated cells 
without glandular structures and a distinct progression of precancerous lesions leading to 
cancer has not been identified17-18.  Furthermore, diffuse-type gastric cancers can be familial in 
distribution as germline mutations leading to reduced E-cadherin (CDH1) have been associated 
with this histologic type19.  In contrast, intestinal-type adenocarcinomas have well-
differentiated neoplastic cells connected by tubules and glands similar to those observed in 
normal intestinal mucosa.  This intestinal phenotype preserve cell polarity, partially due to the 
action of E-cadherin18.  No germline mutations have been associated with this form of gastric 
cancer.  The intestinal-type gastric cancer is associated with tissues with chronic inflammation, 
and follow a clear disease progression described by Correa's model of gastric carcinogenesis20.  
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Briefly, Correa's model characterized the series of sequential lesions that lead to gastric cancer.  
The stages of the precancerous cascade are normal stomach, chronic active nonatrophic 
gastritis, multifocal atrophic gastritis, intestinal metaplasia (complete, followed by incomplete), 
dysplasia and ultimately invasive carcinoma (Figure 1.3)20.  This work focuses on non-cardia, 
intestinal-type gastric adenocarcinomas, which represent the most common form of gastric 
cancer worldwide.   
Mutations associated with gastric cancer. Data from literature examining mutations in gastric 
cancer as well as the sequencing efforts of the Cancer Genome Project is compiled in the 
Catalogue of Somatic Mutations in Cancer (COSMIC).  COSMIC lists the genes most frequently 
mutated as well as the type of mutations seen in these mutations21-23.  According to COSMIC 
data, the top ten mutated genes found in gastric cancer samples are TP53, KRAS, CTNNB1, APC, 
PIK3CA, CDH1, CDKN2A, PTEN, MSH6 and FBXW7 
(http://www.sanger.ac.uk/genetics/CGP/cosmic/ accessed on 2/22/2011).  Analysis of the 
mutational spectra of gastric cancer shows that G:C>A:T (mostly at CpG sites) transitions are 
the most common mutation observed, followed by A:T>G:C transitions and G:C>T:A 
transversions22.  These mutations can be induced by reactive oxygen and nitrogen species 
(RONS)24, such as nitric oxide25.  RONS are constantly released by inflammatory cells in 
response to H. pylori infection.   
Etiology. The role of H. pylori infection in gastric carcinogenesis has been established through 
epidemiological26-28 and experimental evidence29-30.  H. pylori promotes precancerous lesions 
and the development of gastric cancer by inducing a chronic inflammatory state.   The 
association of cancer with inflammation has been recognized since 1863 when Virchow 
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detected leukocytes in neoplastic tissues31.  The causal relationship between RONS produced by 
inflammatory cells and DNA damage that leads to cancer is now widely accepted32.  The 
combination of DNA damage, increased cell proliferation, deregulation of apoptosis and tissue 
remodeling that occurs during chronic inflammation increases the risk of neoplasia33.   These 
processes are largely regulated by proinflammatory cytokines, chemokines and growth factors 
that are part of the inflammatory environment.  This model of persistent H. pylori infection 
leading to chronic inflammation and cancer is supported by chronic viral (hepatitis B-induced 
liver cancer) and parasitic (Schistosomiasis-induced bladder cancer) infections34-35. 
Fifty percent of the world population is infected with H. pylori, but only a small fraction 
(1-2%) develops multifocal atrophic gastritis which leads to gastric cancer.  The majority of 
infected individuals present no clinical symptoms of infection while 5-15% of infected 
individuals develop peptic duodenal ulcers (Figure 1.4)36-37.  Duodenal ulcers are characterized 
by antral predominant nonatrophic gastritis which may reduce the risk of gastric cancer38.  
While H. pylori infection drives gastric carcinogenesis, the outcome of infection is modulated by 
the virulence of the bacterial strain, the genetic susceptibility of the host and the external 
environment.  
 
1.2 Helicobacter pylori 
Overview. The first well-documented report of spiral-shaped bacteria in human stomachs was 
by Bizzozero in 189339.  Early reports linking these microorganisms to gastritis, and even 
carcinomas, were dismissed as the bacteria were not found by others and were considered 
contaminants, as bacteria were not expected to survive in the acidic gastric environment40-42.  
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The field stagnated until 1982 when Marshall and Warren "rediscovered" unidentified curved 
bacilli in gastric biopsies associated with active, chronic gastritis4.  Later, Marshall fulfilled 
Koch's postulates by developing gastritis after swallowing a pure culture of H. pylori43. H. 
pylori's ability to persist for years in the human gastric mucosa was demonstrated in another 
experiment involving self-induced infection, which required antibiotics to eradicate the 
bacterium44. Within the last several decades, investigators around the world have proven that 
H. pylori is the causative agent of gastritis, ulcers, gastric mucosa-associated lymphoid tissue 
lymphoma and gastric cancer in humans and laboratory animal models45.   
Epidemiology. While 50% of the world's population is infected with H. pylori, prevalence differs 
dramatically between developing (>80%) and developed (<40%) nations46.  H. pylori is the most 
common bacterial infection worldwide.  Bacterial phylogenetic studies demonstrate that H. 
pylori has infected humans for at least 58,000 years, before humans migrated out of Africa47.  
Currently, H. pylori incidence has been estimated at 1-3% in developed nations and 3-10% in 
developing nations48-49. H. pylori infection is usually acquired in childhood and normally persists 
for life within the gastric mucosa6. In recent years, H. pylori prevalence worldwide has been 
decreasing coinciding with better hygiene and improved socioeconomic status, particularly in 
the industrialized world46.  
The mechanism of H. pylori transmission remains largely unknown.  The bacterium is 
almost exclusively found in humans and some nonhuman primates with no known reservoirs of 
H. pylori in the environment, which makes direct person-to-person transmission the most likely 
method of infection.  The fecal-oral (e.g. fecal contamination in institutions), oral-oral (e.g. 
premastication of food) and gastric-oral (e.g. iatrogenic infection or vomitus) routes have been 
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proposed but conclusive evidence is not yet available46.  There is a strong association of H. 
pylori infection with family size, as intra-familial transmission is facilitated by increased number 
of siblings, possibly due to reinfection among children6. 
Virulence factors. H. pylori is a microaerophilic, gram-negative, curved rod with multiple 
flagella that is capable of persistently infecting the harsh gastric environment.  The bacterium's 
success is due largely to an array of virulence factors that have adapted to the stomach for 
millennia.  The first obstacle the bacteria have to overcome is navigating the acidic lumen of the 
stomach and finding its niche in the gastric mucosa.  To survive the acid pH, H. pylori utilizes 
urease to convert gastric urea into ammonia and CO2 which may form a protective layer of 
ammonia to neutralize the acid adjacent to the bacteria50.  A second mechanism which utilizes 
an α-carbonic anhydrase takes the CO2 produced and converts it to HCO3
2- which helps 
maintain the periplasmic pH of the bacteria around 6.151.  In order to escape the lumen, H. 
pylori swims following gradients of carbonate and urea secreted by gastric epithelia to 
chemotactically find the mucin layer.  Mutants deficient in chemotaxis (cheW mutant) or 
sensing gradients (TlpB mutant), as well as mutants deficient in motility (nonflagellated mutants 
and flagellated but nonmotile mutants), do not infect the gastric mucosa at all or are 
outcompeted by wild-type counterparts52-54.  Once in the mucin layer, H. pylori's adhesins 
mediate persistent infection by binding sulfated mucin sugars or epithelial cells to prevent the 
sloughing of the bacterium.  The best characterized adhesin is BabA which binds Lewis B 
antigens on epithelial cells.  An allele of BabA, babA2, has been strongly associated with worse 
clinical outcomes55.  Other known H. pylori adhesins include SabA, SabB, OipA, AlpA and AlpB46.  
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The final set of virulence factors have perhaps been the most studied as they are the genes 
associated with H. pylori pathogenicity and epithelial cell damage.   
Damaging epithelial cells or destabilizing tight junctions is believed to release nutrients 
and substrates required by the bacteria to survive56.  The most important virulence factors in 
this set are CagA, VacA, HP-NAP, and LPS.  Recently, a prospective study conducted in Spain 
demonstrated that infection with H. pylori strains harboring CagA and VacA s1/m1 was 
associated with the development of gastric preneoplastic lesions (Odds ratio of 4.80, 95% CI 
1.71–13.5) compared to H. pylori-infected individuals without these virulence factors57.  The 
cytotoxin-associated gene A (CagA) is part of the H. pylori Cag pathogenicity island (CagPAI) 
which contains 31 genes required for the assembly and function of a type IV secretion system.  
CagA is a bacterial effector protein injected into the cytoplasm of gastric epithelial cells that can 
be phosphorylated by human kinases and directly interferes with signaling networks inducing 
changes in morphology and IL-8 secretion (Figure 1.5)58.  H. pylori strains possessing CagA, 
specifically CagA variants common in East Asia, are believed to increase the risk of gastric 
cancer58.  VacA, or vacuolating cytotoxin A, produces large acidified vacuoles in epithelial cells 
in vitro, which leads to cell death. Epithelial cell vacuoles are derived from late endosomes and 
lysosomes, affecting endocytosis.  VacA also forms membrane channels through the epithelial 
layer, increasing its permeability46.  The activity of the s1/m1 type of VacA is strongly correlated 
with increased H. pylori pathogenicity in Western populations46.  HP-NAP is the H. pylori 
neutrophil activation protein that specifically targets and activates neutrophils, presumably to 
increase epithelial damage59.  H. pylori's LPS, or lipopolysaccharide, is interesting as it poorly 
elicits an inflammatory response, as H. pylori's LPS moeities mimic the Lewis antigens x and y on 
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gastric epithelial cells.  This immune mimicry might have two distinct objectives: 1) limit specific 
immune responses to H. pylori, or 2) elicit immune responses against gastric epithelial cells to 
further destabilize epithelial polarity46.  All together, H. pylori has evolved to infect the gastric 
niche and utilizes the appropriate combination of virulence factors to transform the 
environment for its survival.  Determining the role of virulence factors in different strains of H. 
pylori is the purpose of experiments using H. pylori microarrays that are introduced in Appendix 
A. 
Diagnosis and Treatment. The methods for diagnosing H. pylori infection include urea breath 
testing, serology, fecal antigen tests, histology and culture.  Urea breath testing is the least 
invasive and works by detecting the activity of H. pylori's urease.  Patients swallow urea labeled 
with a carbon isotope and breathe into a tube that detects the presence of labeled carbon 
dioxide, which would be produced by the decomposition of urea.  Serological tests detect 
specific antibodies against H. pylori, but cannot definitively determine active infection as 
antibodies can be produced for years after clearance.  Fecal antigen tests use H. pylori-specific 
antibodies to detect H. pylori antigen.  Both histology and culture are used as the gold standard 
of detection but are the most invasive as they require an endoscopy46.   
The current treatment of H. pylori in symptomatic carriers is eradication of the bacteria.  
Antimicrobial therapy to eradicate H. pylori consists of triple or quadruple therapy as individual 
antibiotics are not as effective in the gastric niche.  Triple therapy incorporates two antibiotics, 
usually clarithromycin and amoxicillin, with a bismuth compound or a proton pump inhibitor, 
while quadruple therapy has both the bismuth compound and the proton pump inhibitor46.  
However, these therapies have shown suboptimal results in some studies leading to concerns 
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of antibiotic resistant strains60.  Due to H. pylori's association with gastric cancer, wide-scale 
eradication and vaccines have been proposed to prophylactically prevent gastric cancer. Early 
stage eradication of H. pylori prevents gastric cancer61, and reduces atrophy and physiological 
alterations to the stomach that allow colonization by other microbiota, which may be involved 
in gastric carcinogenesis62-66. The possibility of developing antibiotic resistant strains and the 
possible relationship between H. pylori eradication and development of proximal gastric cancer 
and esophageal cancer have quelled discussions advocating H. pylori eradication in 
asymptomatic carriers worldwide. Efforts to develop a H. pylori vaccine have produced mixed 
results60.  However, a viable solution is aggressive screening by X-ray or endoscopy and 
eradication of the bacteria in symptomatic carriers in high-risk regions.  These methods have 
proven effective in Japan, a nation with one of the highest incidence rates of gastric cancer, as 
they have also experienced the worldwide decrease in gastric cancer incidence and increased 
their overall 5 year survival rate67.  From 1962 to 1992, Japan doubled the overall 5 year 
survival of gastric cancer patients from 20% to 40% by detecting stomach cancer at the 
localized stage and surgically removing cancerous tissues60.   
 
1.3 Host factors 
Although H. pylori is the major causative agent of gastric cancer, the host plays an important 
role in the progression of gastric cancer through its response to the bacterium68. There is a two- 
to three-fold increase in gastric cancer risk in individuals with blood relatives with gastric cancer, 
and 10% of gastric cancer cases show familial clustering69.  While H. pylori infection is likely to 
be transmitted throughout a family, controlling for H. pylori infection indicated that a family 
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history of gastric cancer is still a risk factor for disease.  These families have been shown to have 
increased susceptibility to H. pylori and its associated precancerous lesions which suggest a 
strong host component in disease development70.  As H. pylori pathogenesis is mediated 
through chronic inflammatory processes, the modulation of the host's immune response may 
affect disease development and will be discussed below. 
The adaptive immune response. The current model of persistent H. pylori infection leading to a 
chronic inflammatory state that causes gastric cancer (through DNA damage, errors in 
replication due to hyperproliferative conditions or recruitment of oncogenic bone-marrow 
derived cells) is largely dependent on the host's specific immune response to the bacterium68.  
In response to initial H. pylori infection, circulating phagocytic cells including neutrophils, 
macrophages and monocytes are recruited to the site of infection by the cytokine/chemokine 
system and the complement system (Figure 1.6).  However, failure to eradicate the bacteria by 
the innate immune response and its associated acute inflammation lead to the recruitment of T 
and B lymphocytes and more macrophages, signaling the involvement of the adaptive immune 
system and the establishment of chronic inflammation.  Following their recruitment, immature 
helper T cells (Th0) are activated by H. pylori antigens expressed on antigen presenting cells 
(APCs) and differentiate into several subtypes, including Th1, Th2 and the more recently 
discovered Th17 cells, which secrete different sets of cytokines that modulate the type of 
immune response (Figure 1.6). Broadly, Th1 cells secrete IL-2 and IFN-γ, increase 
proinflammatory cues and are associated with macrophage activation.  Th2 cells secrete IL-4, IL-
5, and IL-10, increase antiinflammatory cues and stimulate B cell responses.  Th17 cells secrete 
IL-17 and IL-22, also increase proinflammatory cues and are associated with neutrophil 
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recruitment and inflammatory disorders. By mechanisms incompletely understood, H. pylori 
infection promotes a strong Th1 and Th17 proinflammatory response71.  Historically, Th1 
responses have been shown to mediate H. pylori-associated gastritis71-75, but there is increasing 
recognition of the role of Th17 cells in H. pylori pathogenesis76-77.  However, due to the recent 
discovery of Th17, its contributions have not been as thoroughly studied.  Based on the 
Th1/Th2 model of H. pylori pathogenesis, the proinflammatory Th1, and possibly now Th17, 
cytokines promote gastritis, while Th2 cytokines, and possibly T regulatory cells that counteract 
Th17 actions, protect against gastric inflammation.  The importance of T cells, particularly Th1 
cells, in the development of Helicobacter-induced gastric disease has been demonstrated in 
mouse models lacking functional lymphocytes and utilizing adoptive transfer to investigate the 
effect of specific T cell subsets74,78-79.  Furthermore, different mouse models of Helicobacter 
spp. infection demonstrate the importance of Th1/Th2 responses, as C57BL/6 mice which are 
susceptible to gastric atrophy caused by H. pylori have stronger Th1 responses while BALB/c 
mice which are less susceptible to gastric atrophy mount Th2 responses68. These models will be 
further discussed in the section on "Mouse models of H. pylori infection" as the effects of the 
immune response in the context of gender of great importance to this thesis. 
 As differences in the host's T cell response affect the outcome of H. pylori infection, it 
has been hypothesized that modulating the host's response might exacerbate or ameliorate 
gastric disease.  Coinfection with Heligmosomoides polygyrus, a murine parasite, and 
Helicobacter felis, a gastric Helicobacter, decreased Th1-associated cytokines and antibodies to 
H. felis leading to attenuated gastritis and less severe premalignant lesions80. Coinfection with 
Helicobacter bilis, an enterohepatic helicobacter that subclinically infects numerous strains of 
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mice, also attenuated H. pylori induced gastritis in C57BL/6 mice81.  The opposite effect was 
observed by modulating the host's response using a parasite that induces a strong Th1 
response, such as Toxoplasma gondii. Coinfection with T. gondii exacerbated H. felis infection 
leading to increased morbidity82.  These results support the "African enigma," the hypothesis 
that the low incidence of gastric cancer observed in some developing nations is due to the 
immunomodulating effect of coinfections leading to Th2 responses83.  This effect has been 
observed in a study involving a coastal population and an Andean population in Colombia with 
vastly different incidences in gastric cancer84.  While H. pylori prevalence (>90%) was similar, the 
coastal population had a lower incidence of gastric cancer which was associated with 
coinfection with enteric helminths and a systemic Th2 response to H. pylori, unlike the Andean 
population that experience a higher incidence of gastric cancer, had fewer parasites and a 
systemic Th1 response84. 
Inflammation, oxidative stress and DNA repair. T helper cells create an environment that 
recruits and activates the appropriate inflammatory cells to deal with specific antigens.  T 
helper cells direct the immune response through the secretion of specific cytokines.  H. pylori-
infected gastric epithelium has increased levels of IL-1β, IL-2, IL-6, IL-8 and TNFα, which is a 
potent proinflammatory combination characterized by the predominance of phagocytes85.  IL-
1β promotes a strong proinflammatory response and inhibits gastric acid secretion70.  IL-8, a 
neutrophil activating chemokine, is strongly induced by H. pylori85-86.  After following cytokine 
and chemokine gradients to the site of infection, phagocytes have two functions: a) eradicate 
H. pylori and b) repair the tissue.  To eradicate H. pylori, phagocytes utilize lysosomal proteins, 
such as proteases, lysozymes, and myeloperoxidases.  Myeloperoxidases produce superoxide 
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(O2
-), a precursor of peroxide (H2O2) and hypochlorous acid.  Monocytes and macrophages 
release nitric oxide (NO) which also forms peroxynitrite (OONO-).  Lysosomal proteins and RONS 
released during H. pylori infection damage adjacent tissues and are the main source of 
epithelial damage. To accomplish the goal of repairing the tissue, phagocytes secrete cytokines 
and growth factors to recruit more inflammatory cells and initiate wound healing responses, 
such as proliferation, ECM degradation, angiogenesis, etc. required to return the tissue to 
homeostasis33.  As H. pylori persistently infects the stomach, the proinflammatory and wound 
healing responses are not shut down and over time can promote cancer. 
Another way in which the host can modulate the inflammatory response is through host 
genetics.  The association of single nucleotide polymorphisms (SNPs) of inflammation-related 
genes with increased risk of gastric cancer highlights the importance of inflammation and 
oxidative stress in H. pylori driven carcinogenesis87-88.  SNPs have been associated with 
increased susceptibility to H. pylori infection, H. pylori-induced gastric atrophy and gastric 
cancer.  SNPs in many inflammatory mediators, such as IL-1β, IL-1RN2, IL-10, IL-8, CXCR2 (IL-
8RB) , IL-4, COX2, TNF, iNOS, and IFNGR2, are relevant in gastric carcinogenesis as they further 
alter the balance of both Th cells and phagocytes (Table 1.1).  The associations of IL1β-31*C and 
-511*T with increased risk of gastric atrophy and cancer in Western populations were among 
the first discovered70.  Studies in East Asian populations have associated SNPs in the IL-1 family 
with increased gastric cancer risk89-91.  Polymorphisms in the promoter region of IL-8 (IL-8 -251 T 
to A) have been associated with increased gastric cancer risk92-93.  The role of CXCL1, a murine 
homolog of IL-8, in H. pylori induced carcinogenesis will be discussed in Chapter 3.  
DNA repair enzymes may play an important role in reducing H. pylori-related 
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carcinogenesis by decreasing oxidative DNA damage. H. pylori-induced chronic inflammation 
increases DNA damage, double-strand breaks and DNA fragmentation in the gastric mucosa 
through the effect of oxidative stress and RONS94-97.  RONS cause DNA damage via multiple 
mechanisms such as direct base oxidation, nucleoside deamination, and the formation of 
etheno adducts by lipid peroxidation24,32,98-99. H. pylori gastritis selectively increases the activity 
of DNA damage and repair proteins, such as Ku, poly (ADP-ribosyl) polymerase, 8-
hydroxyguanine glycosylase (OGG1), and MSH2, in human gastric mucosa96. Studies of SNPs in 
genes related to DNA repair, such as MGMT, and OGG1, have not always demonstrated clear 
links with gastric cancer87-88,100.  MGMT, also known as O6-methylguanine-DNA 
methyltransferase, repairs DNA adducts such as O6-methylguanine and O4-methylthymine101-102, 
and its inactivation by promoter hypermethylation has been associated with increased gastric 
cancer risk103-104.  MGMT Ile143Val polymorphism was associated with increased gastric cancer 
risk, but only in patients with low intake of fruits and vegetables100.  Polymorphisms of OGG1, or 
8-oxoguanine DNA glycosylase, cause the accumulation of 8-oxo-dG during H. pylori gastritis, 
but their association with increased gastric cancer risk is still controversial105-107.  Given their 
role in repairing DNA damage induced by H. pylori, DNA repair proteins may greatly influence H. 
pylori carcinogenesis. 
Gender. Men experience higher rates of infection and its associated mortality than women.  
Normal immune responses are sexually dimorphic with a heightened inflammatory response in 
women compared to men.  This greater inflammatory response in women provides advantages 
during infection, sepsis and trauma but makes women more susceptible to autoimmune 
diseases108. Epidemiological and immunological evidence suggests that the menstrual cycle, 
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pregnancy and menopausal status influence the etiology and progression of chronic 
inflammatory diseases, such as gastric cancer and rheumatoid arthritis, which suggests the 
importance of female sex hormones109-110.   Hormone therapies in men and women are also 
associated with decreased gastric cancer risk13.  Postmenopausal hormone replacement therapy 
(HRT) may lower the rate of gastrointestinal cancer, particularly colonic cancer111-113.  Prostate 
cancer patients treated with estrogen had a decreased risk of gastric cancer110.  Additionally, the 
usage of anti-estrogen therapy, particularly the breast cancer drug Tamoxifen, is linked with 
increased incidence rates of gastrointestinal malignancies.  Considerable evidence exists that 
Tamoxifen, a mixed agonist/antagonist of estrogen signaling, is associated with protection 
against breast cancer, but also increases the risk of endometrial cancers114-115.  However, 
Tamoxifen treatment and its association with gastrointestinal cancers, and gastric cancer in 
particular, is not clear; one study reports no effect115 while others demonstrate Tamoxifen 
treatment with increased risk116-118. 
A review of the effects of estrogens on inflammation indicate that estrogens, of which 
17β-estradiol or E2 is the most important, decrease the apoptosis of immune cells, inhibit 
reactive oxygen species formation, and inhibit nitric oxide production in the presence of 
inflammatory stimuli108.  Another mechanism by which estrogens may affect chronic 
inflammatory diseases is by directly affecting the secretion of cytokines by T cells, B cells and 
macrophages.   Generally E2 in premenopausal women favors the downregulation of T cell-
dependent immunity.  Periovulatory to pregnancy levels of E2 promotes IL-4, IL-10 and IFN-γ 
secretion from CD4+ T cells while inhibiting the production of TNFα.  Furthermore, mouse 
studies demonstrate that high concentrations of E2 increase Th2 and T regulatory transcription 
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factors, thus increasing the antiinflammatory response.  In contrast, B cell antibody secretion is 
normally stimulated by E2 in pre- and post-menopausal women.  Furthermore, very high levels 
of E2 inhibit the secretion of IL-1β and TNFα, while lower levels stimulated both cytokines 
demonstrating the importance of E2 levels in shaping the inflammatory response108.  As 
estrogens can strongly decrease T cell-dependent immunity and the proinflammatory cytokine 
environment, the role of estrogens in gastric cancer is further explored in Chapter 3.   
 
1.4 Environmental factors 
The sharp decrease in the incidence and mortality of gastric cancer in developed countries 
suggest that the environment is a third factor to consider in the etiology of gastric cancer.  As 
mentioned previously, second-generation immigrants had a reduction in gastric cancer risk 
compared to first-generation immigrants indicating that the environment can be more 
important that host genetics and bacterial factors (assuming intra-familial transmission of H. 
pylori)9.  Diet and lifestyle have been associated with increased gastric cancer risk.  High salt 
consumption and low intake of fresh fruits and vegetables are independent dietary factors that 
increase gastric cancer risk119. Of these dietary factors, the intake of high levels of dietary salt 
has been studied most extensively due to the association of high incidences of gastric cancer to 
countries with high salt intake, which is thought to promote further injury to the stomach120-121.  
Animal models assessing the role of high salt in gastric pathology have yielded mixed 
results66,122  Smoking also increases gastric cancer risk123.  Associations between meat 
consumption or alcohol and gastric cancer are not as clear119,124.   Additionally, the impact of 
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long-term proton pump inhibitors in gastric carcinogenesis is now being probed, as proton 
pump inhibitors have been linked to precancerous lesions and cancer in rodents125-126 
 
 
1.5 Mouse models of H. pylori infection 
Many animal models, such as neonatal gnotobiotic piglets, Macaca species and Mongolian 
gerbils, have been utilized to model H. pylori infection in humans127-129.   However, the mouse is 
the most widely used animal model in H. pylori studies due to its myriad advantages, such as 
well-documented immune responses, the sequencing of its genome, availability of reagents and 
transgenic mice and low cost relative to other models.  Early H. pylori experiments with mice did 
not lead to persistent colonization in wild-type strains leading to the use of athymic, or nude 
mice130 or other Helicobacter spp., most notably H. felis131.  H. felis infection of C57BL/6 mice 
causes oxyntic atrophy and gastric cancer by 15 months post-infection (MPI)132-133. The first 
reports of successful adaptation of H. pylori to the mouse model came from Italy in the mid-
1990's134-136, but they were superseded by the adaptation of the cagPAI+ Sydney strain, or SS1, 
which has become the standard for H. pylori mouse studies due to its ability to persistently 
infect many inbred mouse strains, such as C57BL/6, BALB/c, DBA/2 and C3H/He137.  As 
mentioned previously, SS1 elicits a robust chronic active gastritis in C57BL/6 mice accompanied 
by a Th1 immune response while BALB/c mice develop less pathology accompanied by a Th2 
response due to host strain differences (e.g. differences in phospholipase A2 secretion)
132,138-139.  
Each system has particular differences that must be considered in order to address the right 
biological questions.  For example, in C57BL/6 mice, females have a stronger inflammatory 
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response compared to males leading to increased gastritis and cell proliferation, which is an 
important factor to consider when determining the interpretation of data such as 
histopathological scores140.  These differences in the models are useful in determining how 
changes in the immune response and gender affect the formation of gastric lesions. 
Nevertheless, H. pylori infection alone does not reliably induce gastric cancer in either of these 
strains138. Limitations associated with the murine model are differences in gastric architecture, 
the lack of H. pylori-associated ulcers and gastric cancer in some models, and the presence of 
Lactobacillus spp. in the proximal murine stomach, which are not found in the human 
stomach46.   However, new murine models that more closely recreate conditions in humans 
continue to progress.  For example, the development of H. pylori-induced gastric cancer has 
been documented in male hypergastrinemic INS-GAS FVB mice at 7 MPI141 and C57BL/6 × 
129S6/SvEv (B6129) mice at 15 MPI122.  Using two of these models, this thesis probes the 
interactions between gender and immune response in gastric mutagenesis using C57BL/6 mice 
(Chapter 2) and the role estrogens and innate immunity in gastric carcinogenesis in INS-GAS 
mice (Chapter 3). 
 
1.6 Transgenic mouse mutation systems 
Murine mutational analysis systems are mouse models used to detect somatic mutations and 
assess the mutagenicity of chemical, biological or physical agents.  These in vivo models use 
reporter genes to detect mutations under the assumption that damage to reporter genes are 
indicative of mutations to the host genome.  Based on the origin of their reporter genes,  
murine mutational analysis systems are classified as endogenous or exogenous systems.  
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Endogenous systems include the Dlb-1 mouse assay, the Aprt mouse assay, the pink-eyed 
unstable (pun) mouse assay and the mammalian spot assay142.  Exogenous systems include the 
Big Blue® assay, Muta ™Mouse assay and the gpt delta assay143.  The main advantage of the 
endogenous systems is that the reporter genes are host genes that are expressed in their native 
chromosomal conformation142.  This allows the induction of mutations in active genes which can 
often be assessed in vivo.  In the Dlb-1, pun, and mammalian spot models, assessment of the 
induction of mutations can be done visually by examining changes on the fur or staining in 
tissue samples.  An exception is the Aprt system which requires in vitro culture but also allows 
sequencing of mutations144-145.  However, a limitation of endogenous systems is that they can 
only detect mutations in certain cell types.  In contrast, exogenous, or transgenic, systems 
express the reporter genes in every cell of the body which permits the detection of mutations in 
any organ.  Transgenic systems insert multiple tandem copies of lambda phage carrying a 
reporter gene like lacI, lacZ or gpt to detect mutations ex vivo143.  After extracting the DNA, 
lambda phage is repackaged, and used to infect Escherichia coli.  E. coli expresses the transgene 
providing a readout indicating mutations in the transgene.  The genes can be isolated and 
sequenced to determine the exact mutational spectra.  The drawbacks of this method are that 
the reporter genes are 1) not actively expressed in the mouse and 2) are prokaryotic with 
differences in methylation and nucleotide composition.  Furthermore, the ex vivo expression 
makes the reporter genes susceptible to further mutations outside the mouse. 
 Different transgenic systems have been used to measure the induction of mutations 
caused by chronic inflammation, including H. pylori, in the gastrointestinal tract146-149.  The Big 
Blue® assay, Muta ™Mouse assay and the gpt delta assay are attractive candidates to study H. 
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pylori pathogenesis as they are available on the C57BL/6 background which develops 
precancerous lesions in response to H. pylori infection.  As these three transgenic systems utilize 
similar mechanisms to report mutations, the gpt delta assay will be utilized to further describe 
the methods.  The gpt delta transgenic mouse was developed to allow the detection of point 
mutations by the inactivation of gpt, or guanine phosphoribosyltransferase, activity under 6-
thioguanine (6-TG) selection150.  Importantly, in contrast to other transgenic systems, the gpt 
delta mouse can also measure deletions less than 10kb in size using Spi- selection150.   
The 456 bp gpt gene encodes the Gpt enzyme which adds activated ribose-5-phosphate 
to guanine bases creating guanine monophosphate in the purine salvage pathway.  Gpt can also 
salvage 6-TG but the product is toxic to the cell143.  Using this principle, E. coli infected with 
plasmids expressing a functional gpt cannot grow on minimal media plates with 6-TG, whereas 
plasmids with inactivated, or mutant, gpt will form colonies.  The gpt gene was inserted into a 
plasmid construct flanked by lox sites.  After murine genomic DNA is isolated, the phage DNA is 
rescued and packaged into phage particles that transduce E. coli expressing Cre recombinase.  
Cre acts upon the lox sites allowing the propagation of the plasmid.  The plasmid also carries the 
CAT gene which confers resistance to chloramphenicol (Cm). Using Cm alone or Cm and 6-TG 
selection, the total number of E. coli expressing the plasmid and the total number of E. coli 
expressing the plasmid with a mutated gpt gene can be calculated.  6-TG resistant colonies are 
then cultured and a 739 bp DNA product containing the gpt gene is amplified by PCR.  This 
product can then be sequenced to determine the mutational spectra.  Mutations are classified 
as transitions, transversions, deletions, insertions or complex (multiple changes).   
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The Spi- assay selects for lambda phage that are not sensitive to interference from prophage P2.  
Induction of wild-type lambda phage on E. coli carrying prophage P2 results in the host's death 
and inhibition of phage replication, which makes lambda phage sensitive to P2 interference, or 
Spi+151.  However, deficiency in both red and gam gene function, along with chiC expression, 
confer phages with resistance to P2's interference, or a Spi- phenotype, and importantly do not 
immediately kill E. coli allowing phage propagation.  The lambda phage in the gpt delta mouse 
incorporates the red, gam and chiC elements.  When gpt delta mice are exposed to agents that 
cause deletions capable of inactivating both red and gam, the recovered lambda phage are Spi- 
which allows them to form plaques on a lawn of E. coli carrying P2.  Using strains of E. coli with 
and without P2, the total number of lambda phage with red and gam inactivation and the total 
number of lambda phage recovered can be determined.  Mutated phage can be recovered and 
passaged to determine the location of the deletion by a combination of PCR and sequencing.  
Due to its ability to determine the mutagenic potency of infectious agents in the stomach, I 
utilized the gpt delta mouse model on a C57BL/6 background to determine the role of H. pylori  
in the induction of gastric mutations in Chapter 2. 
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1.8 Tables and Figures 
 
 
 
 
 
 
 
 
 
Figure 1.1. Mortality rates of gastric cancer in 2008 for men and women.  Higher mortality rates are observed in 
Eastern Asia, Russia, Central America and the Pacific coast of South America.  Lower mortality rates are observed in 
Western Europe, North America, Africa and Australia. 
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Figure 1.2.  Age-standardized incidence rates of gastric cancer demonstrate a sexual dimorphism with men twice as 
likely as women of developing gastric adenocarcinomas.  This survey compared epidemiological data from 18 
surveys in 13 countries.  The 13 countries encompass a wide range of geographical locations with varying 
incidences of gastric cancer demonstrating that the male predominance is a global phenomenon
11
. 
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Figure 1.3. Histological progression of Helicobacter-induced 
gastric cancer in mouse model.  Normal represents histology of 
the gastric body prior to infection.  Acute gastritis results after 
Helicobacter infection with infiltration of lymphocytes and 
neutrophils.  Subsequently, chronic gastritis ensues with 
moderate to severe inflammation with epithelial defects.  
Atrophic gastritis includes the loss of oxyntic parietal and chief 
cells.  The next step, intestinal metaplasia, is the change of the 
gastric epithelia to an intestinal phenotype with columnar 
elongation, and increased mucins.  High-grade glandular 
dysplasia is characterized by irregular size and shape, infolding, 
branching and cell piling, and marked cellular and nuclear atypia. 
Gastric intraepithelial neoplasia with intramucosal invasion 
(arrow) is classified as cancer.  Scale bars: 160 μm (first panel); 
400 μm (second through fourth panels); 80 μm (fifth panel; 
inset, original magnification, ×400); 40 μm (sixth panel); 800 μm 
(seventh panel)
68
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Figure 1.4. Divergent responses to H. pylori infection lead to three major clinical outcomes.  The majority of H. 
pylori infected individuals do not develop overt clinical symptoms.  Duodenal ulcers are observed in 5-15% of 
patients while 1-2% of infected individuals develop gastric cancer
36-37
. 
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Figure 1.5.  Effects of CagA translocation on host epithelial cells. After being tyrosine-phosphorylated, CagA can 
interact with member of the c-Met signaling pathway including SHP-2, Csk, Crk.  CagA also mediates cell junction 
disruption by affecting PAR1 kinase and E-cadherin.  Destabilization of E-cadherin leads to deregulated Wnt/β-
catenin signaling
152
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Figure 1.6.  Host responses to H. pylori infection.  After encountering H. pylori, epithelial cells create a chemotactic 
gradient leading to the recruitment of neutrophils.  Subsequently, macrophages and lymphocytes arrive at the site 
of infection and proinflammatory cytokines are released
85
. 
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Table 1.1.  Polymorphisms in genes that have been studied for association with gastric cancer (Note: not all SNPs 
presented in the table have effects on gastric cancer)
153
.  
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Chapter 2: Mutagenic potency of Helicobacter pylori in the gastric mucosa of 
mice is determined by sex and duration of infection 
 
A version of this chapter has been previously published and is reprinted here with the 
permission of the publisher: 
 
Sheh, A., Chung Wei Lee, Kenichi Masumura, Barry H. Rickman, Takehiko Nohmi, Gerald N. 
Wogan, James G. Fox, and David B. Schauer. Mutagenic potency of Helicobacter pylori in the 
gastric mucosa of mice is determined by sex and duration of infection. Proc Natl Acad Sci U S A 
107, 15217-15222 (2010). 
 
ABSTRACT 
Helicobacter pylori is a human carcinogen, but the mechanisms evoked in carcinogenesis during 
this chronic inflammatory disease remain incompletely characterized. We determined whether 
chronic H. pylori infection induced mutations in the gastric mucosa of male and female gpt 
delta C57BL/6 mice infected for 6 or 12 mo. Point mutations were increased in females infected 
for 12 mo. The mutation frequency in this group was 1.6-fold higher than in uninfected mice of 
both sexes (P < 0.05). A:T-to-G:C transitions and G:C-to-T:A transversions were 3.8 and 2.0 
times, respectively, more frequent in this group than in controls. Both mutations are consistent 
with DNA damage induced by oxidative stress. No increase in the frequency of deletions was 
observed. Females had more severe gastric lesions than males at 6 mo postinfection (MPI; P < 
0.05), but this difference was absent at 12 MPI. In all mice, infection significantly increased 
expression of IFNγ, IL-17, TNFα, and iNOS at 6 and 12 mo, as well as H. pylori–specific IgG1 
levels at 12 MPI (P < 0.05) and IgG2c levels at 6 and 12 MPI (P < 0.01 and P < 0.001). At 12 MPI, 
IgG2c levels in infected females were higher than at 6 MPI (P < 0.05) and also than those in 
infected males at 12 MPI (P<0.05). Intensity of responses was mediated by sex and duration of 
infection. Lower H. pylori colonization indicated a more robust host response in females than in 
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males. Earlier onset of severe gastric lesions and proinflammatory, Th1-biased responses in 
female C57BL/6 mice may have promoted mutagenesis by exposing the stomach to prolonged 
oxidative stress. 
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2.1 Introduction 
Acting through multiple, complex mechanisms that are incompletely understood, chronic 
inflammation is a significant risk factor for several major human malignancies, including 
stomach cancer. Chronic inflammation induced by Helicobacter pylori infection increases 
lifetime risk of developing gastritis, duodenal and gastric ulcers, mucosa-associated lymphoid 
tissue lymphoma, mucosal atrophy, and gastric carcinoma (1, 2). Indeed, H. pylori has been 
classified by International Agency for Research on Cancer as a group I human carcinogen on the 
basis of its impact on gastric cancer incidence, the second most frequent cause of cancer-
related death worldwide (3). Among postulated mechanisms through which infection may 
contribute to increased cancer risk are overproduction of reactive oxygen and nitrogen species 
(RONS) by inflammatory cells, and the consequent induction of mutations critical for tumor 
initiation in cells of inflamed tissues (4). The inflammatory response to infection results in 
increased production of RONS, including superoxide (O2–·), hydrogen peroxide (H2O2), 
nitric oxide (NO), peroxynitrite (ONO2–), and nitrous anhydride (N2O3), in vitro (5, 6) and in 
vivo (7–9). H. pylori can also directly activate RONS-producing enzymes, such as inducible NO 
synthase (iNOS) and spermine oxidase, in gastric epithelial cells, causing DNA damage and 
apoptosis (5, 6). Chronic inflammatory states increase levels of DNA adducts, such as etheno 
adducts, 8-oxoG, and other mutagenic precursors, in vitro and in vivo (10–12), but tend not to 
alter the frequency of deletions (13). RONS also can damage DNA indirectly by creating adduct-
forming electrophiles via lipid peroxidation (14, 15). RONS have been shown to induce 
mutations in H. pylori by inducing a hypermutation state in the bacteria (16). 
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A widely used experimental model is the H. pylori SS1-infected C57BL/6 mouse, which is 
susceptible to chronic infection and develops robust gastritis and premalignant lesions similar 
to those occurring in humans (17, 18). To date, limited investigation has focused on genetic 
damage associated with infection in these animals, but available data are still incomplete. 
Enhanced DNA fragmentation was observed in gastric cells of infected mice (19), in which 
dsDNA breaks were also detected by TUNEL assay (20, 21). Mutagenicity in reporter genes 
recovered from gastric DNA of male and female Big Blue transgenic mice 6mo after infection 
with H. pylori or Helicobacter felis has also been reported (22). In H. pylori-infected male mice, 
point mutation frequency was increased at 6 mo post infection (MPI), but decreased to control 
levels by 12 MPI, suggesting that the animals may have adapted to infection (22). Female mice 
infected with H. felis also had an increased frequency of point mutations at 7 MPI, compared 
with uninfected controls (23). Mutagenesis resulting from infection has also been associated 
with p53 status. Mutations were found in the lacI reporter genes of a small number of H. felis-
infected female TSGp53/Big Blue mice harboring either one (p53+/−) or two (p53+/+) WT p53 
alleles (23). A 2-fold increase in mutations was found in DNA from the gastric mucosa of 
infected p53+/+ mice, and also in uninfected p53+/− mice; the mutation frequency in infected 
p53+/− mice was further increased by approximately threefold. The intensity of inflammation 
was estimated to be significantly higher in infected p53+/− mice than in infected p53+/+ 
animals, and gastric epithelial proliferation was similarly increased with infection in both latter 
treatment groups. By contrast, in another study, infection of Big Blue transgenic mice (sex not 
specified) with the SS1 strain of H. pylori for 3.5 mo resulted in no significant increase in gastric 
mutations over uninfected controls (13). 
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We used the gpt delta mouse to measure the accumulation of gastric mutations 
associated with H. pylori SS1 infection in male and female animals at 6 and 12 MPI. This 
experimental system comprises λ-EG10–based transgenic C57BL/6 mice harboring tandem 
arrays of 80 copies of the bacterial gpt gene at a single site on chromosome 17. The model was 
specifically designed to facilitate the in vivo detection of point mutations by 6-thioguanine (6-
TG) selection, and deletions up to 10 kb in length by selection based on sensitivity to P2 
interference (Spi−) (24). When phage DNA rescued from mouse tissues is introduced into 
appropriate Escherichia coli strains, both point mutations and large deletions 
can be efficiently detected (24). We also characterized histopathologic changes, expression of 
inflammatory cytokines, and expression of iNOS in gastric mucosa 6 and 12 mo after initial 
infection. In addition, we compared responses of male and female mice to assess the influence 
of sex. We found that H. pylori infection induced significant increases in the frequency of point 
mutations in the gastric mucosa of female, but not male, gpt delta mice. The accumulation of 
point mutations was therefore sex-dependent and was mediated by the duration of infection 
and the severity of disease. 
 
2.2 Results and Discussion 
2.2.1 Pathology, Cytokine and iNOS Expression, and Serologic Responses to H. pylori Infection 
and H. pylori Levels. Inflammatory histopathologic changes resulting from H. pylori infection 
were evaluated (Fig. 2.S1) and gastric histological activity index (GHAI) scores calculated, with 
the following results. Scores were significantly increased in infected animals of both sexes at 6 
and 12 MPI (female, P < 0.001 and P < 0.01, respectively; and male, P < 0.05 and P < 0.001, 
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respectively; Fig. 2.1). Regarding specific types of lesions represented in the GHAI, infected 
females experienced higher levels of hyperplasia (P < 0.05), epithelial defects (P < 0.001), and 
dysplasia (P < 0.05) compared with infected males at 6 MPI, and thus had correspondingly 
higher (P < 0.05) GHAI scores at this time point. At 6 MPI, infected animals of both sexes 
displayed mild to moderate inflammation, comprised chiefly of submucosal and mucosal 
infiltrates of mononuclear and granulocytic cells. In addition, in infected males, mucous 
metaplasia, intestinal metaplasia, oxyntic gland atrophy, and hyalinosis were all significantly 
elevated compared with controls (all P < 0.01; intestinal metaplasia, P < 0.001); no significant 
increases occurred in foveolar hyperplasia, epithelial defects, or dysplasia. In infected females, 
inflammation (P < 0.05), epithelial defects (P < 0.001), mucous metaplasia (P < 0.01), hyalinosis 
(P < 0.001), as well as premalignant lesions of oxyntic gland atrophy (P < 0.001), intestinal 
metaplasia (P < 0.05), and dysplasia (P < 0.05) were significantly elevated compared with 
uninfected controls. At 12 MPI, there were no differences in gastric lesion severity between 
infected males and females; both groups had similar mucosal changes. Infected male mice at 12 
MPI displayed significantly increased epithelial defects but decreased intestinal metaplasia than 
infected males at 6 MPI (P < 0.01 and P < 0.001).  
H. pylori infection significantly increased transcription profiles at 6 and 12 MPI as follows 
(details in Fig. 2.S2): IFNγ (males, P < 0.001; females, P < 0.01 at 6 and 12 MPI); TNF-α (males, P 
< 0.01 at 6 and 12 MPI; females, P < 0.01 and P < 0.05); IL-17 (males, P < 0.05 and P < 0.001; 
females, P < 0.05 and P < 0.01). iNOS expression was increased in male and female mice at 6 
and 12 MPI (males, P < 0.05 and P < 0.01; females, P < 0.01 and P < 0.001) compared with 
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controls at 12 mo. IL-10 expression was not significantly affected by infection in animals of 
either sex (P > 0.05).  
H. pylori infection also resulted in a Th1-predominant IgG2c response in infected mice as 
previously reported (25, 26) (Fig. 2.2). H. pylori-specific IgG2c levels were higher in infected 
than in uninfected animals at 6 and 12 MPI (P < 0.01 and P < 0.001, respectively). At 12 MPI, 
infected females had significantly higher IgG2c levels than infected males (P < 0.05). Duration of 
infection also increased IgG2c levels in infected females, with higher levels noted at 12 versus 6 
MPI (P < 0.05). H. pylori-specific IgG1 (Th2) levels were higher in infected than in uninfected 
animals at 12 MPI (P < 0.05). Females had higher Th1/Th2 ratios than males: at 6 MPI, 8.58 vs. 
4.01; and at 12 MPI, 12.9 vs. 7.51. 
We and others have demonstrated that H. pylori levels are inversely correlated with the 
degree of pathology and the immune response as measured by antibody and cytokine 
production (25, 27). At 6 MPI, H. pylori was detectable by quantitative PCR in all infected males, 
but not in one female. At 12 MPI, there was a salient difference in levels of H. pylori 
colonization between males and females; H. pylori was undetectable in four infected females, 
but undetectable in only one male (Fig. 2.3).  
2.2.2 Frequency and Nature of Mutations. We determined the frequency of gpt point 
mutations in gastric DNA isolated from infected and uninfected mice by selection of mutants 
based on 6-TG resistance. Recognizing the possible confounding effect of clonal expansion of 
sibling mutants (i.e., jackpot mutations), we sequenced the gpt genes from all 566 recovered 
mutants. Any mutation found to duplicate another at the same site within an individual sample 
was excluded from subsequent frequency calculations. After this adjustment, at 12 MPI the gpt 
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mutation frequency in infected females (7.5 ± 2.0 × 10−6; P < 0.05) was significantly (1.6-fold) 
higher than that in all control animals (4.7 ± 1.1 × 10−6), whereas the frequency in infected 
males (6.3 ± 5.4 × 10−6; P = 0.49) was not. At 6 MPI, gpt mutation frequency in infected animals 
of either sex (females, 5.6 ± 2.0 × 10−6, P = 0.72; males, 7.2 ± 2.2 × 10−6, P=0.57) was not 
significantly different from that of controls (6.2± 3.0 × 10−6; Fig. 2.4). 
After sequencing and accounting for clonal expansion, 236 from infected and 156 
mutants from uninfected mice were used to identify effects of H. pylori infection on types of 
mutations causing loss of gpt function, with the results summarized in Table 2.1 and Table 2.S1. 
G:C-to-A:T transitions and G:C-to-T:A transversions were the most prevalent types of mutations 
in both infected and uninfected animals, representing 33% to 50% and 17% to 31%, 
respectively, of total mutations in various treatment groups; mutant frequencies varied from 
2.1 to 3.0 × 10−6 in these transitions and 0.9–1.8 × 10−6 in the transversions. The 1.6-fold 
higher total mutations observed in infected females compared with age-matched controls at 12 
MPI was attributable mainly to two types of mutations: 3.8 times more A:T-to-G:C transitions 
(P < 0.05) and 2.0 times more G:C-to-T:A transversions (P < 0.05). These two mutations are 
consistent with the expected mutational spectrum induced by RONS (28) and have been found 
elevated in another animal model of chronic inflammation (13). An increase in G:C-to-T:A 
transversions was also reported in a previous study documenting H. pylori-induced mutations 
(22). 
A:T-to-G:C transitions can be formed by deamination of adenine to hypoxanthine or 
creation of ethenoadenine. Deamination is mediated by N2O3, the autoxidation product of 
NO·, which directly nitrosates primary amines on DNA bases (28, 29). Hypoxanthine resembles 
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guanine and mispairs with cytosine, resulting in the observed mutation. Alternatively, A:T-to-
G:C transitions can also be created indirectly by lipid peroxidation by RONS, forming etheno 
adducts in DNA such as highly mutagenic ethenoadenine (30, 31). G:C-to-T:A transversions have 
also been associated with increased iNOS expression levels, pointing to the involvement of 
RONS (32). Cells cocultivated with activated macrophages predominantly develop G:C to T:A 
transversions caused by exposure to NO·, O2−·, and H2O2 (33). G:C-to-T:A transversions are 
also caused by adducts produced by oxidative stress or lipid peroxidation, such as 8-oxodG, 
εdC, and M1G (34,35). The presence of 8-oxodG, a major product of oxidative damage to DNA, 
results in mispairing of guanine with adenine during replication, thus inducing transversions 
(36). Although 8-oxodG is believed to be the main cause of this mutation, etheno adducts 
formed by lipid peroxidation may also play a significant role in mutagenesis observed in vivo 
(37). 
Fig. 2.S3 shows the mutation spectrum detected in the gpt gene, of which the following 
features are noteworthy. In both uninfected and infected mice, hotspots occurred at 
nucleotides C64, G110, G115, and G418; C64, G110, and G115 are CpG sites and are known 
hotspots in this assay (38, 39). Hotspots occurring in infected mice were located at A8, G116, 
and G143; A8 and G116 were found predominantly in infected females at both 6 and 12 mo, 
whereas G143, located at a CpG site, was a hotspot in infected animals of both sexes. 
Uninfected mice had hotspots at G406, G416, and A419, one of which (G416) occurred mainly 
in males. Mutations in infected males were concentrated mainly in hotspots common to both 
uninfected and infected animals, whereas in infected females there was an increase in 
mutations throughout the gpt gene at non-G:C sites. This result suggests that the chemistry of 
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DNA damage in mice with a stronger host response to infection may have differed from that in 
mice with mild or minimal gastritis. 
Mutation analysis using the Spi− assay revealed that the frequency of deletion 
mutations in gpt of gastric tissue DNA was not significantly affected by H. pylori infection (Fig. 
2.5). Analyses of 57 samples from 32 mice showed that Spi− mutant frequencies in infected 
mice (females at 6 MPI, 4.8 ± 2.5 × 10−6, P = 0.09; females at 12 MPI, 5.0 ± 2.6 × 10−6, P = 0.30; 
males at 6 MPI, 6.3 ± 2.5 × 10−6, P = 0.87; and males at 12 MPI, 5.2 ± 1.4 × 10−6, P = 0.17) were 
not significantly different from those of age-matched  controls at either time point (all mice at 6 
MPI, 2.9 ± 1.3 × 10−6; all mice at 12 MPI, 3.6 ± 1.8 × 10−6).  
Current models of inflammation-driven carcinogenesis are based on chronic 
inflammation inducing mutations that lead to cancer (40, 41). Female mice at 6 MPI had more 
hyperplasia, epithelial defects, and dysplasia than infected males and age-matched controls, 
but this increase in pathologic findings was not accompanied by increased frequency of 
mutations. This was detected only in infected female mice at 12 MPI, which had experienced 
more severe gastritis for a longer period, suggesting that gastritis is necessary but not sufficient 
to induce mutagenesis. Similarly, duration of infection in itself was insufficient, as mutation 
frequency was not increased in male mice at 12 MPI. Based on the GHAI, infected male mice 
had a weaker response at 6 MPI compared with infected females, whereas by 12 MPI, the level 
of pathologic process was similar in both sexes. These data suggest that the delayed onset of 
severe gastric lesions in males reduced the duration of their exposure to chronic gastritis, 
protecting them from mutagenesis, highlighting the importance of severity and duration of the 
inflammatory response. 
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Our findings agree with current paradigms for the role of inflammation in carcinogenesis 
(4) and with the more severe pathology induced in female versus male C57BL/6 mice infected 
with Helicobacter spp. (42). Our observations in female gpt delta mice are consistent with 
previously reported data from female C57BL/6 Big Blue mice infected with H. felis, which 
induces more severe gastritis at earlier time points than H. pylori, effectively increasing the 
amount of DNA damage inflicted after infection (23, 43, 44). The higher mutation frequency 
found at 7 MPI in H. felis-infected female C57BL/6 Big Blue mice may be comparable to that 
occurring at 12 MPI in female gpt delta mice infected with H. pylori, based on increased 
inflammation and epithelial proliferation. In contrast, another study of DNA point mutations 
induced by H. pylori in male Big Blue mice reported that, although mutant frequency was 
increased at 6 MPI, it returned to control levels by 12 MPI (22). The decrease between 6 and 12 
MPI was accompanied by loss of iNOS expression and reversion of the mutation spectrum to 
one indistinguishable from that of uninfected mice (22). Two possible explanations for these 
results are that (i) the increase in mutations at 6 MPI may have reflected jackpot mutations, 
because clonal expansion was not assessed or (ii) loss of infection resulted in absence of iNOS 
expression and reversion of the mutation spectrum. An additional factor pertinent to 
comparisons of previous mutagenesis studies involving gastric infection by Helicobacter spp. is 
the endogenous Helicobacter status of the mouse colony (45). We recently reported that 
concurrent, subclinical infection in C57BL/6 mice with nongastric Helicobacter bilis significantly 
reduced H. pylori-associated premalignant gastric lesions at 6 and 11 MPI (46). This 
immunomodulatory effect could affect observed mutagenic responses, and it is unknown 
whether Big Blue mice used in previous studies were free of enteric Helicobacter spp. 
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Our observed sex-based effects on mutagenesis induced by H. pylori in mice has not 
been reported previously, but sex bias has been found in other responses to infection. In H. 
pylori–infected Mongolian gerbils, immune responses and cytokine production were reported 
to be affected by sex (47), and H. pylori preferentially induced cancer in male INS-GAS mice 
(48). Greater female susceptibility to gastric Helicobacter infections has been noted previously 
in WT C57BL/6 mice (42), whereby females infected with H. felis experience an earlier onset of 
gastric inflammation, epithelial hyperplasia, atrophy, and apoptosis (42). Mechanisms 
responsible for the observed sex-based effects are incompletely understood, but findings to 
date collectively indicate that sex is an important variable, affecting strength of the host 
response to H. pylori infection, which in turn determines disease outcome.  
The typical host response to Helicobacter infection is a proinflammatory Th1 response 
that causes chronic gastritis (49, 50). However, mouse strains such as BALB/c, which mount a 
strong antiinflammatory Th2 humoral immune response to H. pylori infection, develop less 
severe disease (51). We have previously shown that modulation of the Th1 response by an 
increased Th2 response reduces pathology associated with concurrent helminth infections (27). 
In the current study, the immune response of females to H. pylori infection was biased toward a 
greater Th1/Th2 ratio compared with males at both 6 and 12 mo. Higher Th1/Th2 ratios reflect 
a stronger inflammatory response to H. pylori infection. Furthermore, proinflammatory Th17 
cells and regulatory T cells have been recently shown to modulate host responses to H. pylori 
(52, 53). H. pylori-specific Th17 immunity, mediated by IL-17 (54), increases inflammation 
unless it is suppressed by regulatory T cells, which are up-regulated by TGF-β and IL-10 (53). 
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Higher levels of inflammation, epithelial defects, and atrophy were indeed observed in infected 
females at 6 MPI. At 12 MPI, the level of serum IgG2c was significantly elevated in infected 
females, reflective of increased proinflammatory cytokines in the gastric mucosa, and is 
consistent with the reduction in H. pylori colonization levels. The earlier onset of severe 
pathologic process caused by the Th1- and Th17-biased response to H. pylori was also 
associated with the increase in point mutations seen at 12 MPI.  
In summary, we have shown that chronic H. pylori infection can cause premalignant 
gastric lesions and induce point mutations consistent with inflammatory processes. As our data 
are derived from analysis of nontranscribed DNA, it serves as an indicator of unbiased 
mutations reflecting genetic changes during the early stages of tumor initiation in inflamed 
tissues. At 12 mo, H. pylori-infected female C57BL/6 mice accumulate more inflammation-
mediated point mutations compared with males as a result of a greater Th1-biased response to 
infection inducing earlier and more severe pathology. The sex-biased increase in premalignant 
gastric lesions and induction of mutations highlights the importance of taking into account sex-
based effects in future studies of inflammation-driven disease. 
 
2.3 Materials and Methods 
Bacteria and Animals. H. pylori strain SS1 was grown on blood agar or Brucella broth with 5% 
FBS as described in SI Materials and Methods. Specific pathogen-free (including Helicobacter 
spp.) male and female C57BL/6 gpt delta mice (24) were infected by oral gavage with H. pylori 
SS1 or sham-dosed. At the indicated times, mice were euthanized, gastric tissue collected 
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for histopathology and DNA and RNA extraction, and sera were collected for cytokine and Ig 
analysis. Gastric lesions were scored for inflammation, epithelial defects, atrophy, hyperplasia, 
mucous metaplasia, hyalinosis, intestinal metaplasia, and dysplasia using previously published 
criteria (55). The GHAI is the sum of inflammation, epithelial defects, atrophy, hyperplasia, 
intestinal metaplasia, and dysplasia scores. A detailed description of the husbandry, treatment, 
and histopathology is provided in SI Materials and Methods. 
DNA Isolation and in Vitro Packaging. Genomic DNA was extracted from gastric tissue using 
RecoverEase DNA Isolation Kit (Stratagene) following the manufacturer’s recommendations. λ-
EG10 phages were packaged in vitro from genomic DNA using the Transpack Packaging Extract 
(Stratagene) following the instructions.  
gpt Assay and Sequencing Analysis. The 6-TG selection assay was performed as previously 
described (24, 56). Briefly, phages rescued from murine genomic DNA were transfected into E. 
coli YG6020 expressing Cre recombinase. Infected cells were cultured on plates containing 
chloramphenicol (Cm) and 6-TG for 3 d until 6-TG–resistant colonies appeared. To confirm the 
6-TG–resistant phenotype, colonies were restreaked on plates containing Cm and 6-TG. 
Confirmed 6-TG–resistant colonies were cultured, and a 739-bp DNA product containing the gpt 
gene was amplified by PCR. DNA sequencing of the gpt gene was performed by the Biopolymers 
Facility at Harvard Medical School (Boston, MA) with AMPure beads (Agencourt) and a 3730xL 
DNA Analyzer (Applied Biosystems). Sequences were aligned with the E. coli gpt gene (GenBank 
M13422.1) (57) using Geneious (Biomatters). Mutations were classified as transitions, 
transversions, deletions, insertions, or complex (multiple changes). Duplicate mutations at the 
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samesite within an individual tissue were excluded to account for clonal expansion of sibling 
mutations. More information on primers and methods is provided in SI Materials and Methods. 
Spi– Assay. The Spi– assay was performed as described in SI Materials and Methods. Briefly, 
phages rescued from murine genomic DNA were transfected into E. coli strains with or without 
P2 lysogen. Infected cells were cultured overnight on λ-trypticase agar plates to allow plaque 
formation. The inactivation of red and gam genes was confirmed by respotting plaques 
on another E. coli strain with P2 lysogen (24). 
mRNA Expression. RNA was extracted from gastric tissue and reverse transcribed to cDNA. 
Quantitative real-time PCR was performed using TaqMan Gene Expression Assays (Applied 
Biosystems). TaqMan primers and analysis methods are described in SI Materials and Methods. 
H. pylori Detection. H. pylori levels in the gastric mucosa were quantified by real-time 
quantitative PCR assay of gastric DNA as described in SI Materials and Methods. A threshold of 
15 copies of the H. pylori genome was set as the lower limit for a positive sample.  
Serum IgG Isotype Measurement. Sera were analyzed for H. pylori-specific IgG2c and IgG1 by 
ELISA. Additional information on the measurements is provided in SI Materials and Methods. 
Statistical Analysis. Two-way ANOVA followed by Bonferroni posttests were used to analyze 
GHAI and mRNA expression values. Student two-tailed t-tests were used to analyze mutant and 
mutation frequency data and serum IgG isotypes. Poisson distribution analysis was used to 
determine hotspots at a 99% confidence level (58). For some analyses, age-matched controls of 
both sexes were grouped when no statistical differences were detected between sexes. 
Analyses were done with GraphPad Prism, version 4.0, or Microsoft Excel 2002. P < 0.05 was 
considered significant. 
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2.5 Tables and Figures 
 
 
 
  Fig. 2.1. H. pylori infection elicits more gastric pathologic processes in female mice at 6 mo. H. pylori 
infection increased the GHAI in both male and female C57BL/6 mice at 6 and 12 mo. At 6 mo of 
infection, infected females had significantly more pathologic processes than infected males. 
Uninfected males (○; 6 MPI, n = 7; 12 MPI, n = 3), uninfected females (▽ ; 6 MPI, n = 5; 12 MPI, n = 3), 
infected males (▼ ; 6 MPI, n = 4; 12 MPI, n = 5) and infected females (◆ ; 6 MPI, n = 4; 12 MPI, n = 6). 
Bar represents the mean. *P < 0.05, **P < 0.01, and ***P < 0.001. 
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 Fig. 2.2. The effect of H. pylori infection on H. pylori–specific IgG1 and IgG2c.Serum levels of IgG were 
measured by ELISA in uninfected and H. pylori–infected mice. (A) H. pylori–infected mice (gray bars; 6 
MPI, n =9; 12 MPI, n=12) developed a greater IgG1 response after 12 mo of infection compared with 
uninfected mice (white bars; 6 MPI, n = 6; 12 MPI, n = 6; P < 0.05). H. pylori–infected mice developed a 
greater IgG2 response after 6and 12mo of infection (P < 0.01 and P < 0.001, respectively). (B) At 12 mo, 
infected female mice (light graybars; 6MPI, n=4; 12MPI, n=6) had substantially increased IgG2c 
compared with infected males (dark gray bars; 6 MPI, n = 5; 12 MPI, n = 6) at 12 mo and infected 
females at 6mo (P<0.05, both).Data are mean (SE) of mice in different treatment groups. *P < 0.05, 
**P < 0.01, and ***P < 0.001. 
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  Fig. 2.3. H. pylori levels in the stomach were lower in infected females at 12 MPI. Values represent the 
number of H. pylori organisms per copies of mouse 18s rRNA. At 6 MPI, one infected female mouse 
was under the threshold of detection (15 copies of H. pylori). At 12 MPI, four infected females and one 
infected male were undetectable. Infected males (▼; 6 MPI, n = 5; 12MPI, n = 6) and infected females 
(▽; 6MPI, n = 4; 12MPI, n = 6). Bar represents the mean. 
Detection threshold 
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Fig. 2.4. Twelve-month infection with H. pylori increases the frequency of point mutations in female 
mice. The mutation frequency of point mutations was determined by the gpt assay in uninfected mice 
(white bars; 6 MPI, n = 13; 12 MPI, n = 15), H. pylori-infected males (light gray bars; 6 MPI, n = 4; 12 
MPI, n = 5) and H. pylori-infected females (dark gray bars; 6 MPI, n = 9; 12 MPI, n = 11). Control mice of 
both sexes were grouped for this analysis. Data are mean (SEM) of mutation frequency of mice in 
different treatment groups. *P < 0.05. 
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  Fig. 2.5. Mutant frequency of deletions was unchanged by H. pylori infection. H. pylori infection did not 
alter the levels of deletions detected by the Spi− assay in uninfected mice (white bars; 6 MPI, n = 12; 
12 MPI, n = 16), H. pylori-infected males (light gray bars; 6 MPI, n = 3; 12 MPI, n = 5) and H. pylori-
infected females (dark gray bars; 6 MPI, n = 9; 12 MPI, n = 12). Control mice of both sexes were 
grouped for this analysis. Data are mean (SEM) of mutant frequency of mice in different treatment 
groups. 
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2.6 Supplemental Information 
SI Materials and Methods 
Bacteria and Animals. H. pylori strain SS1 was cultured on blood agar (TSA with sheep blood; 
Remel) or Brucella broth with 5% FBS under microaerobic conditions (10% H2, 10% CO2, 80% 
N2). Specific pathogen-free (including Helicobacter spp.) male and female C57BL/6 gpt delta 
mice (1) bred and maintained in our facilities were used. Mice were maintained in a facility 
accredited by the Association for Assessment and Accreditation of Laboratory Animal Care 
International, housed in polycarbonate microisolator cages on hardwood bedding, and 
provided standard rodent chow and water ad libitum. All protocols were approved by the 
Massachusetts Institute of Technology Committee on Animal Care. 
Experimental Design. Twenty-one 6- to 8-wk-old gpt delta mice (11 male and 10 female) were 
infected by oral gavage with 0.2 mL of H. pylori SS1 on alternate days for a total of three doses 
of approximately 1 × 108 organisms per dose (2, 3). Twelve age-matched uninfected mice were 
dosed with 0.2 mL of tryptic soy broth. Mice were euthanized at 6 or 12 MPI. After CO2 
asphyxiation, blood was immediately collected by cardiac puncture and the stomach and 
proximal duodenum were removed and incised along the greater curvature. For histopathologic 
study, linear gastric strips from the lesser curvature were fixed overnight in 10% neutral-
buffered formalin, embedded, sectioned at 4-μm thickness, and stained with H&E. A board-
certified comparative pathologist (B.H.R.), blinded to treatment groups, scored gastric lesions 
on an ascending scale of 0 to 4 for inflammation, epithelial defects, atrophy, hyperplasia, 
mucous metaplasia, hyalinosis, intestinal metaplasia, and dysplasia according to previously 
published criteria (4). A GHAI was calculated as the sum of scores for inflammation, epithelial 
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defects, atrophy, hyperplasia, intestinal metaplasia, and dysplasia. Hyalinosis and mucous 
metaplasia were excluded from the GHAI as they have been observed to develop 
spontaneously in mice (4, 5). Data for two infected male mice with GHAI scores of 0 were 
excluded from all subsequent analyses, unless specifically noted, as a result of their lack of 
response to infection. The remainder of the gastric tissue was snap-frozen in liquid nitrogen and 
stored at –70 °C for DNA and RNA analyses. 
Assay for gpt Mutagenesis. Fifty-seven samples from 33 mice were processed according to the 
gpt delta mutagenesis procedures to determine frequencies of point mutations (6-TG selection 
assay) and large deletions (Spi– assay). Animals were selected for analysis based on 
histopathological findings, and analyses of tissues from 15 mice were repeated two or three 
times to verify assay reproducibility. Animals studied at 6 MPI included five uninfected males, 
four uninfected females, four infected males, and four infected females; those at 12 MPI were 
three uninfected males, three uninfected females, four infected males, and six infected 
females. In the 6-TG selection assay procedure, genomic DNA was extracted from gastric tissue 
previously kept at −70 °C using the Recoverease DNA Isolation Kit (Stratagene). The Transpack 
Packaging Extract (Stratagene) was used to recover λ-EG10 phages from tissue DNA, and the 6-
TG selection assay was performed as previously described (1, 6). Briefly, E. coli expressing Cre 
recombinase was infected with rescued λ-EG10 phages and incubated for 72 h on selective 
media containing either Cm (25 μg/mL) or Cm (25 μg/mL) plus 6-TG (25 μg/mL) to select 
colonies possessing Cm acetyltransferase activity only (survival) or both Cm acetyltransferase 
activity and loss of gpt function (mutant). Recovered gpt mutants were restreaked onto 
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Cm and 6-TG plates for confirmation. Mutant frequency was expressed as the mutant/survivor 
ratio. 
Confirmed 6-TG–resistant mutants were boiled and pelleted to obtain DNA template for 
sequencing of the gpt gene. A 739-bp DNA fragment containing the gpt gene was amplified by 
PCR using primers P1 (forward) 5′-TACCACTTTATCCCGCGTCAGG-3′ and primer P2 (reverse) 5′-
ACAGGGTTTGGCTCAGGTTTGC-3′. PCR amplification was carried out using Vent DNA 
polymerase (New England Biolabs) on a DNA Engine PTC-200 (MJ Research). The reaction was 
started by incubation at 94 °C for 5 min, followed by 30 cycles of 30 s at 94 °C, 30 s at 56 °C, and 
120 s at 72 °C and finalized by incubating at 72 °C for 5 min before storing at 4 °C (6). PCR 
product cleanup and DNA sequencing were performed by the Biopolymers Facility at Harvard 
Medical School (Boston, MA) using AMPure beads (Agencourt) and a 3730xL DNA Analyzer 
(Applied Biosystems) using sequencing primers A (forward) 5′-GAGGCAGTGCGTAAAAAGAC- 
3′ and A2 (forward) 5′-CTCGCGCAACCTATTTTCCC-3′. Sequences were aligned with the E. coli gpt 
gene (GenBank M13422.1) (7) with Geneious software (Biomatters). Mutations were 
individually corroborated by multiple sequence results and classified as transitions (G:C to A:T, 
A:T to G:C), transversions (G:C to T:A, G:C to C:G, A:T to T:A, A:T to C:G), deletions (1 bp or ≥2 
bp), insertions, or complex (multiple changes). A mutation found repeated at the same site 
within the same sample was excluded from frequency calculations to eliminate 
overrepresentation caused by sibling mutations. Samples from 33 mice were sequenced. 
Mutation frequencies calculated for each animal and each mutation type were subjected to 
statistical analysis. 
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Spi– Assay for Large Deletions. The Spi– assay was carried out as described (1). E. coli strains 
XL-1 Blue MRA or XL-1 Blue MRA P2 lysogen were infected with phages rescued from mouse 
DNA and incubated for 20 min without shaking at 37 °C. The suspensions were poured on λ-
trypticase agar plates (1% trypticase peptone, 0.5% NaCl, 1.2% agar), which were then 
incubated overnight at 37 °C to select for plaques formed in MRA P2 lawns containing phage 
with inactivated red and gam genes. Plaques formed in MRA lawns were counted to determine 
titer. Mutant phages were picked and spotted onto lawns of E. coli strain WL95 P2 lysogen 
(WL95 P2) to confirm the inactivation of red and gam genes. The mutant frequency was 
expressed as mutant plaque/titer ratio. E. coli strain LE392 was infected with recovered Spi– 
mutant phages to obtain phage lysates (8). 
Quantitative Analysis of mRNA Expression. Total RNA was extracted from gastric tissue using 
TRIzol reagent (Invitrogen) and the RNeasy kit (Qiagen). cDNA was synthesized from 5 μg of 
total RNA with SuperScript II RT (Invitrogen). Quantitative real-time PCR was performed on 
cDNA using TaqMan gene expression assays (Applied Biosystems) specific for IFN-γ (assay 
Mm99999071_m1), TNF-α (Mm99999068_m1), IL-10 (Mm00439616_m1), IL-17 
(Mm00439619_m1), iNOS (NOS2 or iNOS; Mm00440485_m1), and GAPDH (Mm99999915_g1). 
mRNA levels for each cytokine were normalized to the mRNA level of internal control GAPDH 
and compared with the data of uninfected mice using the ΔΔCT method (User Bulletin 2; 
Applied Biosystems). Data were log10-transformed for analysis.  
Detection of H. pylori Infection by Quantitative PCR. To quantify infection levels of H. pylori 
strain SS1 within the gastric mucosa, a real-time quantitative PCR assay targeting H. pylori 
urease B was used (9, 10). DNA was extracted from gastric tissue using the High Pure PCR 
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Template purification kit (Roche). A standard curve was generated by using serial 10-fold 
dilutions of H. pylori SS1 genome copies (from 5 × 105 to 5), estimated from an average 
H. pylori genome size of 1.66 Mb (11, 12). Copy numbers of the gastric H. pylori genome were 
standardized using micrograms of murine chromosomal DNA determined by quantitative 
PCR using a mammalian 18S rRNA gene-based primer and probe mixture (Applied Biosystems) 
as described previously (13). A threshold of 15 copies of the H. pylori genome was set as 
the lower limit for a positive sample. Although five infected female mice and one infected male 
mouse had H. pylori levels under the established threshold, these mice had increased cytokine 
expression and higher GHAI scores consistent with that of mice infected with H. pylori and not 
uninfected mice. Despite the low counts, these six mice were considered infected during 
subsequent analyses as a result of serological and histological evidence. Conversely, the two 
mice with the highest number of H. pylori copies (one infected male at 6 MPI and one infected 
male at 12 MPI) had a GHAI of 0 and cytokine production similar to uninfected controls, 
indicating an aberrant response to infection, and they were excluded from subsequent analyses 
unless otherwise noted as a result of lack of pathology.  
Serum IgG Isotype Measurement. Serum was analyzed for H. pylori-specific IgG2c and IgG1 by 
ELISA using an outer membrane protein preparation from H. pylori (SS1 strain) as described 
previously (14). In brief, 96-well flat-bottom plates were coated with 100 μL of antigen (10 
μg/mL) overnight at 4 °C, and sera were diluted 1:100. Biotinylated secondary antibodies for 
detecting IgG2c and IgG1 were from clone 5.7 and A85-1 (BD Pharmingen). Incubation with 
extravidin peroxidase (Sigma-Aldrich) was followed by treatment with 2,2′-azino-bis (3-
ethylbenzthiazoline-6-sulphonic acid) substrate (Kirkegaard and Perry Laboratories) for color 
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development. Optical density was recorded on a plate reader according to the manufacturer’s 
protocol (VersaMax; Molecular Devices). 
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Supplemental images  
Fig. 1.S1. H. pylori-infected mice display significant gastric histomorphological alterations with an accelerated 
development of gastric pathologic processes in females. (A–D) H&E staining of gastric tissue at 6 MPI. (A) 
Uninfected female control shows normal gastric mucosa. (B) H. pylori-infected male mice exhibiting mild gastric 
mucosal inflammation, associated oxyntic loss, metaplasia, and mild foveolar hyperplasia. (C) H. pylori-infected 
female mice had significantly higher histological activity than uninfected mice and infected males as shown by 
the moderate gastric inflammation, associated oxyntic loss, glandular metaplasia, prominent epithelial defects, 
moderate foveolar hyperplasia, and mild dysplasia. (D) Higher magnification of C shows metaplastic glands with 
architectural distortion and loss of orientation (dysplasia). (E–H) H&E staining of gastric tissue at 12 MPI. (E) 
Uninfected male control with minimal gastric morphological changes. (F) H. pylori-infected male with moderate 
inflammation, prominent oxyntic loss, hyperplasia, metaplasia, and mild dysplasia. (G) Higher magnification of F 
shows metaplastic and dysplastic glands. (H) H. pylori-infected female had similar gastric pathological changes as 
male mice. (Scale bars: 75 μM in A, D, E, and G; 150 μM in B, C, F and H.) 
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Fig. 2.S2. H. pylori infection increases the expression levels of IFNγ, TNFα, iNOS, and IL-17. IFNγ, TNFα, iNOS, and IL-
17 transcript levels relative to GAPDH in the gastric mucosa are presented in male (A) and female (B) mice. 
Uninfected mice at 12 mo (white bars; males, n = 3; females, n = 3) and H. pylori-infected mice at 6 mo (light gray 
bars; males, n = 4; females, n = 4) and 12 mo (dark gray bars; males, n = 5; females, n = 6) are presented. H. pylori 
infection increased expression of IFNγ, TNFα, IL-17, and iNOS in both sexes at 6 and 12 mo. *P < 0.05, **P < 0.01, 
and ***P < 0.001. 
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Fig. 2.S3. H. pylori infection targets specific hot spots in the gpt gene. The distribution of mutations induced in 
the gpt gene was determined by sequencing analysis of 411 mutants. Hot spots seen in uninfected and infected 
mice are denoted by▼. (A) Spectra of all uninfected mice. Not shown is a complex mutation from 407 to 429. A 
hot spot mainly seen in uninfected males is marked by □. (B) Spectra of all infected mice. Not shown is a 
complex mutation from 389 to 419. Mutations at 142 and 174 were second mutations. Hot spots mainly seen in 
infected mice of both sexes are represented by ◇ and hot spots seen mostly in infected females are marked •. 
N* represents 3× mutations, d represents a deletion. Underlined mutations denote a single mutation. 
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Abstract 
Gastric cancer (GC) is a male-predominant cancer associated with Helicobacter pylori infection. 
Epidemiological studies suggest that estrogens reduce GC risk and our previous studies 
demonstrated that 17β-estradiol (E2) administered prior to H. pylori infection in INS-GAS mice 
decreases GC risk. We examined the effect of E2 and the anti-estrogen, Tamoxifen (TAM), on H. 
pylori-induced gastric cancer in hypergastrinemic male and female INS-GAS mice infected with 
H. pylori SS1. Sixteen weeks after infection with H. pylori, mice were treated with E2, TAM, both 
E2 and TAM, or placebo subcutaneously implanted pellets for 12 weeks.  Gastric histopathology 
was evaluated at 16 and 28 weeks post-infection (WPI). At 28 WPI, global gastric gene 
expression was evaluated, and serum inflammatory cytokines measured. At 16 WPI, H. pylori 
infection induced robust gastric pathology in mice of both genders (P<0.001).  After 12 weeks of 
treatment, gastric precancerous lesions were significantly reduced in H. pylori-infected E2-, 
TAM- or dual-treated males compared to H. pylori-infected untreated males (P<0.001, 0.01 and 
0.01, respectively).  Forty percent of infected untreated males developed intramucosal gastric 
carcinoma while cancer was not detected in any group treated with E2 or/and TAM.  In contrast, 
TAM did not alter pathology in females regardless of infection status. Infected E2 males 
differentially expressed 363 genes compared to infected untreated males (Q<0.05) while 
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infected TAM males differentially expressed 144 genes compared to controls (Q<0.05). 
Differentially expressed genes from E2 or TAM males were associated with cancer and cellular 
movement as determined using molecular network analysis, indicating similar mechanisms in 
the reduction of gastric lesions.  E2 or TAM decreased expression of metastasis associated genes 
(PLAUR and MMP10) and increased two Wnt signaling repressors (Fzd6 and SFRP2). Gastric 
expression of cytokines involved in cellular movement (CXCL1 and IL-1α) were reduced in E2 or 
TAM treated males.  CXCL1, a potent neutrophil and macrophage chemokine, was also 
decreased in the serum of infected E2 males and infected untreated females (P<0.05 and 0.001 
respectively) compared to controls.  A decrease in neutrophil infiltration was observed by 
immunohistochemistry in infected E2 and TAM males compared to untreated males (P < 0.01 
and P = 0.07, respectively).  Our results demonstrate that E2 and TAM downregulate CXCL1, 
limit recruitment of innate immune cells and therapeutically prevent H. pylori-induced gastric 
cancer.    
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3.1 Introduction 
Acting through multiple, complex mechanisms that are incompletely understood, 
chronic inflammation induced by Helicobacter pylori is a significant risk factor for gastric 
adenocarcinoma (GC).  Chronic inflammation induced by H. pylori infection increases lifetime 
risk of developing gastritis, duodenal and gastric ulcers, mucosa-associated lymphoid tissue 
(MALT) lymphoma, mucosal atrophy and gastric carcinoma 68,85.  Indeed, H. pylori is classified a 
group I human carcinogen by IARC due to its impact on gastric cancer incidence, the second 
most frequent cause of cancer-related death worldwide 34. However, age-standardized and 
cumulative incidence rates of gastric adenocarcinoma are twice as high in men as in women 
with a 2.5-fold difference around age 6011.  The age-specific pattern of the M/F gastric cancer 
incidence curve is a global phenomenon, equally seen in populations with high and low risk for 
GC.  Given the high prevalence of H. pylori worldwide, this implies that intrinsic sex differences 
modulate H. pylori-induced carcinogenesis irrespective of other environmental factors, but the 
mechanisms mediating these differences are unknown.   
Estrogens have been associated with the protection against GC as postmenopausal 
women experience an increase in GC incidence11.  Epidemiological studies indicate that delayed 
onset of menopause, increased length of fertility life and hormone therapies in men and 
women were associated with decreased GC risk13.  Postmenopausal hormone replacement 
therapy (HRT) may lower the rate of gastrointestinal cancer, particularly colonic cancer111-113.  
Prostate cancer patients treated with estrogen had a decreased risk of gastric cancer110.  
Additionally, there is epidemiological data linking the usage of anti-estrogen therapy, 
particularly the breast cancer drug Tamoxifen (TAM), with increased incidence rates of 
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gastrointestinal malignancies.  Due to its suppression of estrogen receptor positive breast 
cancer, TAM is considered an antagonist of estrogen signaling, but considerable evidence exists 
demonstrating that TAM can also act as an agonist leading to increased incidence of 
endometrial cancers in postmenopausal women114-115,154.  However, TAM's function in the 
stomach and its association with gastrointestinal cancers, and GC in particular, is not clear; one 
study reports no effect115 while others have associated TAM treatment with increased risk of 
GC116-118.  Due to their retrospective nature, the studies assessing the effects of estrogen and 
TAM on GC were unable to control for H. pylori infection, a major confounding factor in these 
studies13,110,118.  
Transgenic INS-GAS mice over-express human gastrin, a phenotype associated with 
increased risk for gastric glandular atrophy and cancer in humans30,155. INS-GAS mice infected 
with H. pylori or H. felis develop gastric carcinomas 28 weeks post-infection (WPI) in a male-
predominant fashion141,156.This process parallels the development of human gastric cancer after 
decades of chronic H. pylori gastritis14,30,141,156.  Similar to human patients, INS-GAS mice 
progress to GC following development of gastric atrophy, hypochlorhydria, intestinal metaplasia 
and dysplasia18,68,141,156.  Antibiotic eradication therapy targeting H. pylori in male INS-GAS mice 
reduced GC risk, but this effect was most pronounced with antibiotic treatment at 8 WPI 
compared to mice treated at 12 or 22 WPI61,157, implying that the progression of H. pylori 
carcinogenesis may be reversible up to a point. We previously demonstrated that 
ovariectomized female INS-GAS mice developed H. pylori-induced GC whereas E2 
supplementation of ovariectomized female mice was protective14.  We also reported that E2 
treatment, but not castration, prior to H. pylori infection attenuated gastric lesions by increasing 
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Foxp3+ and interleukin 10 (IL-10) expression and decreasing IFN- IL- expression15. 
In this study, we employed the INS-GAS mouse to determine the effects of E2 and TAM 
treatment on chronically H. pylori-infected mice and examined the mechanisms by which E2 
and/or TAM affect gastric lesions in male and female mice.  Following 16 weeks of sham or H. 
pylori infection, pellets containing placebo, E2, TAM, or both E2 and TAM were subcutaneously 
implanted in male INS-GAS mice, while placebo or TAM pellets were implanted in female mice.  
E2 was administered via the pellets to determine its therapeutic effect during H. pylori infection.  
We sought to clarify TAM's effects on GC incidence, expecting exacerbation of precancerous 
gastric lesions (TAM alone) or the blocking of E2's protective effects (E2 and TAM treatment).  At 
28 WPI, we characterized the effects of E2 and TAM on histopathologic changes in the stomach, 
serum levels of inflammatory cytokines, global gastric gene expression and gastric immune cell 
infiltration.   
 
3.2 Materials and Methods 
Bacteria and Mice. Helicobacter pylori SS1 was cultured on blood agar (TSA with sheep blood, 
Remel, Lenexa, KS) or Brucella broth with 5% fetal bovine serum under microaerobic conditions 
(10% H2, 10% CO2, 80% N2).One hundred and fifty-one (52 females, 99 males) specific 
pathogen-free (including Helicobacter spp.) INS-GAS mice on a FVB background were used in 
this study. Mice were maintained in a facility accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care International, housed on hardwood bedding in 
microisolator, solid-bottom polycarbonate cages and fed regular chow diet (Prolab RMH3000, 
LabDiet, Richmond, IN) and water ad libitum. All protocols were approved by the MIT 
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Committee on Animal Care. 
Experimental design. Eight-week-old male and female mice were either infected by oral gavage 
with approximately 1 × 108 colony forming units of H. pylori SS1 (47 males and 29 females) or 
dosed with broth only (52 males and 23 females) on alternate days for a total of 3 doses137,158.   
At 4 and 16 weeks post-infection (WPI), 4 and 20 mice, respectively, were euthanized to confirm 
H. pylori infection by PCR. At 16 WPI, pathology was assessed to establish severity of gastritis 
prior to pellet implantation.  The remaining mice were divided into six groups for pellet 
implantation: (i) untreated males (n = 23), (ii) E2-treated males (n = 21), (iii) TAM-treated males 
(n = 23), (iv) E2- and TAM-treated males (n = 19), (v) untreated females (n = 19), and (vi) TAM-
treated females (n = 21).  At 28 WPI, the mice were euthanized and the presence of pellets was 
confirmed.  Mice missing pellets were excluded, and the following were used in subsequent 
analyses (i) untreated males (10 infected, 12 uninfected), (ii) E2-treated males (9 infected and 
10 uninfected), (iii) TAM-treated males (7 infected and 6 uninfected), (iv) E2- and TAM-treated 
males (4 infected and 7 uninfected), (v) untreated females (10 infected and 9 uninfected), and 
(vi) TAM-treated females (9 infected and 1 uninfected).  Three of 9 infected E2 males were 
euthanized before 28WPI due to poor body condition.  These 3 mice were excluded from serum 
cytokine analysis. 
Subcutaneous implantation of placebo, 17-β estradiol and Tamoxifen pellets. Surgical 
placement of pellets containing E2 or TAM was performed using sterile techniques and under 
general anesthesia with isoflurane.  All the mice received intraperitoneal injections of 0.5 ml of 
warm lactated Ringer’s solution prior to surgery. Time-release placebo (5 mg, 90 day release NC-
111), E2 (0.25 mg, 90 day release NE-121), TAM (15 mg, 90 day release NE-361) or both E2 and 
92 
 
TAM pellets (Innovative Research of America, Sarasota, FL) were placed subcutaneously at 16 
WPI. Skin incisions were closed using 9 mm surgical clips (MikRon Autoclip, Clay Adams, 
Parsippany, NJ).  The E2 timed-release pellet results in a serum E2 level in the range from 
proestrus levels (~45 pg/ml) to slightly supraphysiological (up to 100 pg/ml) (14).   The TAM 
pellet was expected to result in serum TAM level in the range of 2-3 ng/ml (Personal 
communication from Innovative Research of America, Sarasota, FL). 
Sample collection and histological analysis. Immediately following CO2 euthanasia, blood was 
collected by cardiac puncture, serum was separated and stored at -80°C.  Reproductive tissues 
(testes and epididymis or uterus) were removed and weighed.  The stomach and proximal 
duodenum were removed and incised along the line of the greater curvature. Luminal contents 
were removed and the mucosa was rinsed with sterile PBS.   
Individual linear gastric strips from the lesser curvature were sectioned, flash frozen and 
stored at -80°C for DNA and RNA extraction.  For histopathologic evaluation, linear strips 
extending from the squamocolumnar junction to the proximal duodenum were taken along the 
lesser curvature and  fixed overnight in 10% neutral-buffered formalin.  Tissues were routinely 
processed and embedded in paraffin.  Four μm-thick sections were stained with hematoxylin 
and eosin (H&E) for microscopic examination. A board-certified comparative pathologist 
(N.M.P.), blinded to treatment groups, scored gastric lesions in the corpus on an ascending scale 
of 0 to 4 for inflammation, epithelial defects, atrophy, hyperplasia, mucous metaplasia, 
hyalinosis, intestinal metaplasia, and dysplasia according to previously published criteria122.  
Gastric lesions in the antrum were also scored on an ascending scale of 0 to 4 for inflammation, 
epithelial defects, hyperplasia and dysplasia.  A dysplasia score of 3 was considered carcinoma 
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in situ or low-grade gastrointestinal intraepithelial neoplasia (GIN). In addition, a dysplasia score 
of 3.5-4 represented intramucosal carcinoma or high-grade GIN122,159. Both low grade and high-
grade GIN were classified as gastric cancer.  A gastric histologic activity index (GHAI) was 
calculated as the sum of scores for inflammation, epithelial defects, atrophy, hyperplasia, 
intestinal metaplasia, and dysplasia for the corpus and inflammation, epithelial defects, 
hyperplasia and dysplasia for the antrum. Hyalinosis and mucous metaplasia were excluded 
from the GHAI as they have been observed to develop spontaneously in mice122,160.   
Immunohistochemistry for neutrophils and macrophages. Levels of neutrophils and 
macrophages were quantified by immunohistochemistry as previously described (161) using 
antibodies for 1:75 myeloperoxidase (MPO) (RB-373-A; Thermo Scientific, Waltham, MA), a 
neutrophil-specific marker, and 1:150 F4/80 (MF48015; Caltag Laboratories, Burlingame, CA), a 
macrophage-specific marker, respectively, in 5 mice per group.  Cells expressing MPO+ or 
F4/80+ were counted in the corpus at a magnification of x40.  Five fields were counted per 
mouse and results are presented as the average number of MPO+ or F4/80+ cells/mm2 of 
stomach. 
Detection of H. pylori infection by PCR and qPCR. To confirm infection with H. pylori SS1 within 
the gastric mucosa, DNA was extracted from gastric tissue using the High Pure PCR Template 
purification kit (Roche).  At 4 and 16 WPI, primers (CHP1: 5'-AAAGCTTTTAGGGGTGTTAGGGGTTT, 
CHP2: 5'-AAGCTTACTTTCTAACACTAACGC) specific for the H. pylori ureC gene were used to 
confirm infection as described previously162.  A real-time quantitative PCR assay targeting H. 
pylori urease B was also used to quantify H. pylori infection levels156,163. A standard curve was 
generated by using serial 10-fold dilutions of H. pylori SS1 genome copies (from 5 × 106 to 50), 
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estimated from an average H. pylori genome size of 1.66 Mb164-165. Copy numbers of the gastric 
H. pylori genome were standardized using micrograms of murine chromosomal DNA 
determined by quantitative PCR using a mammalian 18S rRNA gene-based primer and probe 
mixture (Applied Biosystems) as described previously166. A threshold of 50 copies of the H. 
pylori genome was set as the lower limit of detection.  
17β-estradiol serum levels. Serum E2 levels were measured using commercially available 
enzyme immunoassay kits (Cayman Chemical Company, Ann Arbor, MI) with a serum dilution of 
1:4 and following the manufacturer's instruction.  The E2 kits have a limit of detection of 6.6 
pg/ml.   
Analysis of mRNA expression. A longitudinal strip of gastric tissue was frozen in liquid nitrogen 
and stored at -80°C.  Tissue was cut and weighed and total RNA was extracted using Trizol 
reagent (Invitrogen, Carlsbad, CA) and further cleaned up using RNase-free DNAse with an 
RNeasy kit (Qiagen Sciences, Germantown, MD).  Quality of the RNA was determined with the 
Agilent 2100 Bioanalyzer using a RNA 6000 Nano total RNA Kit (Agilent Technologies, Santa 
Clara, CA).   Total RNA was hybridized to Agilent 4x44K Whole Mouse Gene Expression 
Microarrays following the One-Color Microarray-Based Gene expression Analysis, Low Input 
Quick Amp Labeling protocol.  Briefly, the method utilizes a T7 RNA polymerase that amplifies 
RNA to cRNA while incorporating cyanine 3-labeled CTP.  Cy-3 incorporation and cRNA levels 
were measured with a NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, 
Inc., Wilmington, DE).  Arrays were scanned using an Agilent Microarray Scanner and data was 
extracted using Feature Extraction 9.1. 
Processing of the raw gene expression data was performed using Partek® Genomics 
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SuiteTM software (St. Louis, MO), where microarray data were first normalized by quantile using 
Robust Multi-Chip Average (RMA)167. Data were then filtered for expression levels above 
background noise (>abs[180]) which resulted in a reduction of probesets from 41,174 to 21,549. 
Differential gene expression was defined as a significant difference in mRNA levels between the 
groups compared where the following statistical requirements were set: (1) fold change of ≥ 1.5 
or ≤ - 1.5; (2) p-value < 0.05 (ANOVA); and (3) a false discovery rate corrected q-value < 0.05. To 
control the rate of false positives, q-values were calculated as the minimum positive false 
discovery rate that can occur when identifying significant hypotheses168. Comparisons were 
performed between 1) infected males with placebo vs. infected males with 17-β estradiol, and 
2) infected males with placebo vs. infected males with TAM.  Three microarrays were hybridized 
for each group except for infected males with TAM (n=2).   
Serum cytokine and chemokine levels. Serum protein levels of IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, 
IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ, KC (CXCL1), 
MCP-1, MIP-1α, MIP-1β, RANTES and TNF-α were measured using the Bio-Plex Pro Cytokine 
assay (Bio-Rad Laboratories, Hercules, CA).  Sera were diluted 1:4 in mouse-specific diluent and 
50 μl of standard, control and serum samples were added to 96 well plate containing 50 μl of 
antibody coated fluorescent beads (Bio-Plex Mouse Cytokine 23-Plex Panel).  Biotinylated 
secondary and streptavidin-PE antibodies were added to the plate and were read on the Bio-
Plex array reader on the high photomultiplier tube setting with sample levels quantified using 
regression analysis of the standard curve.   IL-9 data were not measured as insufficient counts 
were obtained. 
Statistical analysis. Two-way analysis of variance (ANOVA) followed by Bonferroni post-tests 
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were used to analyze the effect of sex and 17β-estradiol and Tamoxifen on gastric lesions.  
Student two-tailed t-tests were used to analyze serum hormone differences and neutrophil and 
macrophage infiltration. Mann-Whitney tests were used for serum cytokine responses.  
Analyses were done with GraphPad Prism 5.0 (GraphPad, La Jolla, CA), or Microsoft Excel 2007 
(Microsoft, Redmond, WA).  P-values <0.05 were considered significant.  
 
3.3 Results 
3.3.1 E2 and Tamoxifen reduce reproductive tissue size and serum E2 concentrations through 
different mechanisms. Efficacy of the placebo, E2, TAM and dual (E2 and TAM) treatments was 
confirmed histopathologically and by measurement of serum E2.  In male mice, E2 and dual 
treatment reduced the size of testes and seminal vesicles regardless of infection status.  Placebo 
and TAM treatment had no effect on testes and seminal vesicles.  E2 and dual treatment caused 
interstitial cystitis in male mice, which has been associated with E2169, and TAM treatment in 
males caused inguinal hernias (data not shown).  The ratio of reproductive tissues (testes and 
epididymis) to body weight was computed (Fig. 3.1).  Both E2 and dual-treated mice had a 
significant reduction in the ratio compared to either untreated or TAM mice regardless of 
infection status (all P < 0.001, except infected TAM males vs. infected dual males P < 0.01).  
Infection status had no effect on the ratio of reproductive tissues to body weight.  Serum E2 
levels were significantly higher in infected E2 males (137.9 ± 29.9 pg/ml) and dual-treated males 
(154.0 ± 15.5 pg/ml) compared to untreated males (88.9 ± 24.7 pg/ml)  (P < 0.05 and 0.001, 
respectively) (Fig. 3.2).     
In female mice, TAM reduced the ratio of uterus weight to body weight compared to 
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untreated mice (P < 0.001) in infected mice, but not in uninfected mice due to decreased cohort 
size resulting from mice removed from the study because of pellet loss (Fig. 3.1).  Infection 
status had no effect on the ratio of reproductive tissues to body weight.  E2 was significantly 
reduced in infected TAM females compared to uninfected untreated females (P < 0.001) (Fig. 
3.2).   
3.3.2 E2, Tamoxifen and dual treatment prevent gastric cancer in infected males. Gastric 
histopathology was evaluated at 16 and 28 WPI to determine the effect of E2, TAM and dual 
treatment on H. pylori pathogenesis.  H. pylori infection was confirmed at 4 and 16 WPI (n=14) 
by PCR.  Randomly selected uninfected control mice across all time points were negative for 
infection.  H. pylori levels were confirmed at 28 WPI by qPCR with no significant differences 
observed between groups (data not shown). 
At 16 WPI, H. pylori infection induced robust gastric pathology, as quantified by the 
gastric histologic activity index (GHAI), in mice of both genders (M=12.2 ± 1.9, F=11.4 ± 1.2) 
compared to uninfected controls (M=6.5 ± 1.8, F=5.1 ± 0.5)  (both P<0.001).  At this point, both 
infected and uninfected male mice were divided into 4 groups: a) untreated, b) E2, c) TAM and 
d) dual (E2 and TAM).  Infected and uninfected female mice were divided into 2 groups: a) 
untreated and b) TAM.   
After 12 weeks of treatment, GHAI was significantly reduced in infected E2 (12.6 ± 3.7), 
TAM (11.9 ± 0.7) and dual males (13.9 ± 1.9) compared to infected untreated males (17.1 ± 1.2) 
(P<0.001, 0.001 and 0.01, respectively) (Fig. 3.3A and 3.3C).  The reduction in overall gastric 
pathology demonstrated that therapeutic treatment with E2 protects the stomach from lesions 
caused by H. pylori, even after chronic inflammation has been established.   Unexpectedly, TAM 
98 
 
was protective, indicating that TAM may be acting agonistically in this model and activating 
estrogen receptor locally or systemically.  E2 and TAM treatment of infected male mice did not 
provide increased protection against gastric lesions in these mice, suggesting that the two 
treatments may progress through overlapping and/or nonadditive pathways.  Examining the 
individual histologic parameters in infected males, foveolar hyperplasia and dysplasia, two 
precancerous lesions, were found significantly decreased in all three treated groups. A 
significant decrease in inflammation was seen in relation to E2 or TAM treatments alone, while 
epithelial defects were only significantly decreased in relation to E2 treatment (Fig. 3.4 and 
Supplemental Table 3.S6). Intestinal metaplasia was significantly decreased in response to either 
E2 or combined E2 and TAM treatments. Forty percent of infected untreated males had high-
grade gastrointestinal intraepithelial neoplasia (GIN), or intramucosal carcinoma, while infected 
males treated with E2, TAM or both E2 and TAM had no incidence of GIN (Fig. 3.4 and 
Supplemental Table 3.S6).  No significant difference between all treated infected male groups 
and the untreated infected males was observed with regard to mucous metaplasia, hyalinosis 
and oxyntic atrophy.  While H. pylori pathogenesis normally occurs in the corpus in mice, E2, 
TAM and dual treatment (0.4 ± 0.2, 0.6 ± 0.4, 1.1 ± 0.5, respectively) also significantly reduced 
antral pathology compared to infected untreated males (2.5 ± 1.1) (all P<0.001).   
Uninfected male mice treated with E2 and mice with dual treatments also had less 
corpus pathology (3.0 ± 1.1 and 1.8 ± 1.1, respectively) compared to uninfected untreated males 
(5.8 ± 1.8) (P < 0.01 and 0.001, respectively), but uninfected TAM treated males were not 
protected (4.5 ± 0.9) (Fig. 3.3A, 3.3C).  In uninfected males, epithelial defects (including 
glandular ectasia, surface irregularities and mucosal erosions), oxyntic atrophy, and dysplasia 
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(characterized by loss of oxyntic cells, disorganization and branching of glands, loss of columnar 
glandular orientation, cell stratification, pleomorphism and atypia, as well as nuclear changes 
including anisokaryosis and loss of basal polarity) were all significantly decreased with E2 
treatment, as well as with E2 in combination with TAM, compared to untreated males. In 
uninfected male mice, TAM alone produced no significant changes in any of the lesion 
categories. Foveolar hyperplasia was significantly decreased only as a result of combined 
E2/TAM treatment.  There was no significant difference in any of the uninfected male groups 
with regard to inflammation, mucous metaplasia or intestinal metaplasia (characterized by 
columnar elongation of foveolar epithelium with or without interspersed goblet cells) (Fig. 
3.3C). In contrast, TAM treatment in females did not alter the levels of pathology in infected or 
uninfected females.   No significant changes in any of the lesion categories were found in any of 
the female groups (Fig. 3.3 and Supplemental Table 3.S6). 
3.3.3 E2 and Tamoxifen decreased MPO+ neutrophils and F4/80+ macrophages in the 
stomach. Neutrophils expressing myeloperoxidase (MPO) were present in lower numbers in the 
stomach of H. pylori-infected, E2 or TAM treated male mice (10 ± 2 cells/40x field and 13 ± 7 
cells/40x field, respectively) compared to H. pylori infected untreated males (21 ± 4 cells/40x 
field, P<0.01 and 0.072, respectively) (Fig. 3.5A).  H. pylori infection increased the infiltration of 
neutrophils into the stomach in infected male mice compared to uninfected male mice (3 ± 2 
cells/40x field, respectively, P <0.001) and in infected female mice compared to uninfected 
female mice (21 ± 6 cells/40x field vs.1 ± 2 cells/40x field, respectively, P <0.001) (Fig. 3.5A).  
Although neutrophil counts were decreased, infected male mice treated with E2 or TAM still had 
increased neutrophilic infiltration compared to untreated uninfected male mice (P< 0.001 and 
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P<0.05, respectively).  Neutrophils infiltrating the site of infection promote chronic 
inflammation and contribute to the recruitment of other inflammatory cells.  Interestingly, 
significant decreases were observed due to E2 in male mice, while decreasing trends were 
observed due to TAM in male mice, indicating deregulation of neutrophil recruitment through 
estrogen signaling.  
Macrophages expressing F4/80 were present in lower numbers in the stomach of H. 
pylori-infected, E2 or TAM treated male mice (28 ± 7 cells/40x field and 27 ± 8 cells/40x field, 
respectively) compared to H. pylori infected untreated males (macrophages: 34 ± 9 cells/40x 
field, P=0.276 and 0.229, respectively) (Fig. 3.5B).  H. pylori infection increased macrophage 
infiltration into the stomach in infected male mice compared to uninfected male mice (9 ± 5 
cells/40x field, respectively, P <0.001) and in infected female mice compared to uninfected 
female mice (25 ± 9 cells/40x field vs. 5 ± 2 cells/40x field, respectively, P <0.01) (Fig. 3.5B).  As 
seen in the neutrophil data, H. pylori-infected male mice treated with E2 or TAM still had 
greater macrophage infiltration than untreated uninfected male mice (Both P < 0.01).  As 
macrophages are recruited by neutrophils, the decreased neutrophil levels may contribute to 
decreased macrophage numbers in E2 or TAM treated male mice.  
3.3.4 E2 and Tamoxifen modulate cellular movement and immune responses responsible for 
cancer and chronic inflammatory diseases in infected mice. Gene expression analysis was 
performed on longitudinal gastric strips from H. pylori-infected male mice receiving placebo, E2 
or TAM pellets to determine if a characteristic expression profile was observed in E2 and TAM 
reduction of inflammation and gastric adenocarcinoma.  For this analysis, we compared the 
expression level of 41,000 probes and required a fold change of greater than or equal to 1.5, 
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ANOVA p-value < 0.05 and FDR q-value < 0.05 for significance.  363 and 144 genes were 
significantly different between infected males treated with E2 and infected males treated with 
TAM compared to infected untreated males (A complete list of genes is found in Supp. Table 
3.S1A & 3.S1B).  Comparison of both data sets yielded 61 commonly deregulated genes in 
treated mice compared to untreated mice (Supp. Table 3.S1C).   
In order to identify potential biological pathways and functions affected by E2 or TAM, 
molecular networks containing differentially expressed genes were algorithmically constructed 
based on connectivity and the known relationships among proteins using Ingenuity Pathways 
Analysis (IPA).  Genes deregulated by E2 and TAM resulted in the generation of 25 and 12 
networks respectively (For the top 5 networks, see Supp. Table 3.S2A & 3.S2B).  For both 
treatments, the most significant network was highlighted for further evaluation  (Fig. 3.6).  
Analysis of the 61common genes between both E2 and TAM generated 7 networks (Supp. Table 
3.S2C, Fig. 3.6). 
Within the "molecular and cellular functions" category, cellular movement was highly 
associated with both data sets.  Of the top 5 functions, 2 other functions were shared by both 
groups: cellular development, and cell-to-cell signaling and interaction (Supp. Table 3.S3B & 
4.S4B).  Cellular movement and cell-to-cell signaling and interaction were among the top 
"molecular and cellular functions" in the set of common genes (Supp. Table 3.S5B).  Among the 
cytokines associated with cellular movement, CXCL1, a murine IL-8 homolog, as well as IL-1α 
and Fosl1, modulators of IL-8, were downregulated by E2 or TAM.   E2 alone upregulated gastric 
expression of CCL19 (MIP3β), CCL21a, CXCL15 and IL-17b while downregulating IL-33, a IL-1 
family cytokine. TAM alone downregulated CCL2 (MCP-1), CCL7 (MCP-3), and CCL12 (MCP-5) 
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(see Supplemental Table 3.1 for a complete list).  CXCL1 was associated with the most significant 
networks and top biological functions in both treatment groups.  
Cancer was the most associated "disease or disorder" in both datasets with 115/363 and 
41/144 genes associated with E2 and TAM, respectively (Supp. Tables 3.3A & 3.4A), as well as in 
the dataset of overlapping genes (21/61) (Supp. Table 3.5A).  Genes differentially expressed 
affected oncogenic processes such as tumorigenesis, hyperplasia, hyperproliferation, malignant 
tumors, metastasis and neoplasia.  Organismal injury and abnormality was the other disease 
and disorder associated highly with both E2 and TAM treatments.  Furthermore, diseases 
associated with immune and inflammatory responses were significantly changed in both 
treatments, e.g. cardiovascular disease, inflammatory response and hypersensitivity response.  
Among the genes associated with cancer, stress response genes (DNAJA1 and HSPA1A), 
extracellular remodeling genes (MMP10, PLAUR, SERPINE1, and GDF15) and a component of 
the AP-1 transcription complex (FOSL1) were downregulated by E2 or TAM, indicative of the 
reduced severity of gastric lesions.  E2 or TAM upregulated genes associated with the Wnt/β-
catenin pathway including a phosphatase (PPP2R2B) and two receptors (SFRP2 and FZD6).  E2 
alone downregulated gastric expression of additional metalloproteinases (MMP3 and MMP13) 
while upregulating another Wnt receptor (SFRP4).  TAM downregulated the growth factor, IGF1, 
which mediates insulin like effects (see Supplemental Table 3.1 for a complete list of genes).  
3.3.5 E2 modulates inflammatory serum cytokines involved in neutrophil and macrophage 
chemotaxis. To determine if E2 modulated systemic responses to infection, serum cytokine 
protein levels were measured in both uninfected and infected mice of the following groups: 
untreated males, E2 males and untreated females (Fig. 3.7).  Basal differences in immunity were 
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observed between genders as uninfected untreated females had elevated Th2 cytokines, 
interleukin 5 (IL-5) and IL-13, compared to uninfected untreated males (P < 0.05 and 0.01, 
respectively).   
E2 treatment modulated serum cytokine responses in infected E2 males compared to 
infected untreated males. Systemic levels of the neutrophil chemokine, CXCL1, were decreased 
in both infected E2 males and infected untreated females compared to infected untreated males 
(P < 0.05 and 0.001, respectively).  Furthermore, macrophage inflammatory protein 1-alpha 
(MIP1α or CCL3) and MIP1β (or CCL4) were both significantly higher in infected untreated 
females compared to infected untreated males (P < 0.01 and 0.05, respectively) but were not 
different between E2 males and untreated females, indicating a slight E2-mediated increase in 
MIP1α/β levels. IL-6 was increased significantly in infected males receiving E2 compared to 
infected untreated males (P <0.05). 
A subset of cytokines were significantly different between genders and were not 
affected by E2 supplementation.  IL-1β, IL-5 and monocyte chemoattractant protein-1 (MCP-1 or 
CCL2) were significantly decreased in either untreated or E2-treated infected males compared 
to infected untreated females (P < 0.05, 0.01, 0.05 for infected untreated male vs. infected 
untreated female and P <0.05, 0.05 and 0.05 for infected E2 male vs. infected untreated 
female).  IL-12p70 was increased in infected untreated females compared to infected E2 males 
(P < 0.05) but not significantly compared to infected untreated males (P = 0.08). 
 
3.4 Discussion 
Although estrogen is hypothesized to reduce gastric adenocarcinoma in women13 due to 
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its myriad of immunomodulatory effects108, few studies involving male and female animals with 
a recognized sexual dimorphism in GC incidence have analyzed the role of 17β-estradiol and H. 
pylori in gastric carcinogenesis.  In a short term, 6 week study, E2 treatment of ovariectomized 
H. pylori infected gerbils increased acute inflammation and epithelial cell proliferation170.  In 
contrast, previous studies using ovariectomized female H. pylori infected INS-GAS mice 
demonstrated that E2 treatment of mice infected chronically for 28 weeks reduced epithelial 
cell proliferation, attenuated the severity of gastritis and reduced the development of GIN14.  
We hypothesized that E2 was protective due to decreases in proinflammatory mediators like IL-
1β and iNOS and increases in antiinflammatory mediators like IL-1014.  We also demonstrated 
that E2 administered prophylactically, but not castration, reduced H. pylori induced gastric 
lesions in male INS-GAS mice and was associated with an increase in gastric FoxP3+ regulatory T 
cells15.   
In the present study, we investigated the role of E2 and TAM in reducing GC in male and 
female H. pylori infected INS-GAS mice.  Infected male mice treated with E2, TAM or both 
compounds experienced a significant reduction in gastric lesions with no cancer development 
compared to more severe lesions and a 40% incidence of gastric carcinoma in infected 
untreated males.   Progressive H. pylori gastritis results from chronic inflammatory processes 
mediated by proinflammatory Th1 and Th17 cells71,171.  In the present study, the attenuation of 
gastric lesions by E2 and TAM treatments was accompanied by a downregulation of 
proinflammatory cues.  E2-mediated downregulation of inflammatory cues has been observed 
in other chronic inflammatory processes in many organs108.   
Epidemiological studies suggest that E2 decreases GC risk, and that TAM promotes GC by 
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antagonizing E2, presumably by competitively inhibiting binding to estrogen receptors13,110,116-
118.  However, TAM is recognized as a mixed agonist/antagonist of estrogen receptors172-173, and 
the effects of TAM on H. pylori associated GC have not been carefully studied.  Our results 
demonstrated that TAM may act agonistically in the stomach as it was protective in infected 
male mice and had no effect in female mice.  
Two factors that differentiate this mouse study from epidemiological studies associating 
TAM to GC are menopausal status and cumulative dose.  TAM-associated risk of endometrial 
cancers is noted mainly in postmenopausal women154,  and studies associating TAM with 
increased gastrointestinal cancer risk are exclusively composed of, or include a high percentage 
of, postmenopausal women116-118.  It is possible that estrogen cycles in premenopausal women, 
or breeding age female mice as in our study, minimize the aberrant estrogen signaling promoted 
by TAM that leads to increases in cancer.  In the context of male mice, increased estrogen 
signaling via E2 or TAM was protective as seen in men on HRT110.  Additionally, human studies 
indicate that the cumulative dose of TAM is crucial for increasing cancer risk115-116,174.  Breast 
cancer patients are prescribed a daily dose of 20mg (0.3 mg/kg for a 70 kg person) for 5 
years175.  Using TAM concentrations that inhibit breast cancer in mice176, our mice were treated 
with a higher daily dose of 0.18mg (6.8 mg/kg for a 25g mouse) for 12 weeks.  However, given 
the short lifespan of the mouse, as well as differences in drug metabolism177-178, the murine 
model may not be ideal to assess longer term effects of chronic TAM treatment.  While E2 and 
TAM mediated different systemic effects on male mice, the reduction of gastric lesions by E2, 
TAM and their combined use, along with the lack of increased protection with the dual 
treatment, suggests common and/or non-synergistic mechanisms. 
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A systems biology approach was used to understand the biological implications of gastric 
gene expression changes induced by systemic E2 and TAM treatments.  Individual comparisons 
against infected untreated males indicated that both treatments reduced gastric pathology via 
common mechanisms including those affecting the movement of cells and decreasing 
inflammatory signals (Supp. Table 3.3 & 3.4).  Our analysis highlighted the importance of 
decreased expression of CXCL1, also known as keratinocyte chemoattractant (KC) or growth-
related oncogene-α (GROα), in the stomach of both E2 and TAM treated, H. pylori infected male 
mice.  Moreover, serum CXCL1 protein levels were decreased in infected females and infected 
E2 males compared to infected untreated males.  E2 also significantly decreased neutrophilic 
infiltration in infected male mice compared to infected untreated male mice, while a decreasing 
trend was observed in infected TAM male mice.  Macrophages in the corpus were slightly 
decreased in infected E2 or TAM male mice compared to infected untreated mice.  
CXCL1, the murine homolog of human IL-8, is a proinflammatory chemokine that recruits 
neutrophils and is upregulated in colon adenocarcinoma, atherosclerosis and cardiovascular 
disease179-183.  CXCL1 mediates changes in the microenvironment that drive tumor formation184-
186.  CXCL1 and its receptor, CXCR2, which is highly expressed on neutrophils and macrophages, 
are important in the recruitment of immune cells. Both CXCL1-/- and CXCR2-/- mice develop 
fewer lesions and recruit fewer macrophages in a model of atherosclerosis182.  Furthermore, E2 
downregulates expression of both CXCL1 in endothelial cells and CXCR2 in monocytes, affecting 
monocyte adhesion to endothelial cells187-188.  As E2 attenuates nuclear factor kappa beta (NF-
κB) translocation189-190, a potential mechanism by which E2 reduces CXCL1 is by blocking the NF-
κB binding site upstream of CXCL1 (UCSC Genome bioinformatics).   
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Recent clinical and epidemiological studies link high CXCL1 expression and serum levels 
to gastric cancer191-193.   A single nucleotide polymorphism in the IL-8 promoter region (IL-8 -251 
T to A) that increases IL-8 protein levels is associated with increased gastric cancer risk92-93.  In a 
mouse model of gastric cancer, CXCL1 was the main chemokine upregulated by K-ras 
overexpression, and CXCL1 mRNA levels had the highest degree of correlation with dysplasia 
scores184.     
A positive feedback loop couples CXCL1 secretion and neutrophil recruitment.  In 
response to H. pylori-mediated CXCL1 gradients, neutrophils rapidly infiltrate the site of 
infection and aid in the recruitment of macrophages194-195.  In addition to secreting more CXCL1, 
neutrophils induce CXCL1 expression in macrophages and gastric epithelia196.  As CXCL1 recruits 
and activates inflammatory cells establishing a tumorigenic microenvironment184, a decrease in 
CXCL1 levels might inhibit cancer formation by decreasing neutrophil numbers, which directly 
correlate with the severity of H. pylori-related injury59, and by dampening local and systemic 
proinflammatory signals.  Further studies will be required to determine how E2 or TAM initially 
disrupt this positive feedback loop.  Although local CXCR2 expression was not altered by 
treatment, E2 or TAM mediated decreases in CXCL1 or CXCR2 expression in circulating 
neutrophils, or a decrease in epithelial CXCL1 expression, would disturb the feedback 
mechanism and this possibility merits further research.     
Given the importance of CXCL1, we further investigated the deregulation of the gene 
expression of other cytokines due to E2 or TAM treatment of H. pylori-infected male mice as H. 
pylori infection upregulates transcripts encoding chemokines and their receptors197-201.  E2 or 
TAM decreased IL-1α expression compared to untreated controls.   IL-1α exacerbates chronic 
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inflammatory conditions, as evidenced in lipid-mediated atherogenesis202.   E2-treated infected 
males had higher levels of CCL19 and CCL21, both CCR7 ligands, which balance immunity and 
tolerance by mediating the homing of subsets of T cells and dendritic cells to lymph nodes203.  
TAM-treated infected males had decreased expression of MCP-1, MCP-3 and MCP-5, which are 
ligands of CCR2, a receptor linked to multiple sclerosis, rheumatoid arthritis, obesity, 
atherosclerosis, cancer, transplant rejection and asthma204.  Changes in the local expression of 
these cytokines by E2 and TAM treatment may further reduce chronic inflammatory conditions 
delaying tumor progression. 
Systemic effects of sex and E2 treatment were explored by measuring serum cytokine 
levels and our results indicated additional differences in immune responses.  Cytokines 
associated with Th2 immune responses and monocytes were elevated in female mice. 
Uninfected and infected females had higher levels of IL-5, which stimulates B cells and 
antibodies205, compared to male counterparts.  IL-13, which promotes alternative macrophage 
activation206, was also higher in uninfected untreated females compared to males.  Alternatively 
activated, or M2, macrophages promote Th2 immunity and are induced during the resolution 
phase of inflammation.   Compared to the corresponding infected untreated males, infected 
untreated females also produced more monocyte chemokines (MIP1α and MIP1β) and 
cytokines secreted by monocyte-derived cells (IL-1β, IL-12p70 and MCP-1)202,207.  While these 
strong proinflammatory cytokines have been associated with cancer70,208-209, females had less 
severe disease compared to males.  The attenuated gastritis noted in females in the presence of 
high levels of monocytes and macrophages might be mediated by increased levels of Th2 
cytokines leading to the alternative activation of macrophages.  E2 has been shown to increase 
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the number of alternatively activated macrophages and concomitantly reduce the number of 
classically activated macrophages and neutrophils210.  The role of alternatively activated 
macrophages in stabilizing the progression of chronic inflammation in female INS-GAS mice 
requires further research.  Surprisingly, serum IL-6 levels in infected males did not correlate with 
gastric cancer as noted in male-predominant liver cancer211, as untreated infected males had 
lower IL-6 levels than E2 treated infected males.  IL-6 has both pro- and antiinflammatory 
properties209 and can be both downregulated and upregulated by E2108,212-213, so its role in 
gastric cancer and the INS-GAS model requires further study. 
Another mechanism by which E2 and TAM may mediate protection is by decreasing 
oncogenic pathways.  E2 and TAM downregulated the urokinase-type plasminogen activator 
receptor (PLAUR) and two of its regulators, GDF15 and SERPINE1 (also known as PAI-1)214-215.  
PLAUR anchors urokinase and serves as a focal point for proteolytic activity during wound 
healing216.  Increased PLAUR and PAI-1 levels are associated with pathological processes like cell 
invasion, metastasis, and angiogenesis, and have been associated with H. pylori infection as well 
as poor prognosis in gastric cancer patients216-218.  As PLAUR is activated via β-catenin219-220 and 
H. pylori causes nuclear accumulation of β-catenin221-222, suppression of Wnt signaling by E2 and 
TAM was evaluated.  E2 or TAM treated mice upregulated two Wnt signaling inhibitors, secreted 
frizzle-related protein 2 (SFRP2)223 and Frizzled-6 (FZD6)224.  sFRP-2 is modulated by E2225-226, 
and inhibits β-catenin activation by specifically blocking Wnt 1 and Wnt4, but not Wnt3a223,227-
229.  sFRP-2 silencing is associated with increases in gastric cancer and other malignancies230-234.  
As increased Wnt signaling promotes cancer, our microarray data suggest that E2 and TAM 
treatment may in part prevent cancer by increasing Wnt antagonists and downregulating cell 
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invasive processes downstream of β-catenin. 
 Sex differences in gastric cancer incidence, the protective effect of prolonged fertility in 
females and the reduced risk among women taking postmenopausal hormones, are elements 
suggesting that sex hormones play a protective role in H. pylori associated gastric cancer. Our 
findings suggest that both E2 and TAM decrease gastric cancer by decreasing neutrophilic 
infiltration and attenuating the chronic inflammatory response, and by decreasing expression of 
Wnt/β-catenin signaling factors, important in oncogenesis.  As these two mechanisms are highly 
interrelated, we believe that the reduction of neutrophilic infiltrate by CXCL1 reduces the 
exposure of the stomach to oxidative stress, a cause of DNA mutagenesis235, decreases 
proinflammatory cellular infiltrates and delays the progression of gastric cancer.   
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3.6 Tables and Figures 
 
 
Figure 3.1. Ratios of reproductive tissues/body weight.  A.  After 12 weeks of hormone treatment, testes and 
epididymis/body weight ratios were compared in male mice showing efficacy of E2 and combination treatments 
compared to untreated or TAM treated mice.  B. After 12 weeks of treatment, uterus/body weight ratios 
demonstrated the efficacy of TAM treatment.  Only 1 uninfected female with TAM was available for comparison. 
***P<0.001.  Error bars represent SD.   
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Figure 3.2. Serum E2 levels. A. Serum E2 levels were higher in H. pylori-infected male INS-GAS mice treated with E2 
or E2 and TAM compared with untreated controls.  B. Serum E2 levels in infected female mice were decreased by 
TAM treatment compared to uninfected untreated female mice. *P<0.05, **P<0.01, ***P<0.001.  Error bars 
represent SD. 
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Figure 3.3. Corpus pathology after 28 weeks of H. pylori infection and 12 weeks of hormone treatment. A. In 
uninfected males, E2 and combination therapy reduced pathology compared to untreated mice.  In infected male 
mice, E2, TAM and combination treatment reduced pathology compared to untreated mice.  B. Gastric pathology in 
female mice was not affected by TAM treatment. *P<0.05, **P<0.01, ***P<0.001.  Error bars represent SD. C. 
Representative H&E staining of corpus from uninfected and H. pylori-infected male and female mice from 
untreated, E2-treated or TAM-treated groups.  Scale bar = 200μm. 
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Figure 3.4. Individual histological parameters of corpus pathology after 28 weeks of H. pylori infection and 12 
weeks of hormone treatment in infected male mice. *P<0.05, **P<0.01, ***P<0.001.  Error bars represent SD. 
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Figure 3.5. Immune cell infiltration of A) MPO+ neutrophils and B) F4/80+ macrophages.  Error bars represent SD. 
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Figure 3.6. Significant molecular networks affected by hormone treatment.  Networks display interactions using the 
gene targets of A. E2 (P=10
-50
), B. TAM (P=10
-45
), C. common genes between E2 and TAM (P=10
-45
).  P-values 
represent the probability of these interactions occurring by chance.   
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Figure 3.7. Serum levels of cytokines and chemokines in A) uninfected and B) H. pylori-infected untreated males, E2 
males and untreated females. IL-5 and IL-13 were differentially expressed in uninfected females compared to 
uninfected males with placebo. IL-1β, IL-5, IL-6, IL-12p70, KC, MCP-1, MIP1α and MIP1β were differentially 
expressed during infection.  *P<0.05, **P<0.01, ***P<0.001.  Error bars represent SD. 
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3.7 Supplemental Tables 
Supplemental Table legends 
Table 3.S1. Genes differentially expressed by treatment.  A. 169 downregulated and 194 
upregulated genes in infected E2 male mice compared to infected untreated male mice.  B. 69 
downregulated and 75 upregulated genes in infected TAM male mice compared to infected 
untreated male mice. C.  24 downregulated and 37 upregulated genes in both infected E2 and 
TAM male mice compared to infected untreated male mice. 
 
Table 3.S2.  Networks associated to differentially expressed genes by Ingenuity Pathway 
Analysis.  Genes in capital letters represent differentially expressed genes found within the 
network.  A. Top networks associated with E2 treatment of infected male mice.  B. Top networks 
associated with TAM treatment of infected male mice.  C.  Top 3 networks associated with 
commonly induced genes in both E2 and TAM treatments. 
 
Table 3.S3. Biological functions and canonical pathways associated with E2 treatment of 
infected males and genes associated with function or pathway. A.  Diseases and disorders.  B. 
Molecular and Cellular functions. C.  Physiological System and Development and Functions. D. 
Canonical pathways.  
Table 3.S4. Biological functions and canonical pathways associated with TAM treatment of 
infected males and genes associated with function or pathway.   A.  Diseases and disorders.  B. 
Molecular and Cellular functions. C.  Physiological System and Development and Functions. D. 
Canonical pathways.  
 
Table 3.S5. Biological functions and canonical pathways associated with both E2 and TAM 
treatment of infected males and genes associated with function or pathway.   A.  Diseases and 
disorders.  B. Molecular and Cellular functions. C. Physiological System and Development and 
Functions. D. Canonical pathways.  
 
Table 3.S6.   Individual histological parameters in the corpus and antrum at 16 and 28 weeks of 
H. pylori infection.  A) Corpus pathology at 16 WPI. B) Corpus pathology at 28 WPI. C) Antrum 
pathology at 16 WPI.  D) Antrum pathology at 28 WPI. 
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Table 3.S1A. Genes downregulated by E2 treatment 
Probe set ID Gene 
symbol 
Gene title Log2ch
ange 
p-value q-value 
A_51_P430259 1700009P17Rik RIKEN cDNA 1700009P17 gene -0.70 0.029 0.000 
A_51_P225493 1700016C15Rik RIKEN cDNA 1700016C15 gene -0.79 0.020 0.000 
A_51_P450278 2010003K11Rik RIKEN cDNA 2010003K11 gene -0.73 0.018 0.000 
A_51_P334318 2010110P09Rik RIKEN cDNA 2010110P09 gene -0.87 0.013 0.000 
A_51_P281778 2210010C17Rik RIKEN cDNA 2210010C17 gene -0.62 0.017 0.000 
A_52_P321150 2310016C08Rik RIKEN cDNA 2310016C08 gene -0.71 0.004 0.000 
A_52_P644479 4930523C07Rik RIKEN cDNA 4930523C07 gene -0.70 0.000 0.000 
A_51_P445683 4931406C07Rik RIKEN cDNA 4931406C07 gene -0.64 0.000 0.000 
A_52_P110070 5730416F02Rik RIKEN cDNA 5730416F02 gene -0.90 0.004 0.000 
A_51_P394354 5730469M10Rik RIKEN cDNA 5730469M10 gene -1.03 0.001 0.000 
A_52_P747842 9130204L05Rik RIKEN cDNA 9130204L05 gene -1.27 0.009 0.000 
A_51_P118400 9130404H23Rik RIKEN cDNA 9130404H23 gene -1.32 0.029 0.000 
A_51_P456113 9930013L23Rik RIKEN cDNA 9930013L23 gene -0.75 0.041 0.000 
A_52_P349091 A930001A20Rik RIKEN cDNA A930001A20 gene -0.82 0.001 0.000 
A_51_P116419 Abcc5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 -0.62 0.004 0.000 
A_52_P157450 Abhd1 abhydrolase domain containing 1 -0.71 0.012 0.000 
A_51_P440584 Abhd2 abhydrolase domain containing 2 -0.71 0.002 0.000 
A_51_P213515 Acnat2 acyl-coenzyme A amino acid N-acyltransferase 2 -1.54 0.004 0.000 
A_52_P150851 Adamts12 
a disintegrin-like and metallopeptidase (reprolysin type) with 
thrombospondin type 1 motif, 12 -0.79 0.041 0.000 
A_51_P233797 Adh7 alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide -1.09 0.039 0.000 
A_51_P510891 Afp alpha fetoprotein -0.77 0.008 0.000 
A_52_P87843 Aldh1a3 aldehyde dehydrogenase family 1, subfamily A3 -0.75 0.039 0.000 
A_51_P423813 Alpi alkaline phosphatase, intestinal -1.93 0.027 0.000 
A_52_P368690 Amica1 adhesion molecule, interacts with CXADR antigen 1 -0.64 0.023 0.000 
A_51_P201982 Angpt2 angiopoietin 2 -1.00 0.039 0.000 
A_51_P338443 Angptl4 angiopoietin-like 4 -1.55 0.014 0.000 
A_51_P318618 Anks4b ankyrin repeat and sterile alpha motif domain containing 4B -0.62 0.039 0.000 
A_52_P620345 Ano10 anoctamin 10 -0.65 0.019 0.000 
A_52_P62037 Anxa2 annexin A2 -0.67 0.011 0.000 
A_51_P334979 Apoc2 apolipoprotein C-II -1.08 0.006 0.000 
A_51_P503494 Arc activity regulated cytoskeletal-associated protein -0.83 0.014 0.000 
A_51_P339305 Banp BTG3 associated nuclear protein -1.01 0.021 0.000 
A_52_P26794 Basp1 brain abundant, membrane attached signal protein 1 -0.87 0.019 0.000 
A_52_P575900 Bglap bone gamma carboxyglutamate protein -0.92 0.019 0.000 
A_51_P167410 Bglap-rs1 bone gamma-carboxyglutamate protein, related sequence 1 -0.85 0.034 0.000 
A_51_P213266 Bmp8a bone morphogenetic protein 8a -0.62 0.005 0.000 
A_51_P488196 Bmper BMP-binding endothelial regulator -0.69 0.001 0.000 
A_51_P273921 Capg capping protein (actin filament), gelsolin-like -0.69 0.014 0.000 
A_51_P410430 Ccdc19 coiled-coil domain containing 19 -1.08 0.017 0.000 
A_52_P349356 Ccdc92 coiled-coil domain containing 92 -0.67 0.002 0.000 
A_51_P360165 Ccng2 cyclin G2 -0.73 0.008 0.000 
A_52_P218470 Cdhr2 cadherin-related family member 2 -0.97 0.007 0.000 
A_51_P367081 Cdk14 cyclin-dependent kinase 14 -0.93 0.009 0.000 
A_51_P234927 Cdk3-ps cyclin-dependent kinase 3, pseudogene -0.64 0.009 0.000 
A_51_P305843 Chordc1 
cysteine and histidine-rich domain (CHORD)-containing, zinc-
binding protein 1 -0.62 0.035 0.000 
A_51_P199168 Cidea 
cell death-inducing DNA fragmentation factor, alpha subunit-
like effector A -1.18 0.000 0.000 
A_51_P356467 Cldn4 claudin 4 -1.64 0.024 0.000 
A_51_P518001 Creb3l3 cAMP responsive element binding protein 3-like 3 -1.28 0.006 0.000 
A_51_P511000 Cwh43 cell wall biogenesis 43 C-terminal homolog (S. cerevisiae) -0.60 0.012 0.000 
A_51_P363187 Cxcl1 chemokine (C-X-C motif) ligand 1 -0.61 0.007 0.000 
A_52_P681592 Cybrd1 cytochrome b reductase 1 -0.64 0.003 0.000 
A_52_P527775 Cyp2d10 cytochrome P450, family 2, subfamily d, polypeptide 10 -1.03 0.020 0.000 
A_51_P247172 D19Ertd652e DNA segment, Chr 19, ERATO Doi 652, expressed -0.94 0.021 0.000 
A_51_P208603 Dio2 deiodinase, iodothyronine, type II -0.99 0.049 0.000 
A_51_P520650 Dlgap1 discs, large (Drosophila) homolog-associated protein 1 -0.66 0.018 0.000 
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Table 3.S1A. Genes downregulated by E2 treatment (cont.) 
Probe set ID Gene symbol Gene title Log2 
change 
p-value q-value 
A_51_P303346 Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 -0.65 0.020 0.000 
A_51_P153486 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 -0.75 0.002 0.000 
A_52_P141608 E030010A14Rik RIKEN cDNA E030010A14 gene -0.65 0.015 0.000 
A_51_P462918 Ehhadh 
enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A 
dehydrogenase -0.77 0.010 0.000 
A_51_P156222 Elfn1 leucine rich repeat and fibronectin type III, extracellular 1 -0.75 0.027 0.000 
A_52_P120037 Emp1 epithelial membrane protein 1 -1.14 0.009 0.000 
A_51_P505823 Endod1 endonuclease domain containing 1 -0.73 0.038 0.000 
A_52_P518997 Epha2 Eph receptor A2 -0.81 0.036 0.000 
A_52_P423424 Ero1l ERO1-like (S. cerevisiae) -0.67 0.003 0.000 
A_51_P236846 F3 coagulation factor III -1.02 0.008 0.000 
A_51_P336830 Fabp4 fatty acid binding protein 4, adipocyte -1.06 0.025 0.000 
A_52_P19532 Fgd3 FYVE, RhoGEF and PH domain containing 3 -1.02 0.022 0.000 
A_52_P286970 Flnb filamin, beta -0.70 0.039 0.000 
A_52_P476935 Flrt3 fibronectin leucine rich transmembrane protein 3 -0.74 0.030 0.000 
A_51_P308796 Fosl1 fos-like antigen 1 -1.14 0.001 0.000 
A_52_P501733 Ftl1 ferritin light chain 1 -0.73 0.021 0.000 
A_52_P298002 Gch1 GTP cyclohydrolase 1 -0.76 0.000 0.000 
A_52_P363216 Gcnt2 glucosaminyl (N-acetyl) transferase 2, I-branching enzyme -0.60 0.034 0.000 
A_52_P532982 Gdf15 growth differentiation factor 15 -1.02 0.001 0.000 
A_52_P462657 Gm11545 predicted gene 11545 -1.49 0.000 0.000 
A_52_P220933 Gm9758 predicted gene 9758 -1.00 0.000 0.000 
A_52_P382067 Gpr55 G protein-coupled receptor 55 -0.65 0.013 0.000 
A_51_P461684 Gprc5a G protein-coupled receptor, family C, group 5, member A -0.77 0.028 0.000 
A_52_P432124 Gsta3 glutathione S-transferase, alpha 3 -0.71 0.009 0.000 
A_51_P516133 Hist1h1c histone cluster 1, H1c -0.59 0.022 0.000 
A_51_P501260 Hist1h1d histone cluster 1, H1d -0.83 0.004 0.000 
A_51_P182358 Hist1h2bk histone cluster 1, H2bk -0.60 0.007 0.000 
A_51_P449580 Hmga2-ps1 high mobility group AT-hook 2, pseudogene 1 -0.60 0.016 0.000 
A_51_P116039 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2 -0.83 0.030 0.000 
A_51_P465292 Hnmt histamine N-methyltransferase -0.64 0.020 0.000 
A_51_P365152 Hs3st1 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 -0.76 0.019 0.000 
A_52_P132165 Hsd17b11 hydroxysteroid (17-beta) dehydrogenase 11 -0.65 0.006 0.000 
A_52_P590154 Hsd17b6 hydroxysteroid (17-beta) dehydrogenase 6 -0.76 0.038 0.000 
A_51_P117952 Hspa1a heat shock protein 1A -2.94 0.011 0.000 
A_52_P304902 Hspa1b heat shock protein 1B -1.97 0.001 0.000 
A_51_P286488 Ier3 immediate early response 3 -0.62 0.003 0.000 
A_51_P516826 Igf2 insulin-like growth factor 2 -0.60 0.045 0.000 
A_51_P438283 Il1a interleukin 1 alpha -0.82 0.001 0.000 
A_51_P122321 Il33 interleukin 33 -1.03 0.033 0.000 
A_51_P239750 Inhba inhibin beta-A -0.83 0.005 0.000 
A_51_P413097 Ints2 integrator complex subunit 2 -0.87 0.038 0.000 
A_52_P612019 Itga2 integrin alpha 2 -0.70 0.023 0.000 
A_51_P475748 Ivl involucrin -2.05 0.010 0.000 
A_52_P125429 Kif5c kinesin family member 5C -0.91 0.032 0.000 
A_52_P445360 Krt20 keratin 20 -0.95 0.014 0.000 
A_51_P167489 Lama3 laminin, alpha 3 -0.99 0.020 0.000 
A_51_P174943 Lamc2 laminin, gamma 2 -0.71 0.007 0.000 
A_51_P403564 Lhx5 LIM homeobox protein 5 -1.23 0.000 0.000 
A_51_P300493 Lox lysyl oxidase -0.71 0.033 0.000 
A_51_P257457 Ltbp2 latent transforming growth factor beta binding protein 2 -1.06 0.033 0.000 
A_51_P368012 Mdfi MyoD family inhibitor -0.63 0.034 0.000 
A_51_P390508 Mep1b meprin 1 beta -1.11 0.022 0.000 
A_51_P266668 Mlec malectin -0.61 0.001 0.000 
A_51_P120830 Mmp10 matrix metallopeptidase 10 -1.55 0.001 0.000 
A_51_P184484 Mmp13 matrix metallopeptidase 13 -1.58 0.013 0.000 
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Table 3.S1A. Genes downregulated by E2 treatment (cont.) 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_51_P255699 Mmp3 matrix metallopeptidase 3 -0.81 0.035 0.000 
A_52_P46085 Mvp major vault protein -0.62 0.015 0.000 
A_51_P268983 Myom3 myomesin family, member 3 -0.63 0.013 0.000 
A_51_P505521 NA NA -0.79 0.025 0.000 
A_52_P146513 NA NA -0.65 0.019 0.000 
A_52_P299446 NA NA -0.60 0.002 0.000 
A_52_P81677 NA NA -0.63 0.004 0.000 
A_52_P382785 Npnt nephronectin -0.63 0.040 0.000 
A_52_P359819 Ntf5 neurotrophin 5 -0.63 0.014 0.000 
A_51_P519251 Nupr1 nuclear protein 1 -0.89 0.022 0.000 
A_51_P253207 Osta organic solute transporter alpha -0.70 0.009 0.000 
A_51_P280117 Padi2 peptidyl arginine deiminase, type II -0.61 0.020 0.000 
A_52_P37123 Pard6b par-6 (partitioning defective 6) homolog beta (C. elegans) -0.59 0.007 0.000 
A_51_P450623 Phlda2 pleckstrin homology-like domain, family A, member 2 -0.61 0.016 0.000 
A_52_P405465 Piga phosphatidylinositol glycan anchor biosynthesis, class A -0.82 0.001 0.000 
A_52_P681310 Plaur plasminogen activator, urokinase receptor -0.89 0.011 0.000 
A_52_P686218 Plb1 phospholipase B1 -0.66 0.001 0.000 
A_51_P278163 Plcd3 phospholipase C, delta 3 -0.63 0.045 0.000 
A_51_P258150 Plin2 perilipin 2 -0.60 0.020 0.000 
A_51_P431107 Pmm1 phosphomannomutase 1 -0.79 0.046 0.000 
A_51_P314669 Pnliprp2 pancreatic lipase-related protein 2 -1.39 0.006 0.000 
A_51_P375783 Prap1 proline-rich acidic protein 1 -2.85 0.021 0.000 
A_52_P540855 Prdx6 peroxiredoxin 6 -0.65 0.026 0.000 
A_52_P467930 Prdx6-ps2 peroxiredoxin 6 pseudogene 2 -0.66 0.003 0.000 
A_51_P155514 Prl prolactin -1.10 0.012 0.000 
A_51_P312779 Prl2c3 prolactin family 2, subfamily c, member 3 -2.47 0.031 0.000 
A_52_P511450 Prl2c5 prolactin family 2, subfamily c, member 5 -2.29 0.027 0.000 
A_51_P146953 Ripply3 ripply3 homolog (zebrafish) -1.03 0.045 0.000 
A_51_P404377 Rnd2 Rho family GTPase 2 -0.66 0.041 0.000 
A_51_P432288 Rnf183 ring finger protein 183 -0.80 0.049 0.000 
A_51_P406105 Rps4y2 ribosomal protein S4, Y-linked 2 -0.82 0.019 0.000 
A_51_P457989 Rragd Ras-related GTP binding D -0.91 0.019 0.000 
A_52_P488427 Sec14l2 SEC14-like 2 (S. cerevisiae) -0.67 0.045 0.000 
A_51_P457481 Sectm1a secreted and transmembrane 1A -0.72 0.011 0.000 
A_51_P183571 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 -0.84 0.020 0.000 
A_52_P411296 Sh3kbp1 SH3-domain kinase binding protein 1 -0.65 0.042 0.000 
A_52_P196476 Slc11a2 
solute carrier family 11 (proton-coupled divalent metal ion 
transporters), member 2 -0.63 0.024 0.000 
A_51_P371311 Slc1a4 
solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 -0.63 0.002 0.000 
A_51_P265444 Slc28a2 
solute carrier family 28 (sodium-coupled nucleoside 
transporter), member 2 -1.10 0.040 0.000 
A_52_P368057 Slc7a11 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 11 -0.67 0.034 0.000 
A_51_P487487 Speer4d spermatogenesis associated glutamate (E)-rich protein 4d -0.61 0.015 0.000 
A_52_P400436 Sphk1 sphingosine kinase 1 -0.69 0.007 0.000 
A_52_P593200 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) -0.67 0.025 0.000 
A_51_P281333 St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 -0.87 0.001 0.000 
A_52_P149380 St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 -0.67 0.002 0.000 
A_52_P189970 Stc1 stanniocalcin 1 -0.62 0.006 0.000 
A_51_P162564 Tceanc 
transcription elongation factor A (SII) N-terminal and central 
domain containing -0.69 0.017 0.000 
A_52_P426952 Tcf23 transcription factor 23 -0.68 0.001 0.000 
A_51_P362298 Tmprss3 transmembrane protease, serine 3 -0.91 0.020 0.000 
A_52_P351638 Tnfrsf10b tumor necrosis factor receptor superfamily, member 10b -0.62 0.023 0.000 
A_52_P654161 Trim25 tripartite motif-containing 25 -0.62 0.001 0.000 
A_51_P473277 Tspan6 tetraspanin 6 -0.78 0.006 0.000 
A_52_P21 Ttc9 tetratricopeptide repeat domain 9 -0.89 0.000 0.000 
A_51_P334689 Uts2 urotensin 2 -2.20 0.014 0.000 
A_52_P281924 Vamp5 vesicle-associated membrane protein 5 -0.72 0.029 0.000 
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Table 3.S1A. Genes downregulated by E2 treatment (cont.) 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_52_P278327 Vtcn1 V-set domain containing T cell activation inhibitor 1 -0.70 0.018 0.000 
A_52_P537827 Wdr72 WD repeat domain 72 -0.88 0.013 0.000 
A_52_P15536 Zfand2a zinc finger, AN1-type domain 2A -0.62 0.000 0.000 
A_51_P190454 Zfp37 zinc finger protein 37 -0.70 0.002 0.000 
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Table 3.S1A. Genes upregulated by E2 treatment 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_52_P947 2010007H06Rik RIKEN cDNA 2010007H06 gene 0.79 0.035 0.000 
A_52_P324391 2310058N22Rik RIKEN cDNA 2310058N22 gene 0.59 0.018 0.000 
A_51_P216268 2610001A08Rik RIKEN cDNA 2610001A08 gene 0.80 0.009 0.000 
A_52_P555537 2810008D09Rik RIKEN cDNA 2810008D09 gene 0.65 0.025 0.000 
A_51_P417251 6330403K07Rik RIKEN cDNA 6330403K07 gene 0.62 0.000 0.000 
A_52_P290152 6720401G13Rik RIKEN cDNA 6720401G13 gene 0.74 0.001 0.000 
A_52_P504859 A530020G20Rik RIKEN cDNA A530020G20 gene 0.61 0.031 0.000 
A_51_P256902 Abcg5 ATP-binding cassette, sub-family G (WHITE), member 5 1.17 0.020 0.000 
A_52_P306305 Akap2 A kinase (PRKA) anchor protein 2 0.62 0.031 0.000 
A_52_P58145 Aldh1a2 aldehyde dehydrogenase family 1, subfamily A2 1.43 0.010 0.000 
A_51_P486681 Ap3b2 adaptor-related protein complex 3, beta 2 subunit 0.62 0.005 0.000 
A_51_P383524 Art3 ADP-ribosyltransferase 3 1.09 0.009 0.000 
A_52_P549985 Asb13 ankyrin repeat and SOCS box-containing 13 0.91 0.012 0.000 
A_52_P276412 Atpif1 ATPase inhibitory factor 1 0.66 0.002 0.000 
A_52_P12623 Bnipl BCL2/adenovirus E1B 19kD interacting protein like 0.64 0.047 0.000 
A_52_P337126 Bves blood vessel epicardial substance 0.83 0.007 0.000 
A_51_P110301 C3 complement component 3 0.85 0.050 0.000 
A_51_P132849 Camk2g calcium/calmodulin-dependent protein kinase II gamma 0.60 0.001 0.000 
A_52_P208649 Cartpt CART prepropeptide 1.62 0.009 0.000 
A_51_P487518 Casp12 caspase 12 0.60 0.005 0.000 
A_52_P306845 Cav1 caveolin 1, caveolae protein 0.61 0.038 0.000 
A_51_P458258 Ccl19 chemokine (C-C motif) ligand 19 0.69 0.047 0.000 
A_51_P129480 Ccl21a chemokine (C-C motif) ligand 21A (serine) 2.11 0.008 0.000 
A_51_P385718 Cd177 CD177 antigen 1.10 0.039 0.000 
A_51_P489452 Cdo1 cysteine dioxygenase 1, cytosolic 0.99 0.025 0.000 
A_52_P459143 Celf6 CUGBP, Elav-like family member 6 0.75 0.004 0.000 
A_51_P413866 Cfb complement factor B 0.86 0.018 0.000 
A_51_P156955 Cfd complement factor D (adipsin) 4.63 0.049 0.000 
A_51_P191669 Chgb chromogranin B 1.11 0.049 0.000 
A_52_P674808 Chrdl1 chordin-like 1 0.62 0.030 0.000 
A_51_P241319 Cilp 
cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase 1.06 0.010 0.000 
A_51_P265806 Clca2 chloride channel calcium activated 2 1.25 0.041 0.000 
A_51_P189814 Cldn5 claudin 5 0.97 0.017 0.000 
A_51_P141413 Clec10a C-type lectin domain family 10, member A 0.60 0.001 0.000 
A_52_P474902 Col20a1 collagen, type XX, alpha 1 0.61 0.021 0.000 
A_51_P144160 Colec10 collectin sub-family member 10 1.22 0.012 0.000 
A_51_P246001 Cpe carboxypeptidase E 1.05 0.019 0.000 
A_51_P284426 Cstad CSA-conditional, T cell activation-dependent protein 0.61 0.023 0.000 
A_51_P115953 Ctxn3 cortexin 3 1.04 0.002 0.000 
A_51_P384187 Cxcl15 chemokine (C-X-C motif) ligand 15 1.08 0.029 0.000 
A_51_P334104 Dcn decorin 0.62 0.022 0.000 
A_51_P335969 Des desmin 0.92 0.047 0.000 
A_52_P643375 Dmpk dystrophia myotonica-protein kinase 1.02 0.030 0.000 
A_52_P558259 Dtna dystrobrevin alpha 0.62 0.050 0.000 
A_51_P259029 Dusp26 dual specificity phosphatase 26 (putative) 0.89 0.002 0.000 
A_51_P475378 Echdc3 enoyl Coenzyme A hydratase domain containing 3 0.88 0.003 0.000 
A_51_P503722 Elavl4 
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4 (Hu 
antigen D) 0.63 0.000 0.000 
A_52_P303274 Epyc epiphycan 1.85 0.023 0.000 
A_51_P167562 Erdr1 erythroid differentiation regulator 1 0.84 0.039 0.000 
A_51_P307979 Etv1 ets variant gene 1 0.63 0.013 0.000 
A_51_P364391 Fam125b family with sequence similarity 125, member B 0.59 0.014 0.000 
A_51_P283473 Fibin fin bud initiation factor homolog (zebrafish) 1.09 0.008 0.000 
A_52_P644690 Flt3l FMS-like tyrosine kinase 3 ligand 0.66 0.018 0.000 
A_51_P301998 Fmo2 flavin containing monooxygenase 2 0.93 0.000 0.000 
A_51_P287001 Fxyd1 FXYD domain-containing ion transport regulator 1 0.66 0.029 0.000 
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Table 3.S1A. Genes upregulated by E2 treatment (cont.) 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_52_P472302 Fxyd6 FXYD domain-containing ion transport regulator 6 1.07 0.011 0.000 
A_52_P217710 Fzd6 frizzled homolog 6 (Drosophila) 0.76 0.004 0.000 
A_51_P462428 Galntl2 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2 0.83 0.001 0.000 
A_51_P398766 Gbp1 guanylate binding protein 1 0.90 0.035 0.000 
A_52_P675556 Ghrl ghrelin 0.63 0.002 0.000 
A_52_P22611 Gm106 predicted gene 106 0.72 0.023 0.000 
A_51_P402583 Gpld1 glycosylphosphatidylinositol specific phospholipase D1 0.73 0.025 0.000 
A_51_P152990 Grem2 gremlin 2 homolog, cysteine knot superfamily (Xenopus laevis) 0.66 0.026 0.000 
A_51_P356055 Grp gastrin releasing peptide 1.55 0.012 0.000 
A_51_P150489 Gsdmc gasdermin C 0.76 0.007 0.000 
A_52_P87997 Gsdmc2 gasdermin C2 0.73 0.003 0.000 
A_52_P498798 Gsdmc3 gasdermin C3 0.82 0.003 0.000 
A_51_P249313 Herc3 hect domain and RLD 3 0.75 0.036 0.000 
A_51_P124315 Hmcn2 hemicentin 2 1.63 0.000 0.000 
A_51_P374571 Igfbp6 insulin-like growth factor binding protein 6 1.37 0.005 0.000 
A_51_P215849 Il17b interleukin 17B 0.73 0.026 0.000 
A_52_P78033 Ip6k2 inositol hexaphosphate kinase 2 0.62 0.000 0.000 
A_51_P364250 Itih5 inter-alpha (globulin) inhibitor H5 0.60 0.017 0.000 
A_51_P147987 Itln1 intelectin 1 (galactofuranose binding) 1.51 0.011 0.000 
A_51_P500056 Itpr2 inositol 1,4,5-triphosphate receptor 2 0.63 0.017 0.000 
A_51_P338705 Kank1 KN motif and ankyrin repeat domains 1 0.92 0.017 0.000 
A_52_P221776 Kif12 kinesin family member 12 0.87 0.001 0.000 
A_51_P107020 Kif5a kinesin family member 5A 0.70 0.006 0.000 
A_51_P362698 Klhl24 kelch-like 24 (Drosophila) 0.64 0.026 0.000 
A_52_P61273 Leng8 leukocyte receptor cluster (LRC) member 8 0.65 0.025 0.000 
A_51_P218091 Lgr5 leucine rich repeat containing G protein coupled receptor 5 0.92 0.003 0.000 
A_51_P151862 Lims2 LIM and senescent cell antigen like domains 2 0.76 0.006 0.000 
A_51_P173692 Lingo4 leucine rich repeat and Ig domain containing 4 0.59 0.050 0.000 
A_51_P429567 Lmod1 leiomodin 1 (smooth muscle) 0.79 0.012 0.000 
A_52_P614207 LOC100047222 
similar to anti-glycoprotein-B of human Cytomegalovirus 
immunoglobulin Vl chain 1.09 0.042 0.000 
A_52_P49797 LOC100047599 similar to gag protein 1.01 0.003 0.000 
A_52_P559957 Macrod1 MACRO domain containing 1 0.83 0.015 0.000 
A_51_P451458 Mamdc2 MAM domain containing 2 0.65 0.010 0.000 
A_52_P254908 Mcf2l mcf.2 transforming sequence-like 0.60 0.021 0.000 
A_51_P455997 Meg3 maternally expressed 3 1.26 0.030 0.000 
A_52_P290211 Meis2 Meis homeobox 2 0.79 0.018 0.000 
A_52_P414065 Mgl2 macrophage galactose N-acetyl-galactosamine specific lectin 2 0.64 0.003 0.000 
A_51_P426270 Mgp matrix Gla protein 0.99 0.006 0.000 
A_51_P423290 Mmrn1 multimerin 1 0.99 0.025 0.000 
A_51_P377620 Mnda myeloid cell nuclear differentiation antigen 0.83 0.001 0.000 
A_51_P206203 Mrgprf MAS-related GPR, member F 0.72 0.048 0.000 
A_51_P375538 Myb myeloblastosis oncogene 0.61 0.017 0.000 
A_51_P362429 Myh11 myosin, heavy polypeptide 11, smooth muscle 0.83 0.017 0.000 
A_51_P308298 Myl9 myosin, light polypeptide 9, regulatory 1.03 0.011 0.000 
A_52_P575217 Mylk myosin, light polypeptide kinase 0.93 0.004 0.000 
A_51_P122752 NA NA 2.74 0.022 0.000 
A_51_P208490 NA NA 0.69 0.001 0.000 
A_51_P227445 NA NA 0.79 0.033 0.000 
A_51_P266403 NA NA 1.02 0.004 0.000 
A_51_P418884 NA NA 0.60 0.027 0.000 
A_51_P461067 NA NA 2.71 0.025 0.000 
A_52_P1016836 NA NA 0.65 0.001 0.000 
A_52_P1054013 NA NA 2.64 0.030 0.000 
A_52_P186362 NA NA 0.62 0.037 0.000 
A_52_P308875 NA NA 0.71 0.003 0.000 
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Table 3.S1A. Genes upregulated by E2 treatment (cont.) 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_52_P346774 NA NA 0.59 0.035 0.000 
A_52_P474528 NA NA 0.72 0.006 0.000 
A_52_P483983 NA NA 3.82 0.050 0.000 
A_52_P575646 NA NA 0.59 0.002 0.000 
A_52_P65524 NA NA 0.71 0.013 0.000 
A_52_P739682 NA NA 0.69 0.028 0.000 
A_52_P236448 Ngfr nerve growth factor receptor (TNFR superfamily, member 16) 0.63 0.014 0.000 
A_51_P454873 Npy neuropeptide Y 0.80 0.020 0.000 
A_51_P296036 Nrbp2 nuclear receptor binding protein 2 0.76 0.004 0.000 
A_51_P163953 Nsg2 neuron specific gene family member 2 0.60 0.004 0.000 
A_52_P64783 Pabpn1 poly(A) binding protein, nuclear 1 0.65 0.000 0.000 
A_51_P220422 Pacsin1 protein kinase C and casein kinase substrate in neurons 1 0.62 0.000 0.000 
A_51_P171883 Palmd palmdelphin 0.69 0.035 0.000 
A_51_P253984 Pcp4 Purkinje cell protein 4 1.84 0.009 0.000 
A_51_P361150 Pcp4l1 Purkinje cell protein 4-like 1 1.00 0.008 0.000 
A_51_P157677 Pdlim3 PDZ and LIM domain 3 1.00 0.023 0.000 
A_52_P586928 Pdyn prodynorphin 0.69 0.012 0.000 
A_51_P102987 Penk preproenkephalin 1.40 0.002 0.000 
A_51_P167313 Pgbd5 piggyBac transposable element derived 5 0.64 0.001 0.000 
A_51_P451052 Pgm5 phosphoglucomutase 5 0.70 0.022 0.000 
A_51_P182572 Phactr1 phosphatase and actin regulator 1 0.70 0.005 0.000 
A_51_P357606 Phyhd1 phytanoyl-CoA dioxygenase domain containing 1 0.60 0.003 0.000 
A_52_P407239 Pik3r1 
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 
1 (p85 alpha) 0.61 0.048 0.000 
A_51_P337195 Pipox pipecolic acid oxidase 0.73 0.004 0.000 
A_51_P256632 Pla2g2a phospholipase A2, group IIA (platelets, synovial fluid) 1.92 0.015 0.000 
A_52_P94983 Pla2g5 phospholipase A2, group V 1.01 0.020 0.000 
A_51_P141290 Plch2 phospholipase C, eta 2 0.66 0.006 0.000 
A_51_P451588 Plekhb1 
pleckstrin homology domain containing, family B (evectins) 
member 1 0.63 0.040 0.000 
A_51_P495780 Plin4 perilipin 4 0.69 0.018 0.000 
A_52_P340187 Pon2 paraoxonase 2 0.70 0.009 0.000 
A_51_P224311 Popdc2 popeye domain containing 2 0.84 0.013 0.000 
A_52_P576222 Ppl periplakin 0.60 0.035 0.000 
A_51_P220278 Ppp2r2b 
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 
52), beta isoform 1.20 0.000 0.000 
A_51_P280455 Prg4 
proteoglycan 4 (megakaryocyte stimulating factor, articular 
superficial zone protein) 1.20 0.025 0.000 
A_51_P483280 Prnp prion protein 0.76 0.013 0.000 
A_51_P215438 Prodh proline dehydrogenase 0.82 0.000 0.000 
A_51_P251205 Psd pleckstrin and Sec7 domain containing 0.99 0.021 0.000 
A_52_P10793 Ptn pleiotrophin 1.14 0.028 0.000 
A_52_P11441 Rab6b RAB6B, member RAS oncogene family 0.91 0.000 0.000 
A_51_P394244 Rapgefl1 Rap guanine nucleotide exchange factor (GEF)-like 1 0.64 0.031 0.000 
A_52_P557940 Rbm4b RNA binding motif protein 4B 0.73 0.034 0.000 
A_52_P574759 Rbpjl 
recombination signal binding protein for immunoglobulin 
kappa J region-like 0.62 0.006 0.000 
A_52_P269334 Rdh13 retinol dehydrogenase 13 (all-trans and 9-cis) 0.59 0.019 0.000 
A_51_P365369 Reln reelin 0.72 0.003 0.000 
A_51_P257951 Retnla resistin like alpha 2.40 0.020 0.000 
A_51_P419768 Rgs2 regulator of G-protein signaling 2 0.70 0.023 0.000 
A_52_P136782 Rgs5 regulator of G-protein signaling 5 0.64 0.027 0.000 
A_52_P192462 Rims1 regulating synaptic membrane exocytosis 1 0.71 0.031 0.000 
A_52_P470648 Rnf4 ring finger protein 4 0.61 0.001 0.000 
A_51_P142421 Rspo1 R-spondin homolog (Xenopus laevis) 1.41 0.005 0.000 
A_51_P444264 Rtn1 reticulon 1 0.61 0.002 0.000 
A_51_P221223 Scg5 secretogranin V 0.68 0.012 0.000 
A_51_P213691 Scnn1a sodium channel, nonvoltage-gated 1 alpha 0.61 0.000 0.000 
A_51_P277336 Sdpr serum deprivation response 0.60 0.008 0.000 
A_52_P220573 Serpini1 serine (or cysteine) peptidase inhibitor, clade I, member 1 0.70 0.000 0.000 
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Table 3.S1A. Genes upregulated by E2 treatment (cont.) 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_51_P520849 Sfrp2 secreted frizzled-related protein 2 2.31 0.000 0.000 
A_51_P457196 Sfrp4 secreted frizzled-related protein 4 1.42 0.010 0.000 
A_51_P108334 Slc25a4 
solute carrier family 25 (mitochondrial carrier, adenine 
nucleotide translocator), member 4 0.65 0.004 0.000 
A_51_P194415 Slco3a1 solute carrier organic anion transporter family, member 3a1 0.68 0.005 0.000 
A_51_P423880 Smarcd3 
SWI/SNF related, matrix associated, actin dependent regulator 
of chromatin, subfamily d, member 3 1.02 0.027 0.000 
A_51_P118300 Sncg synuclein, gamma 0.70 0.010 0.000 
A_51_P369998 Sntg2 syntrophin, gamma 2 0.73 0.006 0.000 
A_51_P210510 Sparcl1 SPARC-like 1 0.82 0.017 0.000 
A_51_P140690 Stmn3 stathmin-like 3 0.75 0.001 0.000 
A_51_P434332 Sycn syncollin 0.63 0.004 0.000 
A_51_P185593 Synm synemin, intermediate filament protein 0.92 0.007 0.000 
A_52_P948080 Synpo2 synaptopodin 2 0.68 0.025 0.000 
A_52_P103929 Syt1 synaptotagmin I 0.76 0.001 0.000 
A_52_P517683 Tagln transgelin 0.84 0.041 0.000 
A_51_P459944 Tcf21 transcription factor 21 0.71 0.019 0.000 
A_52_P485573 Tef thyrotroph embryonic factor 0.77 0.008 0.000 
A_51_P194099 Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) 1.43 0.010 0.000 
A_51_P175303 Tle2 
transducin-like enhancer of split 2, homolog of Drosophila 
E(spl) 0.63 0.045 0.000 
A_51_P365008 Tns1 tensin 1 0.62 0.034 0.000 
A_51_P505530 Tnxb tenascin XB 0.94 0.007 0.000 
A_52_P315976 Tpm2 tropomyosin 2, beta 1.08 0.021 0.000 
A_51_P246924 Tppp3 tubulin polymerization-promoting protein family member 3 0.93 0.035 0.000 
A_52_P391624 Trnp1 TMF1-regulated nuclear protein 1 0.67 0.003 0.000 
A_51_P433141 Tro trophinin 0.79 0.023 0.000 
A_52_P316712 Ttc19 tetratricopeptide repeat domain 19 0.61 0.002 0.000 
A_51_P475049 Uchl1 ubiquitin carboxy-terminal hydrolase L1 0.89 0.013 0.000 
A_51_P368313 Vip vasoactive intestinal polypeptide 1.25 0.017 0.000 
A_51_P103397 Vwf Von Willebrand factor homolog 0.68 0.008 0.000 
A_51_P462708 Wfdc15b WAP four-disulfide core domain 15B 0.91 0.042 0.000 
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Table 3.S1B. Genes downregulated by Tamoxifen treatment 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_52_P185119 2210010C17Rik RIKEN cDNA 2210010C17 gene -0.77 0.003 0.034 
A_52_P670766 2210415F13Rik RIKEN cDNA 2210415F13 gene -0.67 0.014 0.045 
A_52_P110070 5730416F02Rik RIKEN cDNA 5730416F02 gene -0.71 0.014 0.045 
A_51_P394354 5730469M10Rik RIKEN cDNA 5730469M10 gene -0.71 0.045 0.049 
A_51_P407660 9630033F20Rik RIKEN cDNA 9630033F20 gene -0.61 0.048 0.049 
A_51_P456113 9930013L23Rik RIKEN cDNA 9930013L23 gene -0.82 0.045 0.049 
A_52_P349091 A930001A20Rik RIKEN cDNA A930001A20 gene -0.64 0.011 0.045 
A_51_P116421 Abcc5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 -0.59 0.028 0.045 
A_52_P24280 Abhd2 abhydrolase domain containing 2 -0.60 0.001 0.034 
A_52_P419455 Adora2b adenosine A2b receptor -0.70 0.013 0.045 
A_51_P510891 Afp alpha fetoprotein -0.92 0.033 0.048 
A_52_P620345 Ano10 anoctamin 10 -0.61 0.018 0.045 
A_51_P165342 Anxa2 annexin A2 -0.68 0.026 0.045 
A_51_P334979 Apoc2 apolipoprotein C-II -1.15 0.041 0.049 
A_52_P803082 Apol9a apolipoprotein L 9a -0.59 0.040 0.049 
A_52_P267651 Arntl aryl hydrocarbon receptor nuclear translocator-like -0.65 0.049 0.049 
A_51_P146044 Ccdc92 coiled-coil domain containing 92 -0.85 0.003 0.034 
A_52_P249514 Ccl12 chemokine (C-C motif) ligand 12 -0.64 0.025 0.045 
A_51_P286737 Ccl2 chemokine (C-C motif) ligand 2 -1.09 0.009 0.039 
A_51_P436652 Ccl7 chemokine (C-C motif) ligand 7 -0.67 0.019 0.045 
A_52_P637199 Chordc1 
cysteine and histidine-rich domain (CHORD)-containing, zinc-
binding protein 1 -0.76 0.027 0.045 
A_51_P199168 Cidea 
cell death-inducing DNA fragmentation factor, alpha subunit-
like effector A -1.02 0.006 0.036 
A_51_P363187 Cxcl1 chemokine (C-X-C motif) ligand 1 -0.90 0.006 0.036 
A_51_P509530 Cybrd1 cytochrome b reductase 1 -0.71 0.006 0.037 
A_52_P232637 Dhh desert hedgehog -0.67 0.029 0.045 
A_51_P208603 Dio2 deiodinase, iodothyronine, type II -0.77 0.033 0.048 
A_51_P303346 Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 -0.96 0.021 0.045 
A_51_P153486 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 -0.74 0.023 0.045 
A_51_P308796 Fosl1 fos-like antigen 1 -0.93 0.009 0.040 
A_51_P297579 Gch1 GTP cyclohydrolase 1 -0.87 0.009 0.040 
A_52_P532982 Gdf15 growth differentiation factor 15 -0.96 0.021 0.045 
A_52_P462657 Gm11545 predicted gene 11545 -1.09 0.009 0.039 
A_52_P220933 Gm9758 predicted gene 9758 -0.89 0.008 0.039 
A_52_P597775 Gprc5a G protein-coupled receptor, family C, group 5, member A -0.60 0.039 0.049 
A_52_P304902 Hspa1b heat shock protein 1B -2.02 0.020 0.045 
A_52_P652704 Hspa4l heat shock protein 4 like -0.72 0.023 0.045 
A_51_P110455 Hsph1 heat shock 105kDa/110kDa protein 1 -1.28 0.043 0.049 
A_51_P327751 Ifit1 interferon-induced protein with tetratricopeptide repeats 1 -1.14 0.025 0.045 
A_52_P351116 Igf1 insulin-like growth factor 1 -0.68 0.015 0.045 
A_52_P100926 Il1a interleukin 1 alpha -0.88 0.025 0.045 
A_51_P239750 Inhba inhibin beta-A -0.74 0.041 0.049 
A_51_P394728 Kti12 KTI12 homolog, chromatin associated (S. cerevisiae) -0.59 0.028 0.045 
A_51_P120830 Mmp10 matrix metallopeptidase 10 -1.22 0.020 0.045 
A_51_P514085 Mx2 myxovirus (influenza virus) resistance 2 -0.77 0.045 0.049 
A_52_P314181 NA NA -0.61 0.035 0.049 
A_52_P374395 NA NA -0.59 0.045 0.049 
A_51_P111492 Nfil3 nuclear factor, interleukin 3, regulated -0.72 0.030 0.046 
A_52_P359819 Ntf5 neurotrophin 5 -0.66 0.028 0.045 
A_52_P455764 Pard6b par-6 (partitioning defective 6) homolog beta (C. elegans) -0.61 0.045 0.049 
A_52_P405465 Piga phosphatidylinositol glycan anchor biosynthesis, class A -0.60 0.027 0.045 
A_52_P681310 Plaur plasminogen activator, urokinase receptor -1.05 0.044 0.049 
A_51_P314669 Pnliprp2 pancreatic lipase-related protein 2 -0.99 0.019 0.045 
A_52_P467930 Prdx6-ps2 peroxiredoxin 6 pseudogene 2 -0.62 0.025 0.045 
A_52_P252737 Rangap1 RAN GTPase activating protein 1 -0.59 0.013 0.045 
A_51_P340699 Rasl11a RAS-like, family 11, member A -0.67 0.013 0.045 
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Table 3.S1B. Genes downregulated by Tamoxifen treatment (cont.) 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_52_P59318 Rdh10 retinol dehydrogenase 10 (all-trans) -0.61 0.044 0.049 
A_51_P433127 Rdm1 RAD52 motif 1 -0.73 0.042 0.049 
A_51_P457481 Sectm1a secreted and transmembrane 1A -0.73 0.021 0.045 
A_52_P312102 Sema3g 
sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3G -0.62 0.042 0.049 
A_51_P183571 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 -0.66 0.036 0.049 
A_51_P213940 Sfn stratifin -0.59 0.044 0.049 
A_51_P371311 Slc1a4 
solute carrier family 1 (glutamate/neutral amino acid 
transporter), member 4 -0.68 0.003 0.034 
A_52_P589268 Smg7 
Smg-7 homolog, nonsense mediated mRNA decay factor (C. 
elegans) -0.60 0.003 0.034 
A_52_P381484 Spon2 spondin 2, extracellular matrix protein -0.75 0.039 0.049 
A_51_P330125 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) -0.82 0.034 0.049 
A_52_P116896 Tinagl1 tubulointerstitial nephritis antigen-like 1 -0.62 0.014 0.045 
A_51_P325152 Trmt61a tRNA methyltransferase 61 homolog A (S. cerevisiae) -0.65 0.008 0.039 
A_51_P473272 Tspan6 tetraspanin 6 -0.61 0.039 0.049 
A_52_P21 Ttc9 tetratricopeptide repeat domain 9 -0.63 0.029 0.045 
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Table 3.S1B. Genes upregulated by Tamoxifen treatment 
Probe set ID Gene 
symbol 
Gene title Log2 
change 
p-value q-value 
A_51_P144801 2210403K04Rik RIKEN cDNA 2210403K04 gene 0.73 0.005 0.036 
A_52_P324391 2310058N22Rik RIKEN cDNA 2310058N22 gene 0.61 0.044 0.049 
A_51_P195862 6030487A22Rik RIKEN cDNA 6030487A22 gene 0.63 0.049 0.049 
A_52_P290152 6720401G13Rik RIKEN cDNA 6720401G13 gene 0.73 0.026 0.045 
A_51_P443946 9030607L20Rik RIKEN cDNA 9030607L20 gene 0.62 0.043 0.049 
A_51_P120066 9330151L19Rik RIKEN cDNA 9330151L19 gene 0.60 0.007 0.039 
A_51_P423804 9530010C24Rik RIKEN cDNA 9530010C24 gene 0.71 0.049 0.049 
A_52_P504859 A530020G20Rik RIKEN cDNA A530020G20 gene 0.75 0.043 0.049 
A_51_P239236 Acacb acetyl-Coenzyme A carboxylase beta 0.75 0.021 0.045 
A_52_P549985 Asb13 ankyrin repeat and SOCS box-containing 13 0.85 0.048 0.049 
A_52_P83888 Cflar CASP8 and FADD-like apoptosis regulator 0.61 0.025 0.045 
A_51_P191669 Chgb chromogranin B 0.65 0.005 0.036 
A_51_P167292 Chi3l3 chitinase 3-like 3 1.12 0.024 0.045 
A_52_P61903 Chka choline kinase alpha 0.60 0.046 0.049 
A_51_P486239 Clec3b C-type lectin domain family 3, member b 0.61 0.042 0.049 
A_51_P115953 Ctxn3 cortexin 3 0.73 0.020 0.045 
A_51_P212308 Cxadr coxsackie virus and adenovirus receptor 0.78 0.006 0.036 
A_52_P257774 Cyp4a10 cytochrome P450, family 4, subfamily a, polypeptide 10 0.72 0.037 0.049 
A_51_P346715 D4Wsu53e DNA segment, Chr 4, Wayne State University 53, expressed 0.71 0.033 0.048 
A_51_P180492 Dbp D site albumin promoter binding protein 1.44 0.042 0.049 
A_51_P468876 Dixdc1 DIX domain containing 1 0.66 0.002 0.034 
A_51_P475378 Echdc3 enoyl Coenzyme A hydratase domain containing 3 0.73 0.041 0.049 
A_52_P81533 F730002C09Rik RIKEN cDNA F730002C09 gene 0.69 0.006 0.036 
A_52_P356343 Fam13a family with sequence similarity 13, member A 0.75 0.004 0.036 
A_52_P231075 Fcrls Fc receptor-like S, scavenger receptor 0.66 0.042 0.049 
A_52_P217710 Fzd6 frizzled homolog 6 (Drosophila) 0.72 0.006 0.036 
A_51_P462428 Galntl2 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 2 0.62 0.020 0.045 
A_51_P292073 Haghl hydroxyacylglutathione hydrolase-like 0.60 0.002 0.034 
A_51_P124315 Hmcn2 hemicentin 2 1.27 0.022 0.045 
A_51_P476091 Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 0.64 0.033 0.048 
A_52_P78033 Ip6k2 inositol hexaphosphate kinase 2 0.63 0.003 0.034 
A_51_P500056 Itpr2 inositol 1,4,5-triphosphate receptor 2 0.75 0.047 0.049 
A_52_P584058 Ivns1abp influenza virus NS1A binding protein 0.62 0.048 0.049 
A_51_P505689 Kifc2 kinesin family member C2 0.78 0.005 0.036 
A_52_P118161 Lss lanosterol synthase 0.63 0.027 0.045 
A_52_P432464 Luc7l2 LUC7-like 2 (S. cerevisiae) 0.60 0.027 0.045 
A_52_P391505 Meg3 maternally expressed 3 0.93 0.037 0.049 
A_52_P4482 NA NA 0.59 0.040 0.049 
A_52_P891818 NA NA 0.60 0.024 0.045 
A_51_P432892 NA NA 0.62 0.025 0.045 
A_51_P208490 NA NA 0.65 0.008 0.039 
A_52_P963820 NA NA 0.67 0.028 0.045 
A_52_P739682 NA NA 0.77 0.013 0.045 
A_51_P279898 NA NA 0.80 0.023 0.045 
A_52_P287811 NA NA 0.91 0.030 0.046 
A_51_P234692 Neat1 nuclear paraspeckle assembly transcript 1 (non-protein coding) 0.71 0.008 0.039 
A_51_P233727 Ng23 Ng23 protein 0.66 0.024 0.045 
A_52_P303891 Nr1d2 nuclear receptor subfamily 1, group D, member 2 0.87 0.003 0.034 
A_51_P296036 Nrbp2 nuclear receptor binding protein 2 0.66 0.014 0.045 
A_52_P19606 Osbpl1a oxysterol binding protein-like 1A 0.69 0.027 0.045 
A_52_P64783 Pabpn1 poly(A) binding protein, nuclear 1 0.60 0.005 0.036 
A_51_P361150 Pcp4l1 Purkinje cell protein 4-like 1 0.90 0.014 0.045 
A_52_P239511 Pde1c phosphodiesterase 1C 0.62 0.046 0.049 
A_52_P79889 Per1 period homolog 1 (Drosophila) 1.17 0.033 0.048 
A_51_P258493 Per3 period homolog 3 (Drosophila) 0.66 0.002 0.034 
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Table 3.S1B. Genes upregulated by Tamoxifen treatment (cont.) 
Probe set ID 
Gene 
symbol 
Gene title 
Log2 
change 
p-value q-value 
A_51_P150105 Ppnr per-pentamer repeat gene 0.70 0.034 0.048 
A_51_P220278 Ppp2r2b 
protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 
52), beta isoform 0.76 0.035 0.049 
A_51_P273433 Prkg2 protein kinase, cGMP-dependent, type II 0.60 0.044 0.049 
A_52_P557940 Rbm4b RNA binding motif protein 4B 0.91 0.017 0.045 
A_52_P195772 Rbmx RNA binding motif protein, X chromosome 0.72 0.024 0.045 
A_52_P209527 Rgs11 regulator of G-protein signaling 11 0.89 0.029 0.045 
A_51_P250590 Sbf2 SET binding factor 2 0.64 0.016 0.045 
A_51_P319289 Sdr9c7 4short chain dehydrogenase/reductase family 9C, member 7 0.87 0.004 0.034 
A_51_P520849 Sfrp2 secreted frizzled-related protein 2 1.25 0.008 0.039 
A_51_P108334 Slc25a4 
solute carrier family 25 (mitochondrial carrier, adenine 
nucleotide translocator), member 4 0.59 0.018 0.045 
A_51_P296182 Slc43a2 solute carrier family 43, member 2 0.60 0.028 0.045 
A_52_P326502 Sox21 SRY-box containing gene 21 0.69 0.003 0.034 
A_52_P424308 Sybu syntabulin (syntaxin-interacting) 0.60 0.048 0.049 
A_52_P485573 Tef thyrotroph embryonic factor 1.00 0.001 0.034 
A_52_P115996 Thrap3 thyroid hormone receptor associated protein 3 0.65 0.028 0.045 
A_51_P194099 Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) 0.77 0.020 0.045 
A_51_P344770 Tnrc6b trinucleotide repeat containing 6b 0.60 0.045 0.049 
A_51_P433141 Tro trophinin 0.64 0.027 0.045 
A_52_P564625 Ube2b 
ubiquitin-conjugating enzyme E2B, RAD6 homology (S. 
cerevisiae) 0.60 0.045 0.049 
A_51_P402160 Zfp750 zinc finger protein 750 0.60 0.017 0.045 
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Table 3.S1C. Genes downregulated by both E2 and Tamoxifen treatment 
Probe set ID 
Gene 
symbol 
Gene title 
A_52_P110070 5730416F02Rik RIKEN cDNA 5730416F02 gene 
A_51_P394354 5730469M10Rik RIKEN cDNA 5730469M10 gene 
A_51_P456113 9930013L23Rik RIKEN cDNA 9930013L23 gene 
A_52_P349091 A930001A20Rik RIKEN cDNA A930001A20 gene 
A_51_P116419 Abcc5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 
A_51_P510891 Afp alpha fetoprotein 
A_52_P620345 Ano10 anoctamin 10 
A_51_P165342 Anxa2 annexin A2 
A_51_P334979 Apoc2 apolipoprotein C-II 
A_51_P146044 Ccdc92 coiled-coil domain containing 92 
A_51_P305843 Chordc1 cysteine and histidine-rich domain (CHORD)-containing, zinc-binding protein 1 
A_51_P199168 Cidea cell death-inducing DNA fragmentation factor, alpha subunit-like effector A 
A_51_P363187 Cxcl1 chemokine (C-X-C motif) ligand 1 
A_52_P681592 Cybrd1 cytochrome b reductase 1 
A_51_P208603 Dio2 deiodinase, iodothyronine, type II 
A_51_P303346 Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 
A_51_P153486 Dnajb1 DnaJ (Hsp40) homolog, subfamily B, member 1 
A_51_P308796 Fosl1 fos-like antigen 1 
A_51_P297579 Gch1 GTP cyclohydrolase 1 
A_52_P532982 Gdf15 growth differentiation factor 15 
A_52_P462657 Gm11545 predicted gene 11545 
A_52_P220933 Gm9758 predicted gene 9758 
A_52_P304902 Hspa1b heat shock protein 1B 
A_51_P438283 Il1a interleukin 1 alpha 
A_51_P239750 Inhba inhibin beta-A 
A_51_P120830 Mmp10 matrix metallopeptidase 10 
A_52_P359819 Ntf5 neurotrophin 5 
A_52_P405465 Piga phosphatidylinositol glycan anchor biosynthesis, class A 
A_51_P112405 Plaur plasminogen activator, urokinase receptor 
A_51_P314669 Pnliprp2 pancreatic lipase-related protein 2 
A_52_P467930 Prdx6-ps2 peroxiredoxin 6 pseudogene 2 
A_51_P457481 Sectm1a secreted and transmembrane 1A 
A_51_P183571 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 
A_51_P371311 Slc1a4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 
A_51_P330125 Srxn1 sulfiredoxin 1 homolog (S. cerevisiae) 
A_51_P473272 Tspan6 tetraspanin 6 
A_52_P21 Ttc9 tetratricopeptide repeat domain 9 
A_52_P110070 5730416F02Rik RIKEN cDNA 5730416F02 gene 
A_51_P394354 5730469M10Rik RIKEN cDNA 5730469M10 gene 
A_51_P456113 9930013L23Rik RIKEN cDNA 9930013L23 gene 
A_52_P349091 A930001A20Rik RIKEN cDNA A930001A20 gene 
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Table 3.S1C. Genes upregulated by both E2 and Tamoxifen treatment 
Probe set ID 
Gene 
symbol 
Gene title 
A_52_P324391 2310058N22Rik RIKEN cDNA 2310058N22 gene 
A_52_P290152 6720401G13Rik RIKEN cDNA 6720401G13 gene 
A_52_P504859 A530020G20Rik RIKEN cDNA A530020G20 gene 
A_52_P549985 Asb13 ankyrin repeat and SOCS box-containing 13 
A_51_P191669 Chgb chromogranin B 
A_51_P115953 Ctxn3 cortexin 3 
A_51_P475378 Echdc3 enoyl Coenzyme A hydratase domain containing 3 
A_52_P217710 Fzd6 frizzled homolog 6 (Drosophila) 
A_51_P462428 Galntl2 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-
like 2 
A_51_P124315 Hmcn2 hemicentin 2 
A_52_P78033 Ip6k2 inositol hexaphosphate kinase 2 
A_51_P500056 Itpr2 inositol 1,4,5-triphosphate receptor 2 
A_51_P208490 NA NA 
A_52_P739682 NA NA 
A_51_P296036 Nrbp2 nuclear receptor binding protein 2 
A_52_P64783 Pabpn1 poly(A) binding protein, nuclear 1 
A_51_P361150 Pcp4l1 Purkinje cell protein 4-like 1 
A_51_P220278 Ppp2r2b protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta isoform 
A_52_P557940 Rbm4b RNA binding motif protein 4B 
A_51_P520849 Sfrp2 secreted frizzled-related protein 2 
A_51_P108334 Slc25a4 
solute carrier family 25 (mitochondrial carrier, adenine nucleotide translocator), 
member 4 
A_52_P485573 Tef thyrotroph embryonic factor 
A_51_P194099 Thrsp thyroid hormone responsive SPOT14 homolog (Rattus) 
A_51_P433141 Tro Trophinin 
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Table 3.S2A. Top 5 Networks affected by E2 
Associated Network 
Function 
Molecules in Network Score 
# of 
molecules 
Cardiovascular System 
Development and Function, 
Antigen Presentation, 
Cellular Function and 
Maintenance 
ABCG5, Angiotensin II receptor type 1, ANGPT2, CaMKII, CCDC92 (includes 
EG:80212), CCL19, CCL21, CDO1, CHGB, CLDN4, Creb, CXCL2, DLGAP1, 
EPHA2, FLNB, FOSL1, IER3, ITPR2, IVL, LOX, MYH11, NUPR1, p70 S6k, p85 
(pik3r), PCP4, PDGF BB, PI3K (complex), PIK3R1, PSD, RIMS1, SH3KBP1, 
SNCG, SYT1, VIP, VWF 
50 28 
Cell Death, Respiratory 
Disease, Cardiovascular 
Disease 
ALDH1A3, APOC2, C3, C1q, CAMK2G, CDK14, CFB, CFD, CLEC10A, ETS, 
GCH1, GDF15, Growth hormone, Hemoglobin, IL33, IL-1R, IL17B, IP6K2, Ldh, 
MIR1, MYLK, NFkB (complex), PABPN1, PI3, PLIN2, Proinflammatory 
Cytokine, SAA, SCNN1A, SLC11A2, SLC25A4, SPHK1, SRXN1, TEF, 
TNFRSF10A (includes EG:8797), XDH 
40 25 
Behavior, Digestive System 
Development and Function, 
Cell-To-Cell Signaling and 
Interaction 
CARTPT, Cytochrome c, Cytokeratin, DES, DTNA, EMP1, FABP4, GHRL, hCG, 
HIST1H1C, HIST1H1D (includes EG:3007), Histone H1, Histone h3, Insulin, Jnk, 
KIF5A, KIF5C, KRT20, MAP2K1/2, MCF2L, MEG3 (includes EG:17263), Mlc, 
MYB (includes EG:4602), MYL9 (includes EG:98932), PDYN, PP2A, PPP2R2B, 
PRL, RGS2, SFRP2, SFRP4, SNTG2, STC1, SYNM, TRO 
38 25 
Cell-To-Cell Signaling and 
Interaction, Renal and 
Urological System 
Development and Function, 
Embryonic Development 
Akt, Alp, ANXA2, BGLAP, Calpain, CASP12 (includes EG:12364), Caspase, 
CAV1, Caveolin, Collagen Alpha1, DNAJA1, DNAJB1, E2f, HIST4H4, Histone 
h4, HSP, Hsp70, Hsp90, HSPA1A, INHBA, LTBP2, NGFR, PLAUR, PRAP1, 
PRNP, Raf, Rb, RNF4, SDPR, SEC14L2, SERPINE1, SPARCL1, TAGLN, Tgf 
beta, TRIM25 
33 21 
Connective Tissue Disorders, 
Genetic Disorder, Ophthalmic 
Disease 
ANGPTL4, CELF6, CHP2, CIITA, CLDN4, CYP2D10, ERBB2, EXPI, FLRT3, 
FOXC2, FSTL3, GCNT2, HNF1A, HNMT, HSD17B6, IGFBP6, INS1, ITPR2, 
KIAA1199, KIF12, LAMC2, LTBP2, MIR24-1 (includes EG:407012), PAX4, 
PDHB, PDLIM4, PMM1, PRKCDBP, PRODH, RALB, SCG5, SDPR, SPARCL1, 
TGFB1, TGFBI 
31 20 
 
Table 3.S2B. Top 5 Networks affected by Tamoxifen 
Associated Network 
Function 
Molecules in Network Score 
# of 
molecules 
Behavior, Nervous System 
Development and Function, 
Cellular Movement 
Alp, APOC2, ARNTL, C8, CCL2, CCL7, CXADR, CXCL2, CYP4A11, DBP, 
GCH1, GDF15, HSPA1A, IFIT1B, Ifn, IFN Beta, IgG, Igm, IL12 (complex), IL1A, 
Immunoglobulin, Interferon alpha, IP6K2, LDL, MIR1, MX1, NFIL3, NFkB 
(complex), NR1D2, PER1, PER3, SAA, SLC25A4, SRXN1, TEF 
45 22 
Nutritional Disease, 
Organismal Injury and 
Abnormalities, Neurological 
Disease 
ACACB, ADORA2B, ANXA2, APLNR, ARL2BP, ATXN1, BDKRB1, CCR4, 
CDC42EP5, CHADL (includes EG:150356), CYBRD1, F2RL3, FNBP1, GPRC5A, 
GTP, HMGB1L1, HNRPDL, iron, ITPR2, KIAA1199, LSS, MMP10, MSR1, 
PIGA, RBM7, RBMX, SEMA3G, SLC1A4, SLC43A2, SYBU, TARDBP, TCF3, 
TGFB1, TNF, ZFP36 
32 17 
Cellular Growth and 
Proliferation, Hematological 
System Development and 
Function, Nervous System 
Development and Function 
Ap1, CCDC92 (includes EG:80212), CFLAR, CHGB, Collagen Alpha1, Collagen 
type IV, Collagen(s), Creb, ERK1/2, Fibrinogen, FOSL1, FSH, hCG, IGF1, 
INHBA, ITPR2, Laminin, Lh, MAP2K1/2, MMP10, NTF4, P38 MAPK, p70 S6k, 
Pdgf, PDGF BB, PLAUR, PP2A, PPP2R2B, PRKG2, SERPINE1, SMG7, Tgf beta, 
THRSP, TRO, Vegf 
29 16 
Cell Death, Dermatological 
Diseases and Conditions, 
Connective Tissue Disorders 
ABL1, beta-carotene, beta-hydroxyisovaleric acid, C10ORF58, C12ORF5, CHD3, 
CHI3L3, DBP, FAM173A, HCN2, HMGB1L1, IK, IL6, IL1/IL6/TNF, IL1F8, 
IVNS1ABP, KIFC2, LUC7L2, MAN2A2, MIR103-1 (includes EG:406895), 
NEAT1 (includes EG:66961), NFKB1, NFKBIZ, OSBPL1A, PARD6B, PDE1C, 
PTEN, SOX21, TAC1, TERT, TNRC6B, TP53, TSPAN6, UBE2B, ZCCHC10 
26 15 
Cellular Compromise, Cell 
Morphology, Cellular Growth 
and Proliferation 
A2M, ABHD2, ARNTL, ASB13, BAG1, CACNA1B, CARM1, CD7, CEBPA, 
CEBPG, CHORDC1, CTSL2, DNAJB4, DNAJC3, DNM1, FAM13A, FGR, GBP1 
(includes EG:2633), GNAO1, GNB5, HIF1AN, HSP90AA1, LITAF, MEG3 
(includes EG:17263), MFGE8, MIR124-1 (includes EG:406907), NOD1, PABPN1, 
PER3, PRL, RBM4B, RGS11, SECTM1, SFRP2, SMARCA4 
21 12 
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Table 3.S2C. Top 3 Networks affected by both E2 and Tamoxifen 
Associated Network 
Function 
Molecules in Network Score 
# of 
molecules 
Tumor Morphology, Cell 
Morphology, Hair and Skin 
Development and Function 
CCDC92 (includes EG:80212), CHGB, Collagen type IV, CXCL2, DNAJA1, 
DNAJB1, FOSL1, FSH, GCH1, GDF15, hCG, HSP, Hsp70, HSPA1A, IL1, IL1A, 
Immunoglobulin, INHBA, IP6K2, ITPR2, LDL, MIR1, Mmp, MMP10, NFkB 
(complex), P38 MAPK, Pdgf, PDGF BB, PLAUR, SERPINE1, SLC25A4, SRXN1, 
Tgf beta, TRO, Vegf 
45 19 
Tissue Development, Cell 
Death, Drug Metabolism 
ABCC5, ANXA2, APOC2, ASB13, BAG4, BAMBI, beta-estradiol, CASP3, 
CHORDC1, CIDEC, DNAJB4, DNM1, DPM2, FNBP1, GCHFR, HMCN1 
(includes EG:83872), HNF4A, HSP90AA1, IL15, KIAA1199, lipoprotein lipase, 
PABPN1, PCP4L1, PIGA, RBM5, RBM4B, SFRP2, SLC1A4, ST13, TEF, TGFB1, 
TNF, TSPAN6, TTC9, ZFP36 
36 16 
Cell Signaling, Molecular 
Transport, Nucleic Acid 
Metabolism 
13(S)-hydroxyoctadecadienoic acid, ADRB, AFP, Akt, APLNR, C10ORF58, 
CHGA, CIDEA, DIO2, DSPP, DUSP6, ELK4, ERK, ERK1/2, F2RL3, FZD6, 
gamma-linolenic acid, GDF15, Histone h3, IL1F8, Insulin, Jnk, lauric acid, Lh, 
Mac1, MAP3K8, Ncx, NTF4, Pkc(s), PPP2R2B, PPP2R2C, PRKAG1, TERT, 
THRSP, triiodothyronine, reverse 
18 9 
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Table 3.S3A. Top Biological Functions affected by E2: Diseases and disorders 
Biological Function Molecules in Network p-value 
# of 
molecules 
Cancer 
ABCC5, AFP, ALDH1A2, ALDH1A3, ANGPT2, ANGPTL4, ANXA2, BNIPL, C3, 
C7ORF68, C8ORF84, CAPG, CAV1, CCL19, CCL21, CD177, CDK3, CFB, CFD, 
CLDN4, CLEC10A, CREB3L3, CXCL2, DCN, DLGAP1, DMPK, DNAJA1, 
DTNA, EHHADH, EMP1, EPHA2, ETV1, F3, FABP4, FLT3LG, FOSL1, FTL, 
GCH1, GDF15, GHRL, GPRC5A, GRP, HNMT, HSD17B6, HSD17B11, HSPA1A, 
IER3, IGF2, IL33, IL17B, IL1A, INHBA, ITGA2, ITIH5, ITLN1, KIAA1199, 
KRT20, LAMA3, LAMC2, LOX, MGP, MMP3, MMP10, MMP13, MYB (includes 
EG:4602), MYH11, NGFR, NOS1, NUPR1, PCP4, PDLIM3, PHLDA2, PIK3R1, 
PIPOX, PLA2G2A, PLAUR, PLEKHB1, PLIN2, POPDC2, PPL, PPP2R2B, PRL, 
PRNP, PTN, RBM4B, RELN, RETNLA, RGS2, RGS5, RTN1, SCG5, SDPR, 
SECTM1, SERPINE1, SFRP2, SFRP4, SLC1A4, SLC7A11, SMARCD3, SNCG, 
SPARCL1, SPHK1, STC1, STMN3, SYNPO2, TAGLN, TCF21, TNFRSF10A 
(includes EG:8797), TNS1, TNXB, TPM2, TRO, UCHL1, VTCN1, VWF 
4.41E-07 - 
2.18E-02 
115 
Reproductive System Disease 
ABCC5,  AFP,  ALDH1A2,  ALDH1A3,  ANGPT2,  ANXA2,  APOBEC3B, 
BNIPL, C3, C7ORF68, C8ORF84, CAV1, CCL19, CCL21, CFB, CLDN4, 
CLEC10A, DCN, DLGAP1, DTNA, EPHA2, ETV1, F3, FABP4, FOSL1, GDF15, 
GHRL, GPRC5A, HSD17B6, IER3, IL1A, INHBA, ITLN1, KIAA1199, MGP, 
MMP3, NOS1, PENK, PIK3R1, PLAUR, PLEKHB1, PRL, RBM4B, SERPINE1, 
SFRP4, SLC1A4, SMARCD3, STC1, TNXB, TRO, UCHL1, VTCN1 
3.82E-04 - 
2.18E-02 
52 
Cardiovascular Disease 
ABCC5, ABCG5, ADAMTS12, AMICA1, ANGPT2, ANGPTL4, ANO10, ANXA2, 
APOC2, ASB13, BGLAP, BMPER, C3, C9ORF71, CAMK2G, CARTPT, CAV1, 
CDK14, CFB, COLEC10, DES, DIO2, DTNA, F3, FABP4, FGD3, FLT3LG, 
FOSL1, FXYD6, GDF15, GHRL, HMP19, HNMT, IGF2, IL33, IL1A, ITGA2, 
ITIH5, ITPR2, KIAA1199, LIMS2, LTBP2, MAMDC2, MCF2L, MEIS2, MGP, 
MMP3, MYH11, MYLK, NGFR, NOS1, NTF4, PHACTR1, PLA2G5, PLA2G2A, 
PLEKHB1, PON2, PPL, PPP1R12B, PRL, PRNP, PRODH, RELN, RGS2, RGS5, 
RIMS1, SCNN1A, SERPINE1, SLC1A4, SNTG2, SYNPO2, SYT1, TNS1, TTC9, 
UTS2, VIP, VWF, WDR72, XDH 
4.73E-04 - 
2.18E-02 
79 
Organismal Injury and 
Abnormalities 
ANGPT2, ANXA2, CAV1, F3, INHBA, ITGA2, LIMS2, NGFR, PLA2G2A, PRNP, 
SCNN1A, SERPINE1, SERPINI1, SPHK1, UTS2, VWF 
4.73E-04 - 
2.18E-02 
16 
Genetic Disorder 
ABCG5, ALDH1A2, ALDH1A3, ANGPTL4, ANXA2, C3, CARTPT, CAV1, CFB, 
CHGB, CIDEA, CLDN5, CPE, DCN, DLGAP1, DTNA, ELAVL4, ETV1, FABP4, 
FLNB, FTL, FXYD1, FXYD6, GCH1, GDF15, GHRL, GPRC5A, HMGCS2, 
HSD17B6, IER3, IL1A, KIF5A, LAMA3, LAMC2, MMP13, MYH11, NGFR, 
NOS1, NPY, NTF4, PCP4, PIK3R1, PLAUR, PLEKHB1, PMM1, PRG4 (includes 
EG:10216), PRL, PRNP, PRODH, RELN, RTN1, SCG5, SERPINE1, SERPINI1, 
SLC1A4, SLC7A11, SMARCD3, SYT1, TNXB, UCHL1, XDH 
5.30E-04 - 
2.18E-02 
61 
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Table 3.S3B. Top Biological Functions affected by E2: Molecular and Cellular functions 
Biological Function 
 
Molecules in Network p-value 
# of 
molecules 
Cellular Movement 
ABHD2, ANGPT2, ANGPTL4, ANXA2, C3, CARTPT, CAV1, CCL19, CCL21, 
CFB, CLDN4, CXCL2, CXCL15, DCN, DNAJA1, EPHA2, ETV1, F3, FABP4, 
FLNB, FLT3LG, FOSL1, GDF15, GHRL, GRP, IGF2, IGFBP6, IL33, IL1A, 
INHBA, ITGA2, LAMA3, LAMC2, LIMS2, LOX, LTBP2, MCF2L, MGP, MMP3, 
MMP10, MMP13, MYH11, MYLK, NGFR, NPY, NTF4, PARD6B, PENK, 
PIK3R1, PLA2G5, PLAUR, PON2, PRAP1, PRL, PRNP, PTN, RELN, RETNLA, 
SERPINE1, SFRP2, SFRP4, SNCG, SPHK1, STC1, STMN3, SYNM, TAGLN, 
TNFRSF10A (includes EG:8797), TNS1, UTS2, VIP, VTCN1, VWF, XDH 
3.91E-09 - 
2.02E-02 
74 
Cellular Development 
ABCC5, ALDH1A2, ANGPTL4, ANXA2, BGLAP, BMPER, BNIPL, BVES, 
CAPG, CARTPT, CAV1, CCDC92 (includes EG:80212), CCL19, CDO1, CHRDL1, 
CXCL2, CXCL15, DCN, DES, DIO2, EPHA2, ERO1L, FABP4, FLT3LG, FOSL1, 
FTL, GDF15, GHRL, GRP, HSPA1A, IER3, IFI16, IGF2, IGFBP6, IL33, IL17B, 
IL1A, INHBA, ITGA2, IVL, LAMA3, LOX, MGP, MMP3, MMP13, MYB 
(includes EG:4602), MYH11, MYLK, NGFR, NTF4, PENK, PIGA, PIK3R1, 
PLAUR, PRG4 (includes EG:10216), PRL, PRNP, PTN, RELN, RETNLA, RGS2, 
SEC14L2, SERPINE1, SFRP2, SFRP4, SLC7A11, SMARCD3, SNCG, SPHK1, 
STC1, TCF21, TCF23, TRIM25, UCHL1, UTS2, VIP, XDH 
7.48E-06 - 
2.18E-02 
77 
Cell-To-Cell Signaling and 
Interaction 
AFP, AMICA1, ANGPT2, ANXA2, C3, CARTPT, CAV1, CCL19, CCL21, CD177, 
CLDN4, CLDN5, CLEC10A, CXCL2, DCN, EPHA2, F3, FGD3, FLT3LG, GHRL, 
GRP, HS3ST1, IFI16, IGF2, IL33, IL1A, INHBA, ITGA2, ITLN1, LAMA3, LOX, 
MMP13, NGFR, NPY, NTF4, PARD6B, PENK, PIK3R1, PLA2G2A, PLAUR, 
PRL, PRNP, PTN, RELN, RETNLA, SERPINE1, STC1, TNFRSF10A (includes 
EG:8797), TNS1, VIP, VTCN1, VWF, XDH 
8.25E-06 - 
2.18E-02 
53 
Lipid Metabolism 
ABCG5, ADH7, AFP, ALDH1A2, ALDH1A3, ANGPT2, ANGPTL4, ANXA2, 
APOC2, C3, CARTPT, CAV1, CFD, CIDEA, CPE, DNAJA1, DNAJB1, EHHADH, 
FABP4, GHRL, GREM2, GRP, IGF2, IL33, IL1A, INHBA, NGFR, NPY, 
OSTALPHA, PIK3R1, PLA2G5, PLA2G2A, PLCH2, PLIN2, PNLIPRP2, PON2, 
PRL, PRNP, RGS2, SCG5, SCNN1A, SEC14L2, SERPINE1, SPHK1, ST3GAL6, 
ST8SIA6, STC1, THRSP, TNXB, VIP, XDH 
3.42E-05 - 
2.18E-02 
51 
Molecular Transport 
ABCG5, AFP, ANGPT2, ANGPTL4, ANXA2, C3, CAMK2G, CARTPT, CAV1, 
CCL19, CCL21, CFD, CIDEA, CPE, DCN, DIO2, DNAJB1, FABP4, FXYD1, 
GCH1, GHRL, GRP, IGF2, IL33, IL1A, INHBA, ITGA2, ITPR2, KRT20, LTBP2, 
MYB (includes EG:4602), NGFR, NOS1, NPY, OSTALPHA, PIK3R1, PLA2G5, 
PLA2G2A, PLAUR, PLIN2, PON2, PRL, PRNP, RGS2, SCG5, SCNN1A, 
SEC14L2, SERPINE1, SLC11A2, SPHK1, STC1, SYT1, UTS2, VIP, XDH 
3.42E-05 - 
2.18E-02 
55 
 
Table 3.S3C. Top Biological Functions affected by E2: Physiological System and Development and 
Function 
Biological Function Molecules in Network p-value 
# of 
molecules 
Behavior 
ARC, CARTPT, CCL21, GCH1, GHRL, GRP, HSPA1A, NGFR, NOS1, NPY, 
NTF4, PDYN, PENK, PLAUR, PRNP, RGS2, RIMS1,UCHL1 
2.55E-05 - 
1.90E-02 
18 
Organismal Development 
ALDH1A2, ANGPT2, ANGPTL4, ANXA2, ATPIF1, C3, CARTPT, CAV1, EPHA2, 
F3, FABP4, FLNB, GCH1, GHRL, HSPA1A, IGF2, IGFBP6, IL17B, IL1A, 
INHBA, ITGA2, ITPR2, LOX, MEP1B, MMP3, MMP13, MYB (includes 
EG:4602), NOS1, NPY, NTF4, PIK3R1, PLAUR, PLCD3, PON2, PRL, RGS5, 
SCNN1A, SERPINE1, SPHK1, STC1, UTS2,VIP 
4.52E-05 - 
1.90E-02 
42 
Cardiovascular System 
Development and Function 
ALDH1A2, ANGPT2, ANGPTL4, ANXA2, ATPIF1, C3, CARTPT, CAV1, 
CXCL15, DCN, DIO2, EMP1, EPHA2, F3, FABP4, GCH1, GHRL, GRP, IFI16, 
IGF2, IL17B, IL1A, INHBA, ITGA2, LOX, MGP, MMP3, MMP13, MYB (includes 
EG:4602), MYH11, NOS1, NPY, NUPR1, PIK3R1, PLAUR, PLCD3, PRL, PTN, 
RGS2, RGS5, SCNN1A, SERPINE1, SPHK1, STC1, UTS2, VIP, VWF 
4.91E-05 - 
1.90E-02 
47 
Embryonic Development 
ALDH1A2, ALDH1A3, ANXA2, C3, CAV1, EPHA2, GRP, IGF2, INHBA, ITGA2, 
LIMS2, MYH11, NPNT, PIGA, PIK3R1, PLAUR, PRL, RELN, SFRP4, SPHK1, 
TCF21, TRO 
9.18E-05 - 
2.18E-02 
22 
Hair and Skin Development and 
Function 
ANXA2, CAV1, HSPA1A, INHBA, PLAUR, RELN, SERPINE1 
9.18E-05 - 
8.86E-03 
7 
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Table 3.S3D. Top Canonical Pathways affected by E2 
Canonical Pathway p-value 
LPS/IL-1 Mediated Inhibition of RXR Function 4.43E-03 
Coagulation System  4.90E-03 
Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 5.90E-03 
Aldosterone Signaling in Epithelial Cells  8.99E-03 
Atherosclerosis Signaling  1.11E-02 
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Table 3.S4A. Top Biological Functions affected by Tamoxifen: Diseases and disorders 
Biological Function Molecules in Network p-value # of 
molecules 
Cancer 
ABCC5, ADORA2B, AFP, ANXA2, C1ORF63, CCL2, CCL13, CFLAR, 
CLEC3B, CXADR, CXCL2, CYP4A11, DHH, DNAJA1, FOSL1, GCH1, GDF15, 
GPRC5A, HNRPDL, HSPA1A, IGF1, IL1A, INHBA, KIAA1199, KIFC2, 
MMP10, MX1, NFIL3, PER1, PLAUR, PPP2R2B, RBM4B, SECTM1, 
SERPINE1, SFN, SFRP2, SLC1A4, SPON2, TNRC6B, TRO, UBE2B 
1.29E-05 - 
1.60E-02 
41 
Hypersensitivity Response CCL2, CCL7, CCL13, CHI3L3, PLAUR 
2.86E-05 - 
8.16E-03 
5 
Inflammatory Response 
ABHD2, ADORA2B, ANXA2, ARNTL, CCL2, CCL7, CCL13, CHI3L3, CXCL2, 
HSPA1A, IGF1, IL1A, INHBA, MX1, NFIL3, PLAUR, SECTM1, SERPINE1, 
SPON2 
6.15E-05 - 
1.63E-02 
19 
Nutritional Disease 
ACACB, ARNTL, CCL13, CIDEA, DIO2, GCH1, HSPA1A, IGF1, NTF4, 
SERPINE1 
8.99E-05 -  
1.18E-02 
10 
Organismal Injury and 
Abnormalities 
CCL2, CCL13, CFLAR, IGF1, IL1A, INHBA, MX1, PLAUR, SERPINE1 
1.04E-04 -  
1.62E-02 
9 
 
Table 3.S4B. Top Biological Functions affected by Tamoxifen: Molecular and Cellular functions 
Biological Function Molecules in Network p-value 
# of 
molecules 
Cellular Movement 
ANXA2, CCL2, CCL7, CCL13, CHI3L3, CXCL2, DNAJA1, FOSL1, GDF15, 
IGF1, IL1A, INHBA, MMP10, MX1, NTF4, PLAUR, SERPINE1, SFRP2 
1.51E-05 - 
1.62E-02 
18 
Cell Morphology 
ANXA2, CCL2, CCL7, CCL13, CXADR, CXCL2, DHH, FZD6, HSPA1A, IGF1, 
INHBA, NTF4, OSBPL1A, PARD6B, PIGA, PLAUR, SERPINE1, SFN 
2.86E-05 - 
1.41E-02 
18 
Cellular Development 
ABCC5, CCDC92 (includes EG:80212), CCL2, CCL7, CCL13, CHKA, CXADR, 
CXCL2, DHH, DIO2, FOSL1, FZD6, GDF15, HSPA1A, IGF1, IL1A, INHBA, 
NTF4, PARD6B, PIGA, PLAUR, PRKG2, SERPINE1, SFN, SFRP2 
2.86E-05 - 
1.62E-02 
25 
Cell-To-Cell Signaling and 
Interaction 
AFP, ANXA2, CCL2, CCL7, CCL13, CXADR, CXCL2, DHH, HSPA1A, IGF1, 
IL1A, INHBA, NTF4, PARD6B, PLAUR, SERPINE1, SPON2, SYBU, UBE2B 
6.15E-05 - 
1.63E-02 
19 
Antigen Presentation 
ANXA2, ARNTL, CCL2, CCL7, CCL13, CXCL2, IGF1, IL1A, INHBA, PLAUR, 
SPON2 
8.29E-05 - 
8.16E-03 
11 
 
Table 3.S4C. Top Biological Functions affected by Tamoxifen: Physiological System and 
Development and Function 
Biological Function Molecules in Network p-value 
# of 
molecules 
Hematological System 
Development and Function 
ANXA2, ARNTL, CCL2, CCL7, CCL13, CFLAR, CHI3L3, CXCL2, CYP4A11, 
HSPA1A, IGF1, IL1A, INHBA, NFIL3, PLAUR, SERPINE1, SPON2 
2.86E-05 - 
1.63E-02 
17 
Tumor Morphology GDF15, IGF1, IL1A, PLAUR, SERPINE1 
2.86E-05 - 
1.62E-02 
5 
Immune Cell Trafficking 
ANXA2, CCL2, CCL7, CCL13, CHI3L3, CXCL2, HSPA1A, IGF1, IL1A, 
INHBA, PLAUR, SERPINE1, SPON2 
6.15E-05 - 
1.63E-02 
13 
Auditory and Vestibular 
System Development and 
Function 
DIO2, IGF1 
6.59E-05 - 
8.16E-03 
2 
Organ Development CCL13, DIO2, IGF1, INHBA 
6.59E-05 - 
1.37E-02 
4 
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Table 3.S4D. Top Canonical Pathways affected by Tamoxifen 
Canonical Pathway p-value 
LXR/RXR Activation 2.53E-03 
Aldosterone Signaling in Epithelial Cells 4.76E-03 
Role of Hypercytokinemia/hyperchemokinemia in the Pathogenesis of Influenza 1.62E-02 
Chemokine Signaling 1.73E-02 
Circadian Rhythm Signaling 2.03E-02 
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Table 3.S5A. Top Biological Functions affected by both E2 and Tamoxifen: Diseases and disorders 
Biological Function Molecules in Network p-value 
# of 
molecules 
Cancer 
ABCC5, AFP, ANXA2, CXCL2, DNAJA1, FOSL1, GCH1, GDF15, HSPA1A, 
IL1A, INHBA, KIAA1199, MMP10, PLAUR, PPP2R2B, RBM4B, SECTM1, 
SERPINE1, SFRP2, SLC1A4, TRO 
1.89E-05 - 
2.77E-02 
21 
Nutritional Disease CIDEA, DIO2, GCH1, HSPA1A, NTF4, SERPINE1 
5.28E-04 - 
2.37E-02 
6 
Reproductive System Disease 
ABCC5, AFP, ANXA2, FOSL1, GDF15, IL1A, INHBA, KIAA1199, PLAUR, 
SERPINE1, SLC1A4, TRO 
5.45E-04 - 
2.64E-02 
12 
Organismal Injury and 
Abnormalities 
ANXA2, IL1A, INHBA, NTF4, PLAUR, SERPINE1 
1.44E-03 - 
2.56E-02 
6 
Genetic Disorder 
ABCC5, ANO10, APOC2, ASB13, CIDEA, GCH1, GDF15, IL1A, ITPR2, 
KIAA1199, NTF4, SERPINE1, SLC1A4, SLC25A4, TTC9 
2.44E-03 - 
2.66E-02 
15 
 
Table 3.S5B. Top Biological Functions affected by both E2 and Tamoxifen: Molecular and Cellular 
functions 
Biological Function Molecules in Network p-value 
# of 
molecules 
Cell Morphology 
ANXA2,  CXCL2, FOSL1, FZD6, GDF15, HSPA1A, IL1A, INHBA, NTF4, 
PIGA, PLAUR, SERPINE1 
5.16E-05 - 
3.13E-02 
12 
Cell-To-Cell Signaling and 
Interaction 
ANXA2, CXCL2, HSPA1A, IL1A, INHBA, NTF4, PLAUR, SERPINE1 
6.94E-05 - 
2.92E-02 
8 
Cell Death 
ABCC5, AFP, CIDEA, CXCL2, DNAJA1, DNAJB1, FOSL1, GDF15, HSPA1A, 
IL1A, INHBA, IP6K2, ITPR2, MMP10, NTF4, PIGA, PLAUR, PPP2R2B, 
RBM4B, SERPINE1, SFRP2, SLC25A4, SRXN1 
1.06E-04 - 
2.92E-02 
23 
Cellular Movement 
ANXA2, CXCL2, DNAJA1, FOSL1, GDF15, IL1A, INHBA, MMP10, NTF4, 
PLAUR, SERPINE1, SFRP2 
2.78E-04 - 
3.06E-02 
12 
Drug Metabolism ABCC5, AFP, ANXA2, DIO2, DNAJA1, DNAJB1, GCH1, IL1A, INHBA 
2.78E-04 - 
2.92E-02 
9 
 
Table 3.S5C. Top Biological Functions affected by both E2 and Tamoxifen: Physiological System 
and Development and Function 
Biological Function Molecules in Network p-value 
# of 
molecules 
Tumor Morphology GDF15, IL1A, PLAUR, SERPINE1, SFRP2 
2.62E-06 - 
2.56E-02 
5 
Hair and Skin Development and 
Function 
ABCC5, ANXA2, CXCL2, FOSL1, HSPA1A, IL1A, INHBA, NTF4, PLAUR, 
SERPINE1 
5.16E-05 - 
2.83E-02 
10 
Embryonic Development ABCC5, ANXA2, IL1A, INHBA, PIGA, PLAUR, SERPINE1, SFRP2 
6.94E-05 - 
1.84E-02 
8 
Endocrine System Development 
and Function 
AFP, DIO2, DNAJA1, DNAJB1, IL1A, INHBA 
3.70E-04 - 
2.92E-02 
6 
Nervous System Development 
and Function 
CXCL2, DIO2, GDF15, IL1A, INHBA, NTF4, PLAUR 
4.23E-04 - 
2.92E-02 
7 
 
Table 3.S5D. Top Canonical Pathways affected by both E2 and Tamoxifen 
Canonical Pathway p-value 
Aldosterone Signaling in Epithelial Cells 1.48E-03  
Coagulation System 6.19E-03  
Wnt/b-catenin Signaling 2.12E-02 
Dopamine Receptor Signaling 2.47E-02 
LXR/RXR Activation 2.76E-02 
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Table 3.S6A. Corpus pathology scores at 16 WPI 
Treatment Count Inflammation Epithelial 
defects 
Oxyntic 
atrophy 
Foveolar 
hyperplasia 
Intestinal 
metaplasia 
Dysplasia GHAI 
Uninfected 
female 
5 1.0 ± 0.0 0.3 ± 0.4 1.0 ± 0.0 2.6 ± 0.2 0.0 ± 0.0 0.2 ± 0.3 5.1 ± 0.5 
Uninfected male 5 0.8 ± 0.3 0.9 ± 0.7 1.4 ± 0.2 2.0 ± 0.0 0.7 ± 0.7 0.7 ± 0.7 6.5 ± 1.8 
Infected female 5 1.7 ± 0.3 0.7 ± 0.3 2.4 ± 0.4 3.5 ± 0.0 2.1 ± 0.2 1.0 ± 0.4 11.4 ± 1.2 
Infected male 5 1.8 ± 0.3 1.7 ± 0.3 2.4 ± 0.4 3.2 ± 0.3 1.9 ± 0.7 1.2 ± 0.4 12.2 ± 1.9 
 
Table 3.S6B. Corpus pathology scores at 28 WPI 
Treatment Count Inflammation 
Epithelial 
defects 
Oxyntic 
atrophy 
Foveolar 
hyperplasia 
Intestinal 
metaplasia 
Dysplasia GHAI 
Uninfected 
untreated male 
12 0.8 ± 0.3 1.2 ± 0.7 1.2 ± 0.5 1.4 ± 0.5 0.3 ± 0.3 0.9 ± 0.4 5.8 ± 1.8 
Uninfected 
estradiol male 
10 0.6 ± 0.4 0.6 ± 0.5 0.5 ± 0.2 1.0 ± 0.5 0.1 ± 0.2 0.3 ± 0.3 3.0 ± 1.1 
Uninfected 
Tamoxifen male 
6 0.8 ± 0.3 0.9 ± 0.2 1.1 ± 0.6 0.9 ± 0.2 0.3 ± 0.3 0.6 ± 0.2 4.5 ± 0.9 
Uninfected E2 + 
Tam male 
7 0.4 ± 0.2 0.3 ± 0.3 0.3 ± 0.3 0.8 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 1.8 ± 1.0 
         
Infected 
untreated male 
10 2.5 ± 0.0 2.8 ± 0.3 2.5 ± 0.3 3.5 ± 0.4 2.9 ± 0.2 2.9 ± 0.5 17.1 ± 1.2 
Infected estradiol 
male 
9 1.9 ± 0.6 1.4 ± 0.9 2.6 ± 0.5 2.7 ± 0.7 2.4 ± 0.8 1.6 ± 0.7 12.6 ± 3.7 
Infected 
Tamoxifen male 
7 1.9 ± 0.3 2.4 ± 0.5 2.9 ± 0.2 1.9 ± 0.5 2.8 ± 0.4 1.6 ± 0.2 13.6 ± 0.7 
Infected E2 + 
Tam male 
4 2.1 ± 0.3 2.5 ± 0.7 2.3 ± 0.3 2.5 ± 0.4 2.4 ± 0.3 2.1 ± 0.5 13.9 ± 1.9 
         
Uninfected 
untreated female 
9 0.8 ± 0.4 0.3 ± 0.4 1.3 ± 0.3 1.8 ± 0.7 0.0 ± 0.0 0.4 ± 0.2 4.6 ± 1.5 
Uninfected 
Tamoxifen 
female 
1 0.5 0.0 0.5 1.0 0.0 0.0 2.0 
         
Infected 
untreated female 
10 1.3 ± 0.3 0.9 ± 0.5 2.8 ± 0.4 2.3 ± 0.5 2.6 ± 0.6 1.6 ± 0.5 11.4 ± 1.9 
Infected 
Tamoxifen 
female 
9 1.6 ± 0.3 1.2 ± 0.8 2.9 ± 0.2 2.1 ± 0.3 2.8 ± 0.4 1.7 ± 0.4 12.2 ± 1.2 
 
 
Table 3.S6C. Antrum pathology scores at 16 WPI 
Treatment Count Inflammation 
Epithelial 
defects 
Hyperplasia Dysplasia GHAI 
Uninfected 
female 
5 0.0 ± 0.0 0.0 ± 0.0 0.7 ± 0.8 0.3 ± 0.3 1.0 ± 0.9 
Uninfected 
male 
5 0.1 ± 0.2 0.0 ± 0.0 0.6 ± 0.2 0.3 ± 0.3 1.0 ± 0.5 
Infected female 5 0.4 ± 0.2 0.3 ± 0.3 1.3 ± 0.7 0.8 ± 0.6 2.8 ± 1.4 
Infected male 5 0.3 ± 0.3 0.2 ± 0.3 1.1 ± 0.5 0.5 ± 0.4 2.1 ± 1.1 
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Table 3.S6D. Antrum pathology scores at 28 WPI 
Treatment Count Inflammation 
Epithelial 
defects 
Hyperplasia Dysplasia GHAI 
Uninfected 
untreated male 
12 0.1 ± 0.2 0.0 ± 0.0 0.8 ± 0.3 0.6 ± 0.2 1.4 ± 0.4 
Uninfected 
estradiol male 
10 0.0 ± 0.0 0.0 ± 0.0 0.7 ± 0.2 0.5 ± 0.0 1.2 ± 0.2 
Uninfected 
Tamoxifen male 
6 0.0 ± 0.0 0.0 ± 0.0 0.7 ± 0.3 0.4 ± 0.2 1.1 ± 0.4 
Uninfected E2 
+ Tam male 
7 0.0 ± 0.0 0.0 ± 0.0 0.6 ± 0.2 0.4 ± 0.2 0.9 ± 0.3 
       
Infected 
untreated male 
10 0.7 ± 0.2 0.0 ± 0.0 1.1 ± 0.6 0.8 ± 0.3 2.5 ± 1.1 
Infected 
estradiol male 
9 0.0 ± 0.0 0.0 ± 0.0 0.3 ± 0.3 0.1 ± 0.2 0.4 ± 0.2 
Infected 
Tamoxifen male 
7 0.0 ± 0.0 0.0 ± 0.0 0.5 ± 0.3 0.1 ± 0.2 0.6 ± 0.4 
Infected E2 + 
Tam male 
4 0.1 ± 0.3 0.0 ± 0.0 0.6 ± 0.3 0.4 ± 0.3 1.1 ± 0.5 
       
Uninfected 
untreated 
female 
9 0.1 ± 0.2 0.0 ± 0.0 0.4 ± 0.2 0.4 ± 0.2 0.9 ± 0.2 
Uninfected 
Tamoxifen 
female 
1 0.0 0.0 0.5 0.5 1.0 
       
Infected 
untreated 
female 
10 0.4 ± 0.3 0.0 ± 0.0 0.8 ± 0.4 0.3 ± 0.3 1.5 ± 0.7 
Infected 
Tamoxifen 
female 
9 0.3 ± 0.3 0.0 ± 0.0 0.6 ± 0.4 0.2 ± 0.3 1.2 ± 0.6 
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Chapter 4: Summary 
 
4.1 Summary 
 
This thesis reported studies on gender effects on the pathogenesis of the carcinogenic 
bacterium Helicobacter pylori.  To this end, two research goals were planned: 1) characterize the 
effect of gender, in response to H. pylori infection, on somatic mutations in gpt delta mice and 
2) characterize the effect of estrogen and Tamoxifen, in response to H. pylori infection, on 
carcinogenesis in INS-GAS mice.  The first research aim was to investigate if chronic H. pylori 
infection was associated with an increase in mutations in male and female gpt delta mice on a 
C57BL/6 background.  Given the ability to detect point mutations and deletions with the gpt 
delta mouse and the robust inflammatory response to H. pylori in female C57BL/6 mice, a1.6-
fold increase in mutation frequency was observed 12 months post infection in H. pylori infected 
female mice.  This result confirmed the mutagenic effects of H. pylori infection and led to the 
realization that the strength of the immune response and the length of exposure are necessary 
for the induction of point mutations.  Increased severity of gastric lesions were observed in 
female mice at 6 months post infection. Decreased counts of H. pylori were also observed in 
female mice at 6 and 12 months post infection, as well as an increased proinflammatory, Th1 
response at 12 months post infection.  Altogether, the increased gastric pathology, the 
decreased H. pylori counts and the increased Th1 response were indicative of a more robust 
immune response to the bacterium in female mice, seen previously in the literature1, which 
caused more mutations.  Sequencing analysis demonstrated that A:T to G:C transitions and G:C 
to T:A transversions were the mutations induced by H. pylori.  The spectrum of mutations point 
toward oxidative damage as the underlying mechanism of mutagenesis, as had been noted in 
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other models of chronic inflammation2 and human gastric cancers3, indicating that the model 
closely recapitulates pathogenic processes in humans.  Our results show a direct link between 
H. pylori infection, the severity of inflammation and the induction of mutations in C57BL/6 
mice.      
The second research aim was to characterize the effect of 17β-estradiol (E2) and 
Tamoxifen (TAM) treatment on H. pylori-induced carcinogenesis in INS-GAS FVB mice.  INS-GAS 
mice develop gastric adenocarcinoma in a male-predominant manner making them an ideal 
mouse model to study the modulatory effects of E2 and TAM in male and female mice.  This 
study led to the discovery of the protective effects of E2 and TAM in this model of gastric cancer, 
as both compounds prevented the formation of gastric carcinomas in H. pylori-infected male 
mice, and did not exacerbate disease in females.  Indeed, this was a surprising result as 
epidemiological data indicated that TAM might promote the development of gastric cancer in 
postmenopausal women4.  Global gene expression analysis revealed evidence of the role of 
deregulation of cellular movement and oncogenic pathways in mediating protection.  Further 
investigation of the role of cellular movement demonstrated that CXCL1, a potent neutrophil 
chemokine, was downregulated by E2 or TAM treatment in infected male mice.  Serum levels of 
CXCL1 were also decreased in infected E2 treated males as well as infected untreated females.  
The downregulation of gastric CXCL1 expression and the lower serum protein levels were 
supported by significant decreases in neutrophilic infiltration in infected E2-treated males, with 
a similar decreasing trend in infected TAM-treated males.  These results suggest that estrogen 
signaling may mediate protection in infected males by downregulating trafficking of neutrophils 
reducing the inflammatory response to H. pylori and abrogating cancer formation in our model.  
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Analysis of genes associated with cancer that were affected by E2 and TAM treatment showed a 
common downregulation of the receptor for plasminogen activator, urokinase, or PLAUR, and 
several of its immediate regulators (GDF15 and SERPINE1). PLAUR serves as a focal point of 
proteolytic activity during extracellular matrix (ECM) remodeling5-6. PLAUR overexpression has 
been associated with increased gastric cancer and poorer survival of gastric cancer patients due 
to its role in metastasis and invasion5-7.   Therefore, E2 and TAM may prevent gastric 
carcinogenesis by decreasing aberrant ECM remodeling.  As PLAUR is activated by β-catenin8, 
genes involved in regulating Wnt/β-catenin signaling were explored.  SFRP2 and FZD6, two Wnt 
signaling repressors, were upregulated by E2 and TAM, suggestive of a possible interaction 
between estrogen signaling and the Wnt/β-catenin pathway.  Further work is necessary to 
determine the role of PLAUR and its regulation by β-catenin.  Our results demonstrated that E2 
and TAM reduced gastric carcinogenesis in infected INS-GAS male mice by decreasing 
inflammatory cell recruitment and downregulating oncogenic pathways. 
This thesis sought to characterize gender differences in H. pylori-mediated gastric cancer 
using mouse models in order to provide greater insights into inflammation-mediated 
carcinogenesis in humans.  When working with mouse models it is necessary to keep in mind 
the advantages and disadvantages of the system while determining the translational potential 
of the data.  This final section will attempt to summarize insights into the roles of gender, 
mutations, cancer, immune cell trafficking and hormone therapy in H. pylori pathogenesis 
gained through this thesis (Table 4.1). 
 In humans, H. pylori promotes male-predominant gastric cancer9.  Different mouse 
models have different sexual dimorphisms in gastric disease, e.g. a stronger immune response 
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in female C57BL/6 mice and male-predominant carcinogenesis in INS-GAS mice.  It is of great 
importance to adequately account for the role of gender in mouse models in relation to the 
hypothesis queried.  The strength of the proinflammatory response, regardless of gender, is a 
better indicator of H. pylori-driven gastric disease in mice. In C57BL/6 mice, female mice had a 
stronger proinflammatory response to H. pylori and had an increased mutation frequency.  The 
A:T to G:C and G:C to T:A mutations are among the top three mutations observed in the 
mutation spectra of human gastric cancers3, indicating that the model closely recapitulated the 
immune response, pathogenic progression and mutation spectra observed in humans in spite of 
the female predominance in disease. This result is in agreement with current paradigms of 
gastric carcinogenesis in which H. pylori causes gastric cancer development in humans after 
decades of chronic inflammation.  Dampening the proinflammatory response results in 
protection against gastric cancer in humans and animal models of H. pylori infection, as seen in 
the literature reviewing the antiinflammatory effect of parasitic coinfection10-11.   E2 and TAM 
treatment mediated the dampening of the proinflammatory response by deregulating 
neutrophilic infiltration via CXCL1, which led to prevention of gastric adenocarcimona in the 
model.  Increases in both IL-8 and CXCL1 have been associated to increased gastric cancer 
incidence in humans12-15, corroborating the importance of this pathway, and immune cell 
recruitment, in gastric carcinogenesis.  Although the mechanisms by which E2 mediates 
protection in humans have not been fully clarified, studies in INS-GAS mice have highlighted the 
importance of decreasing proinflammatory cytokines like IL-1β and increasing antiinflammatory 
cytokines like IL-1016-17, as well as decreasing neutrophilic infiltration as seen in the current 
study, in preventing gastric cancer.  The picture is less clear for TAM, as the epidemiological data 
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is less clear about its role in the induction of gastric cancer4,18-21.  In the current study, TAM was 
protective in infected male mice and shared many common features with E2 treatment 
indicating a similar mechanism.  Contrary to our initial hypothesis, TAM did not block estrogen 
signaling causing more severe gastric lesions.  Further studies must be conducted to address 
this difference between the mouse model and human epidemiological data.  These studies will 
need to focus on the recreating chronic TAM treatment and controlling for the effects of 
baseline estrogen signaling.  The studies presented here have contributed to the understanding 
of Helicobacter pylori mediated mutagenesis and carcinogenesis in the stomach by exploring 
the role of gender in modulating the inflammatory response to H. pylori. 
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4.3 Table 4.1. Comparison of H. pylori pathogenesis in mice and humans 
H. pylori & 
inflammation  
Mouse models  Humans  
Gender  Sexual dimorphisms depend 
on mouse model  
Male predominant disease  
Mutations  A:T>G:C & G:C>T:A mutations 
observed associated with 
oxidative stress and similar to 
humans  
G:C>A:T, A:T>G:C & G:C>T:A are top 
mutations in survey of mutation spectra 
of GC. Associated with oxidative stress.  
Cancer  Proinflammatory responses 
lead to cancer while 
decreased inflammation may 
reduce oncogenic pathways. 
Dampened proinflammatory responses in 
humans may prevent gastric cancer  
Immune cell 
trafficking 
Deregulation of CXCL1 
affected infiltration and 
decreased cancer  
CXCL1 associated to gastric cancer. IL-8 
polymorphism also associated with 
increased GC.  
Estrogen  Prophylactic and therapeutic 
estrogen is protective  
Estrogen associated with reduced  GC 
incidence in women.  Mechanism?  
Tamoxifen  Protective therapeutically in 
reproductive age females.  
OVX or postmenopausal 
mice?  
GC studies have large percentage of 
postmenopausal women. Stronger effect?  
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Appendix A: Functional classification of Helicobacter pylori isolates by gene 
expression analysis during coculture with gastric epithelial cells 
Alexander Sheh, Abhinav Arneja, Forest M. White, Pelayo Correa, James G. Fox 
 
Abstract 
While Helicobacter pylori infects over 50% of the world's population, the mechanisms involved 
in the development of gastric disease are not fully understood.  Bacterial, host and 
environmental factors play a role in the outcome of disease.  To determine the role of bacterial 
factors in the outcome of H. pylori pathogenesis in vitro, side-by-side comparisons of global 
gene expression of eight H. pylori strains were analyzed.  Comparison of two laboratory strains 
(ATCC43504 and SS1) yielded 6692 of 13469 differentially expressed probes.  Clustering analysis 
of 6 Colombian clinical isolates from a region with low gastric cancer risk and a region with high 
gastric cancer risk, clustered two low risk strains together and the three high risk strains with 
the remaining low risk strain.  This suggests that a potential signature that may distinguish 
strains from regions with higher gastric cancer incidence from regions with lesser risk.  
Interleukin 8 (IL-8) production, cell deformation and activation of Erk and Akt in AGS cells were 
also measured during coculture with ATCC43504 or SS1.  ATCC43504 induced greater IL-8 
secretion, more cell deformation and prolonged Erk and Akt activation compared to SS1.  Future 
work will correlate these phenotypes in eukaryotic cells with bacterial pathways to develop a 
system to distinguish virulence potential among H. pylori strains.   
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A.1 Introduction 
Helicobacter pylori infects over 50% of the world’s population and has been associated 
with the development of gastritis, ulcers, and gastric cancer1. In spite of its high prevalence, 
chronic H. pylori infection leads to clinical symptoms in approximately 20% of infected 
individuals, with only 1-2% developing gastric adenocarcinoma.  These divergent outcomes 
suggests that host, environmental and bacterial factors determine the outcome of H. pylori 
infection.   
Among these bacterial factors, H. pylori genes utilized for motility/chemotaxis2-4, acid 
acclimation5-6, adherence to the mucosa7 and damaging host epithelial cells8-9 are necessary for 
the colonization of the gastric mucosa and have been associated with increased gastric disease1.  
The absence of these virulence factors results in reduced pathogenicity or inability to colonize2-
9.  Early studies comparing diverse H. pylori strains indicated that increased virulence correlated 
with morphological changes and vacuolization of cells in vitro, and specifically to cytotoxin 
associated gene A (CagA), a 128-140 kDa protein10-11. The CagA gene is present in 50-70% of H. 
pylori strains and is part of the cytotoxin-associated gene pathogenicity island (CagPAI)1.  In 
vitro, isogenic mutants of H. pylori lacking the CagPAI region cause very mild, if any, disease and 
behave similarly to commensals12.  CagA mediates its pathogenic effects through translocation 
to the host cell cytoplasm via a type IV secretion system.  Upon translocation, CagA is 
phosphorylated by tyrosine kinases and affects eukaryotic signaling networks by interacting 
with a variety of host proteins, such as c-Met, SHP-2, PAR1, and Csk, leading to the activation of 
NF-kB via Erk and signaling linked to hyperproliferation, inflammation, apoptosis and cancer13-15.  
Erk is a member of the MAP kinase family which is involved in signaling cascades affecting 
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differentiation, cell cycle and cell proliferation in response to extracellular cues and growth 
factors16.  Akt,  a serine/threonine protein kinase, also activates NF-kB, regulates cell 
proliferation, apoptosis, cell survival, migration and tumorigenesis and has been found 
aberrantly expressed in many cancers, including gastric cancer17-19.  Both of these kinases are 
activated during H. pylori-mediated pathogenesis15.   
 Both in vivo and in vitro, H. pylori, partly through the effects of CagA, strongly induces 
the secretion of the proinflammatory cytokine, interleukin-8 (IL-8)20-23, and the deformation of 
epithelial cells24-27.  IL-8 is a potent chemokine that recruits neutrophils to infection site, which 
release reactive oxygen species (ROS) to eradicate H. pylori.  The epithelial cells are damaged by 
the ROS, which in conjunction with H. pylori-mediated actin remodeling, allow the flow of 
nutrients into H. pylori-infected gastric mucosa8.  Constant exposure to ROS due to persistent H. 
pylori infection is the initial step in the pathogenic progression leading to oxyntic gland atrophy, 
intestinal metaplasia and eventually cancer28.   
Classification of the potential virulence of H. pylori strains is normally performed 
through PCR genotyping of virulence factors such as CagA, VacA, and BabA, due to their 
importance to human disease1,9,29.  However, identification of the gene does not guarantee 
expression in the context of the host, as demonstrated by the lack of CagA translocation in mice 
of H. pylori SS1, a CagA positive strain30.  Other studies have also demonstrated that IL-8 
secretion varies between strains with similar genotypes23, suggesting that a systems approach 
would be useful in determining how the interaction of bacterial genes affect phenotypes 
observed in the host.  Previous microarray studies, in vitro and in vivo, have focused on the 
effects of the environment or the host31-35 on a single strain of H. pylori, or on isogenic 
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mutants12, but have not focused on how different isolates of H. pylori interact under similar 
conditions.   
Variation between H. pylori strains may partly account for differences in gastric cancer 
incidence rates in different geographical locations worldwide.  In Colombia, there is a high 
prevalence of H. pylori infection, but geographically distinct areas differ greatly in gastric cancer 
risk36-37.  Colombian populations in the high Andes have a higher incidence of gastric cancer 
associated with H. pylori, while coastal populations have a reduced incidence of gastric cancer37. 
Preliminary Multi Locus Sequence Typing (MLST) analysis of Colombian H. pylori strains from 
these regions have revealed an association between strains from high risk areas and ancestral 
European strains of H. pylori while strains from low risk regions associated phylogenetically with 
African strains (Pelayo Correa, unpublished results).  However, the mechanisms by which these 
genetic changes mediate greater virulence have not been characterized.   
In the present study, Erk and Akt activation, IL-8 secretion and cell deformation were 
measured in a gastric epithelial cell line (AGS) infected with two laboratory strains of H. pylori 
(SS1 and ATCC43504).  Concurrently, early changes in H. pylori SS1 or ATCC43504 gene 
expression during coculture with AGS cells were assessed using a custom H. pylori microarray 
created using the genomes of 7 H. pylori strains (26695, J99, P12, HPAG1, B38, Shi470, and 
G27).  After validating the microarray, 6 clinical isolates from areas with low and high incidence 
of gastric cancer were classified using the system to detect signatures relevant to 
carcinogenesis.  Further work will involve annotating the microarray to determine specific 
functions involved in virulence and characterizing the induction of cell signaling, IL-8 secretion 
and cell deformation by the 6 clinical isolates to better assess how H. pylori functions correlate 
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with host phenotypes.  
 
A.2 Materials and Methods 
Bacteria and cells. Helicobacter pylori strains SS1, ATCC43504, PZ5004, PZ5024, PZ5026, 
PZ5056, PZ5080 and PZ5086 were cultured on blood agar (TSA with sheep blood, Remel, 
Lenexa, KS) or Brucella broth with 5% fetal bovine serum under microaerobic conditions (10% 
H2, 10% CO2, 80% N2).  AGS cells (CRL-1739, ATCC, Manassas, VA) were grown in DMEM, Ham's 
F12-K or a 50:50 mixture with 10% fetal bovine serum.  Phenol-red free medium was used for 
the Western blot and gene expression studies.  Confluent AGS cells were infected at an MOI of 
100 and incubated at 5% CO2 for the predetermined time.   
IL-8 measurements.  The supernatant of AGS cells infected with H. pylori was collected at 4, 8, 
and 27 hours.  Supernatant was centrifuged to remove cells and frozen at -20C.  The BD OPT-EIA 
human IL-8 kit (BD Biosciences, Franklin Lakes, NJ) was used according to manufacturer's 
instructions.  Briefly, 96-well plates were pre-coated with anti-IL-8 capture antibody.  Following 
blocking, supernatants and standards were incubated in each well.  Subsequently, biotinylated 
anti-IL-8 detection antibody and substrate were added, and the colorimetric signal was detected 
on a VersaMax spectrophotometer at 450nm with the wavelength correction at 570nm.  
Morphology.  For the morphology studies, an autoclaved, round coverslip was placed at the 
bottom of each well of a 12-well plate prior to seeding with AGS cells.  AGS cells were not 
allowed to reach confluency prior to 24-hour infection with H. pylori to permit cell elongation.  
Coverslips were immediately removed and fixed in 10% formalin and stained with hematoxylin 
and eosin with ethanol and xylene washes.  Coverslips were then mounted on a microscope 
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slide using Permount.   Area and perimeter of individual cells were calculated using Zeiss 
Axiovision software.  A dimensionless "aspect ratio" was calculated using the formula: 
                               .  The aspect ratio allows the quantification of the 
morphology as a perfect line would have an aspect ratio of 0 while a perfect circle would have a 
ratio of 1.  More than 120 cells were counted from different fields from either uninfected, 
ATCC43504-infected or SS1-infected AGS cells. Student t-tests were used to calculate statistical 
significance with P<0.05 considered significant. 
Western blots.  Levels of pERK, pAkt, tubulin and CagA were determined by Western blot 
analysis.  AGS cells infected with H. pylori for 0.25, 1, 4 and 8 hours were lysed at 4°C using cell 
scrapers and RIPA buffer with Phospho-Stop and cOmplete, Mini protease inhibitor cocktail 
tablets (Roche, Basel, Switzerland).  Protein concentration was quantified using a BCA 
(bicinchoninic acid) protein assay (Thermo Scientific, Waltham, MA).  Primary antibodies used 
were antiphosphotyrosine 4G10 (Upstate Biotechnology, Lake Placid, NY), anti-pERK1/2, anti-
Akt S473 and anti-β-Tubulin (Cell Signaling Technologies, Beverly, MA). HRP-conjugated 
secondary antibodies used were goat anti-rabbit or anti-mouse antibodies (Jackson 
Immunoresearch, West Grove, PA).  
Microarray design.  Seven annotated H. pylori genomes (26695 [NC_000915], J99 [NC_000921], 
HPAG1 [NC_008086 & NC_008087], B38 [NC_012973], P12 [NC_011498 & NC_011499], G27 
[NC_011333 & NC_011334], and Shi470 [NC_010698]) were utilized to design probes using the 
Agilent earray software (Agilent Technologies, Santa Clara, CA).  Individual 60bp oligonucleotide 
probes were designed for each gene within a genome.  Additionally, 60-mer oligonucleotide 
probes were designed based on previously published sequences of H. pylori probes used by the 
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Pathogen Functional Genomics Resource Center (pfgrc.jcvi.org).  The accuracy of the probes was 
checked by using BLAST38 prior to printing by Agilent.  13469 probes for H. pylori genes were 
utilized in creating the array. 
Analysis of mRNA expression. Following coculture of H. pylori and AGS cells for 1 hour.  At the 
end of the infection, RNAProtect Bacteria (Qiagen, Germantown, MD) was added to the culture 
media at a 2:1 ratio to prevent RNA degradation.  AGS cells were scraped and allowed to 
incubate prior to collection by centrifugation. RNA was extracted following the RNeasy Mini Kit 
with RNase-free DNase treatment (Qiagen).  Total prokaryotic and eukaryotic RNA was further 
purified using the Microbenrich kit (Applied Biosystems, Foster City, CA).  Quality of the RNA 
was determined with the Agilent 2100 Bioanalyzer using a RNA 6000 Nano total RNA Kit (Agilent 
Technologies) before and after the Microbenrich step to determine the removal of eukaryotic 
RNA.   Total RNA was hybridized to the custom Agilent 8x15K H. pylori Microarrays following the 
One-Color Microarray-Based Gene expression Analysis, Low Input Quick Amp Labeling protocol.  
Briefly, the method utilizes a T7 RNA polymerase that amplifies RNA to cRNA while 
incorporating cyanine 3-labeled CTP.  Cy-3 incorporation and cRNA levels were measured with a 
NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE).  
Arrays were scanned using an Agilent Microarray Scanner and data was extracted using Feature 
Extraction 9.1. 
Processing of the raw gene expression data was performed using the limma library in R 
(Vienna, Austria).  Microarray data were first corrected for background and then normalized by 
quantile using the NormalizeBetweenArrays function39. Data were log2 transformed, and 
statistical significance was determined using empirical Bayes statistics for differential expression 
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and corrected for family-wise error rates using the Benjamini-Hochberg correction.  To control 
the rate of false positives, q-values were calculated as the minimum positive false discovery rate 
that can occur when identifying significant hypotheses40. Significant differential gene expression 
between groups was defined as a false discovery rate corrected q-value < 0.05.  Comparisons 
were performed between 1) H. pylori strain SS1 vs. H. pylori strain ATCC43504 2) Colombian 
strains from a low gastric cancer risk area (PZ5004, PZ5024 and PZ5026) and from a high gastric 
cancer risk area (PZ5056, PZ5080 and PZ5086).  The clustergram function of Matlab 
(Mathworks, Natick, MA) was used to classify microarray data.  Clustering was performed on the 
entire set of genes prior to analysis of significance and after removal of non-significant genes. 
 
A.3 Results 
 
A.3.1 ATCC43504 elicits greater IL-8 secretion and elongation of AGS cells.  ATCC43504 induced 
higher levels secretion of IL-8 from infected AGS cells compared to SS1 at 4, 8 and 27 hours 
post-infection (HPI) (ATCC43504 vs. SS1, at 4 hours: 868 vs. 420 pg/ml; at 8 hours: 2774 vs. 52 
pg/ml; and at 27 hours, 2130 vs. 269 pg/ml)  (Fig. A.1).  ATCC43504 ∆CagA elicited slightly lower 
levels of IL-8 than the parental strain, but at levels higher than SS1 (data not shown).  
Additionally, ATCC43504 also mediated greater elongation of AGS cells compared to SS1.  After 
24 hours of coculture of H. pylori and AGS cells, AGS cells were formalin fixed and stained with 
hematoxylin and eosin for better visualization of the cell.  Evaluating the elongation of over 120 
cells per group, there was no significant difference in elongation between uninfected AGS cells 
and SS1-infected AGS cells (aspect ratio = 0.58 and 0.57, respectively).  ATCC43504 significantly 
altered the morphology of AGS cells (aspect ratio = 0.41, P < 0.001 for both) (Fig. A.2).  
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A.3.2 ATCC43504 injects more CagA and induces greater phosphorylation of Erk and Akt.  Four 
hours after infection, CagA levels in ATCC43504-infected AGS cells were elevated compared to 
SS1-infected AGS cells.    There was increasing accumulation of CagA noted in both strains of H. 
pylori (Fig. A.3A). pAkt levels were increased 15 minutes post-infection by both strains 
compared to uninfected AGS cells.  Increased pAkt levels were sustained at one hour by both 
SS1 and ATCC43504.  pAkt levels in SS1-infected cells decreased by four hours but were 
sustained in ATCC43504-infected AGS cells (Fig A.3A).  pAkt levels in ATCC43504-infected cells 
decreased at 8 hours post-infection (data not shown).  pErk1/2 levels increased more rapidly 
upon ATCC43504 infection, with increased phosphorylation from 15 minutes to one hour, which 
decreased by four hours.  SS1 slightly increased the phosphorylation of pErk1/2 at 15 min but 
this was not seen at later time points (Fig. A.3B).   
A.3.3 Microarray Validation. To determine the microarray's ability to detect enriched 
prokaryotic RNA, AGS cells, before and after eukaryotic RNA removal, as well as AGS cells 
infected with ATCC43504 or SS1, before and after the Microbenrich step, were hybridized to the 
custom H. pylori microarrays (Fig. A.4).  Total RNA from AGS, before and after eukaryotic RNA 
removal, was hybridized to a custom H. pylori microarray, but little hybridization occurred from 
either eukaryotic sample.  Hybridization did occur with samples containing H. pylori regardless 
of microbial enrichment (Fig. A.4). 6692 out of 13469 probes were differentially expressed 
between ATCC43504 and SS1.  Clustering analysis of the entire gene set, clearly separated the 
replicates of the two strains, distinguishing them from one another (Fig. A.5).   
A.3.4 Classification of Colombian strains. To further explore the ability of gene expression 
profiling to classify virulent and avirulent strains, three H. pylori strains from a Colombian region 
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with high gastric cancer incidence (PZ5056, PZ5080 and PZ5086) and three strains from a 
Colombian region with low gastric cancer incidence (PZ5004, PZ5024 and PZ5026) were 
analyzed (n = 3 for each strain).  Classification by clustering separated the six strains into two 
main clusters with two strains from the area of low incidence (PZ5004 and PZ5024) clustering 
very similarly while the three strains from the area of high incidence (PZ5026) as well as PZ5026 
were clustered in the other group (Fig. A.6).  The second cluster was subdivided into two closely 
clustered high risk strains (PZ5080 and PZ5086) and a group with a low risk strain (PZ5026) and 
a high risk strain (PZ5056).  Both PZ5026 and PZ5056 show similarities and differences to the 
other two strains from the area they belong to.  Analysis of all the low risk strains vs. all the high 
risk strains yielded 4349 of 13469 probes differentially expressed based on the geographic 
location of patients from which the strains were isolated.   
Analysis of differentially expressed genes between one low risk (PZ5004) and one high 
risk (PZ5080) strain reduced the probe set from 13469 to 7198.  This reduced probe set was 
used to classify the remaining four isolates (Fig. A.7).  Similar to the previous classification 
attempt, PZ5056 clustered with the strains from the higher risk region.  The reduced probe set 
from the SS1 and ATCC43504 comparison was used to determine if a more virulent lab strain 
would cluster with isolates from a high cancer risk area, while a less virulent lab strain would 
cluster with low risk isolates (Fig. A.8).  Interestingly, ATCC43504 did not cluster closely with any 
Colombian strains, and SS1 was clustered most closely with a subgroup of high strains (PZ5080 
and PZ5086).  The remaining Colombian strains clustered as before with PZ5056 and PZ5026 
clustering closely while PZ5004 and PZ5024 clustered tightly with one another.   
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A.4 Discussion 
Helicobacter pylori has infected human hosts for many millennia41.  Due to the plasticity 
of its genome, this protracted association, along with laterally acquired genes from bacterial 
donors in the environment,  has allowed H. pylori to adapt to its niche in the gastric mucosa and 
develop an extensive array of virulence factors that facilitate its survival in the harsh gastric 
environment8,42.  However, some strains of H. pylori elicit a mild immune response and can 
effectively act as commensals12.  The existence of non-virulent strains may be explained by 
concurrent infection with multiple strains of H. pylori if virulence is presumed to be necessary 
for persistent infection8.  However, the coexistence of a virulent strain in the gastric mucosa of 
every patient with a non-virulent isolate has not been determined systematically, and animal 
studies have demonstrated that less virulent strains can persistently infect the host43, suggesting 
that less pathogenic strains can adequately inhabit the niche.  A better understanding of the 
intricate pathogenic mechanisms developed by H. pylori will improve our ability to treat chronic 
inflammatory conditions, while the ability to functionally classify strains will increase our 
knowledge of the nature of H. pylori pathogenesis.   
Using laboratory strains, ATCC43504 and SS1, we demonstrated that ATCC43504 is a 
more virulent strain as it induces greater IL-8 secretion, cell deformation and prolonged Erk and 
Akt activation.  Increased IL-8 secretion has been associated with increased virulence of H. 
pylori strains.  East Asian CagA motifs, which are highly associated with gastric carcinoma13,44, 
induce greater IL-8 release from epithelial cells compared to Western CagA motifs23.  As IL-8 
recruits neutrophils to the site of infection, increased IL-8 leads to higher concentrations of 
reactive oxygen and nitrogen species and increased adhesion, migration and invasion in gastric 
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cells45.  Indeed, a single nucleotide polymorphism associated with the IL-8 promoter region, 
which increases IL-8 protein levels, is correlated with increased gastric cancer risk46-47.   
Cell deformation is an in vitro representation of tight junction deregulation in vivo; 
strains that robustly induce this phenotype may promote epithelial-to-mesenchymal 
transitions48.  The gastric epithelium is the interface that separates the host's cells from the 
lumen.  In order to achieve adequate separation of the host and the external environment, 
adjacent epithelial cells form tight junctions that limit the diffusion of molecules from the host 
to the environment, and vice versa13.  The deregulation of these tight junctions is necessary for 
H. pylori survival as it causes the release of nutrients unavailable in the gastric mucosa8.  
Highlighting the importance of disrupting tight junctions and cell polarity, two key bacterial 
virulence factors, VacA and CagA, mediate structural changes in epithelial cells1.  As we 
demonstrated in this study, the ability to mediate this changes in epithelial cells is variable 
among strains, and we propose that the ability to induce greater deformation is a proxy of the 
strain's virulence. 
Another measure of H. pylori's pathogenicity is the bacterium's ability to hijack host 
signaling pathways. Increased Erk and Akt activation are associated with increased IL-8 secretion 
and other cell responses to H. pylori; therefore, aberrant activation may mediate oncogenic 
processes such as deregulated proliferation, apoptosis, and tumorigenesis15.  Both ATCC43504 
and SS1 affected the phosphorylation of Erk and Akt in epithelial cells.  However, the 
perturbations in host signaling had different kinetics with ATCC43504 eliciting a prolonged 
activation of the two signaling proteins.  As CagA is greatly associated with changes in host cell 
signaling, the higher levels of ATCC43504's CagA in the AGS cells may be responsible for the 
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sustained stimulation of Erk and Akt. Other possibilities include a different CagA variant or a 
lesser immunogenic potential in SS1.   Further work is needed to elucidate the mechanisms by 
which diverse H. pylori strains modulate the duration of host signals, but characterization of the 
level and duration of pathway activation may be useful in determining the degree of pathogen-
host interactions.  
6692 probes were differentially expressed between ATCC43504 and SS1.  This probe set 
will be analyzed to determine the differences in bacteria-host interactions between the more 
virulent ATCC43504 and the less immunogenic SS1.  Further work needs to be done to annotate 
the microarray, but our initial analysis demonstrates that it can be useful to distinguish strains 
that have markedly different phenotypes in vitro and in vivo.  H. pylori strain 26695 has 1630 
genes49, so we expect that the differentially expressed probes will be greatly reduced (at least 7-
fold).  Similarly, classification of the Colombian strains showed a potential signature for low and 
high strains as 2 of the strains evaluated from each region displayed very similar gene 
expression.  While Multi Locus Sequence Typing (MLST) has provided a platform to characterize 
the origins of H. pylori strains50-52  and their putative virulence by association with their 
geographic origin, gene expression analysis will provide a mechanistic understanding of how 
variations in the bacterial genome affect pathogenicity.  In the present study, we propose a 
systems level approach that studies the H. pylori pathways involved in the generation of the 
pathological phenotypes associated with H. pylori infection.  Upon completion, these results will 
provide a comprehensive view of the information flow from H. pylori infection to generation of 
the pathological phenotypes and help probe the differences between commensals and 
pathogens.   
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A.6 Figures 
 
Figure A.1.  IL-8 secretion was higher in AGS cells cocultured with ATCC43504 at 4, 8 and 27 hours post-infection 
(n=2). 
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Figure A.2.  ATCC43504 significantly deformed AGS cells compared to uninfected and SS1-infected AGS cells 
(P<0.001).  A dimensionless ratio based on the area and perimeter of AGS cells was calculated for over 120 cells per 
group.  
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Figure A.3. ATCC43504 also injects more CagA than SS1 (3A). Akt (3A) and Erk1/2 (3B) are phosphorylated for a 
greater time by ATCC43504 compared to SS1.   
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Figure A.5. Clustering analysis of bacterial RNA isolated from coculture system.  ATCC43504 (n=3) and SS1 (n=3) 
samples were separated by clustering analysis and demonstrated different gene expression signatures. 
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Figure A.6. Clustering analysis of 6 Colombian isolates.  Three strains from a low gastric cancer risk area and three 
strains for a high gastric cancer risk area were assessed (all n=3).  Clustering analysis created to main clusters 
composed of 1) 2 low risk strains and 2) 3 high risk strains and 1 low risk strain. 
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Figure A.7. Clustering analysis of 6 Colombian strains after reduction of probe set to differentially expressed genes 
between low risk strain PZ5004 and high risk strain PZ5080.  Two low risk strains still composed one cluster, while 3 
high risk strains and 1 low risk strain composed the second cluster.   
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Figure A.8. Using the reduced probe set from comparing ATCC43504 and SS1, the 6 Colombian strains were 
classified to determine if virulence in laboratory strains correlated with gastric cancer risk.  ATCC43504 had little 
similarity to other strains, while SS1 clustered most closely with 2 high risk strains. 
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Appendix B: Published version of Chapter 2: Sheh et al. "Mutagenic potency of Helicobacter 
pylori in the gastric mucosa of mice is determined by sex and duration of infection."  PNAS 
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Helicobacter pylori is a human carcinogen, but the mechanisms
evoked in carcinogenesis during this chronic inﬂammatory dis-
ease remain incompletely characterized. We determined whether
chronic H. pylori infection induced mutations in the gastric mucosa
of male and female gpt delta C57BL/6 mice infected for 6 or 12 mo.
Point mutations were increased in females infected for 12 mo. The
mutation frequency in this group was 1.6-fold higher than in un-
infected mice of both sexes (P < 0.05). A:T-to-G:C transitions and
G:C-to-T:A transversions were 3.8 and 2.0 times, respectively, more
frequent in this group than in controls. Both mutations are consis-
tent with DNA damage induced by oxidative stress. No increase in
the frequency of deletionswas observed. Females hadmore severe
gastric lesions than males at 6 mo postinfection (MPI; P < 0.05), but
this difference was absent at 12 MPI. In all mice, infection signiﬁ-
cantly increased expression of IFNγ, IL-17, TNFα, and iNOS at 6 and
12 mo, as well as H. pylori–speciﬁc IgG1 levels at 12 MPI (P < 0.05)
and IgG2c levels at 6 and 12 MPI (P< 0.01 and P< 0.001). At 12MPI,
IgG2c levels in infected femaleswere higher than at 6MPI (P< 0.05)
andalso than those in infectedmalesat12MPI (P<0.05). Intensityof
responses was mediated by sex and duration of infection. Lower
H. pylori colonization indicated a more robust host response in
females than in males. Earlier onset of severe gastric lesions and
proinﬂammatory, Th1-biased responses in female C57BL/6 mice
may have promoted mutagenesis by exposing the stomach to pro-
longed oxidative stress.
gpt delta mouse | Helicobacter | inﬂammation | mutagenesis | sexual
dimorphism
Acting through multiple, complex mechanisms that are in-completely understood, chronic inﬂammation is a signiﬁcant
risk factor for several major human malignancies, including stom-
ach cancer. Chronic inﬂammation induced by Helicobacter pylori
infection increases lifetime risk of developing gastritis, duodenal
and gastric ulcers, mucosa-associated lymphoid tissue lymphoma,
mucosal atrophy, and gastric carcinoma (1, 2). Indeed,H. pylori has
been classiﬁed by International Agency for Research on Cancer as
a group I human carcinogen on the basis of its impact on gastric
cancer incidence, the secondmost frequent cause of cancer-related
death worldwide (3). Among postulated mechanisms through
which infection may contribute to increased cancer risk are over-
production of reactive oxygen and nitrogen species (RONS) by
inﬂammatory cells, and the consequent induction of mutations
critical for tumor initiation in cells of inﬂamed tissues (4). The in-
ﬂammatory response to infection results in increased production of
RONS, including superoxide (O2
–·), hydrogen peroxide (H2O2),
nitric oxide (NO), peroxynitrite (ONO2
–), and nitrous anhydride
(N2O3), in vitro (5, 6) and in vivo (7–9). H. pylori can also directly
activateRONS-producing enzymes, such as inducibleNO synthase
(iNOS) and spermine oxidase, in gastric epithelial cells, causing
DNA damage and apoptosis (5, 6). Chronic inﬂammatory states
increase levels of DNA adducts, such as etheno adducts, 8-oxoG,
and other mutagenic precursors, in vitro and in vivo (10–12), but
tend not to alter the frequency of deletions (13). RONS also can
damage DNA indirectly by creating adduct-forming electrophiles
via lipid peroxidation (14, 15). RONS have been shown to induce
mutations in H. pylori by inducing a hypermutation state in the
bacteria (16).
A widely used experimental model is the H. pylori SS1-infected
C57BL/6 mouse, which is susceptible to chronic infection and
develops robust gastritis and premalignant lesions similar to those
occurring in humans (17, 18). To date, limited investigation has
focused on genetic damage associated with infection in these
animals, but available data are still incomplete. Enhanced DNA
fragmentationwas observed in gastric cells of infectedmice (19), in
which dsDNAbreakswere also detected byTUNELassay (20, 21).
Mutagenicity in reporter genes recovered from gastric DNA of
male and femaleBigBlue transgenicmice 6moafter infectionwith
H. pylori or Helicobacter felis has also been reported (22). In H.
pylori-infectedmalemice, point mutation frequency was increased
at 6 mo post infection (MPI), but decreased to control levels by 12
MPI, suggesting that the animals may have adapted to infection
(22). Female mice infected with H. felis also had an increased
frequency of point mutations at 7 MPI, compared with uninfected
controls (23). Mutagenesis resulting from infection has also been
associated with p53 status. Mutations were found in the lacI re-
porter genes of a small number of H. felis-infected female TSG-
p53/Big Blue mice harboring either one (p53+/−) or two (p53+/+)
WT p53 alleles (23). A 2-fold increase in mutations was found in
DNA from the gastric mucosa of infected p53+/+mice, and also in
uninfectedp53+/−mice; themutation frequency in infected p53+/−
mice was further increased by approximately threefold. The in-
tensity of inﬂammation was estimated to be signiﬁcantly higher in
infected p53+/−mice than in infected p53+/+ animals, and gastric
epithelial proliferation was similarly increased with infection in
both latter treatment groups. By contrast, in another study, in-
fection of Big Blue transgenicmice (sex not speciﬁed) with the SS1
strain of H. pylori for 3.5 mo resulted in no signiﬁcant increase in
gastric mutations over uninfected controls (13).
We used the gpt delta mouse to measure the accumulation of
gastric mutations associated with H. pylori SS1 infection in male
and female animals at 6 and 12 MPI. This experimental system
comprises λ-EG10–based transgenic C57BL/6 mice harboring
tandem arrays of 80 copies of the bacterial gpt gene at a single site
on chromosome 17. The model was speciﬁcally designed to fa-
cilitate the in vivo detection of point mutations by 6-thioguanine
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(6-TG) selection, and deletions up to 10 kb in length by selection
based on sensitivity to P2 interference (Spi−) (24). When phage
DNA rescued from mouse tissues is introduced into appropriate
Escherichia coli strains, both point mutations and large deletions
can be efﬁciently detected (24). We also characterized histo-
pathologic changes, expression of inﬂammatory cytokines, and
expression of iNOS in gastric mucosa 6 and 12 mo after initial
infection. In addition, we compared responses of male and female
mice to assess the inﬂuence of sex. We found that H. pylori in-
fection induced signiﬁcant increases in the frequency of point
mutations in the gastric mucosa of female, but not male, gpt delta
mice. The accumulation of point mutations was therefore sex-
dependent and was mediated by the duration of infection and the
severity of disease.
Results and Discussion
Pathology, Cytokine and iNOS Expression, and Serologic Responses to
H. pylori Infection and H. pylori Levels. Inﬂammatory histopatho-
logic changes resulting from H. pylori infection were evaluated
(Fig. S1) and gastric histological activity index (GHAI) scores
calculated, with the following results. Scores were signiﬁcantly
increased in infected animals of both sexes at 6 and 12 MPI
(female, P < 0.001 and P < 0.01, respectively; and male, P < 0.05
and P < 0.001, respectively; Fig. 1). Regarding speciﬁc types of
lesions represented in the GHAI, infected females experienced
higher levels of hyperplasia (P < 0.05), epithelial defects (P <
0.001), and dysplasia (P < 0.05) compared with infected males at
6 MPI, and thus had correspondingly higher (P < 0.05) GHAI
scores at this time point. At 6 MPI, infected animals of both sexes
displayed mild to moderate inﬂammation, comprised chieﬂy of
submucosal and mucosal inﬁltrates of mononuclear and granu-
locytic cells. In addition, in infected males, mucous metaplasia,
intestinal metaplasia, oxyntic gland atrophy, and hyalinosis were
all signiﬁcantly elevated compared with controls (all P < 0.01;
intestinal metaplasia, P< 0.001); no signiﬁcant increases occurred
in foveolar hyperplasia, epithelial defects, or dysplasia. In infec-
ted females, inﬂammation (P < 0.05), epithelial defects (P <
0.001), mucous metaplasia (P < 0.01), hyalinosis (P < 0.001), as
well as premalignant lesions of oxyntic gland atrophy (P < 0.001),
intestinal metaplasia (P < 0.05), and dysplasia (P < 0.05) were
signiﬁcantly elevated compared with uninfected controls. At 12
MPI, there were no differences in gastric lesion severity between
infected males and females; both groups had similar mucosal
changes. Infected male mice at 12 MPI displayed signiﬁcantly
increased epithelial defects but decreased intestinal metaplasia
than infected males at 6 MPI (P < 0.01 and P < 0.001).
H. pylori infection signiﬁcantly increased transcription proﬁles
at 6 and 12 MPI as follows (details in Fig. S2): IFNγ (males, P <
0.001; females, P < 0.01 at 6 and 12MPI); TNF-α (males, P < 0.01
at 6 and 12MPI; females, P< 0.01 and P< 0.05); IL-17 (males,P<
0.05 and P < 0.001; females, P < 0.05 and P < 0.01). iNOS ex-
pression was increased in male and female mice at 6 and 12 MPI
(males, P < 0.05 and P < 0.01; females, P < 0.01 and P < 0.001)
compared with controls at 12 mo. IL-10 expression was not sig-
niﬁcantly affected by infection in animals of either sex (P > 0.05).
H. pylori infection also resulted in a Th1-predominant IgG2c
response in infected mice as previously reported (25, 26) (Fig. 2).
H. pylori-speciﬁc IgG2c levels were higher in infected than in
uninfected animals at 6 and 12 MPI (P < 0.01 and P < 0.001, re-
spectively). At 12 MPI, infected females had signiﬁcantly higher
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Fig. 1. H. pylori infection elicits more gastric pathologic processes in female
mice at 6 mo. H. pylori infection increased the GHAI in both male and female
C57BL/6 mice at 6 and 12 mo. At 6 mo of infection, infected females had
signiﬁcantly more pathologic processes than infected males. Uninfected
males (○; 6 MPI, n = 7; 12 MPI, n = 3), uninfected females (▽; 6 MPI, n = 5; 12
MPI, n = 3), infected males (▼; 6 MPI, n = 4; 12 MPI, n = 5) and infected
females (◆; 6 MPI, n = 4; 12 MPI, n = 6). Bar represents the mean. *P < 0.05,
**P < 0.01, and ***P < 0.001.
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Fig. 2. The effect of H. pylori infection on H. pylori–speciﬁc IgG1 and IgG2c.
Serum levels of IgG were measured by ELISA in uninfected and H. pylori–
infectedmice. (A)H.pylori–infectedmice (graybars; 6MPI,n=9; 12MPI,n=12)
developed a greater IgG1 response after 12 mo of infection compared with
uninfected mice (white bars; 6 MPI, n = 6; 12 MPI, n = 6; P < 0.05). H. pylori–
infectedmicedevelopedagreater IgG2 responseafter6and12moof infection
(P < 0.01 and P < 0.001, respectively). (B) At 12mo, infected female mice (light
graybars;6MPI,n=4;12MPI,n=6)hadsubstantially increased IgG2ccompared
with infected males (dark gray bars; 6 MPI, n = 5; 12 MPI, n = 6) at 12 mo and
infectedfemalesat6mo(P<0.05,both).Dataaremean (SE)ofmice indifferent
treatment groups. *P < 0.05, **P < 0.01, and ***P < 0.001.
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IgG2c levels than infected males (P < 0.05). Duration of in-
fection also increased IgG2c levels in infected females, with
higher levels noted at 12 versus 6 MPI (P < 0.05). H. pylori-
speciﬁc IgG1 (Th2) levels were higher in infected than in un-
infected animals at 12 MPI (P < 0.05). Females had higher Th1/
Th2 ratios than males: at 6 MPI, 8.58 vs. 4.01; and at 12 MPI,
12.9 vs. 7.51.
We and others have demonstrated that H. pylori levels are in-
versely correlated with the degree of pathology and the immune
response as measured by antibody and cytokine production (25,
27). At 6 MPI, H. pylori was detectable by quantitative PCR in all
infected males, but not in one female. At 12 MPI, there was
a salient difference in levels of H. pylori colonization between
males and females; H. pylori was undetectable in four infected
females, but undetectable in only one male (Fig. 3).
Frequency and Nature of Mutations. We determined the frequency
of gpt point mutations in gastric DNA isolated from infected and
uninfectedmice by selection of mutants based on 6-TG resistance.
Recognizing the possible confounding effect of clonal expansion
of sibling mutants (i.e., jackpot mutations), we sequenced the gpt
genes from all 566 recovered mutants. Any mutation found to
duplicate another at the same site within an individual sample was
excluded from subsequent frequency calculations. After this ad-
justment, at 12 MPI the gpt mutation frequency in infected
females (7.5 ± 2.0 × 10−6; P < 0.05) was signiﬁcantly (1.6-fold)
higher than that in all control animals (4.7 ± 1.1 × 10−6), whereas
the frequency in infected males (6.3 ± 5.4 × 10−6; P = 0.49) was
not. At 6MPI, gptmutation frequency in infected animals of either
sex (females, 5.6 ± 2.0 × 10−6, P = 0.72; males, 7.2 ± 2.2 × 10−6,
P=0.57)was not signiﬁcantly different from that of controls (6.2±
3.0 × 10−6; Fig. 4).
After sequencing and accounting for clonal expansion, 236
from infected and 156 mutants from uninfected mice were used
to identify effects of H. pylori infection on types of mutations
causing loss of gpt function, with the results summarized in Table
1 and Table S1. G:C-to-A:T transitions and G:C-to-T:A trans-
versions were the most prevalent types of mutations in both
infected and uninfected animals, representing 33% to 50% and
17% to 31%, respectively, of total mutations in various treatment
groups; mutant frequencies varied from 2.1 to 3.0 × 10−6 in these
transitions and 0.9–1.8 × 10−6 in the transversions. The 1.6-fold
higher total mutations observed in infected females compared
with age-matched controls at 12 MPI was attributable mainly to
two types of mutations: 3.8 times more A:T-to-G:C transitions
(P < 0.05) and 2.0 times more G:C-to-T:A transversions (P <
0.05). These two mutations are consistent with the expected
mutational spectrum induced by RONS (28) and have been found
elevated in another animal model of chronic inﬂammation (13).
An increase in G:C-to-T:A transversions was also reported in
a previous study documenting H. pylori-induced mutations (22).
A:T-to-G:C transitions can be formed by deamination of ade-
nine to hypoxanthine or creation of ethenoadenine. Deamination
is mediated by N2O3, the autoxidation product of NO·, which
directly nitrosates primary amines on DNA bases (28, 29). Hy-
poxanthine resembles guanine and mispairs with cytosine, result-
ing in the observed mutation. Alternatively, A:T-to-G:C tran-
sitions can also be created indirectly by lipid peroxidation by
RONS, forming etheno adducts in DNA such as highly mutagenic
ethenoadenine (30, 31). G:C-to-T:A transversions have also been
associated with increased iNOS expression levels, pointing to the
involvement of RONS (32). Cells cocultivated with activated
macrophages predominantly develop G:C to T:A transversions
caused by exposure to NO·, O2
−·, and H2O2 (33). G:C-to-T:A
transversions are also caused by adducts produced by oxidative
stress or lipid peroxidation, such as 8-oxodG, εdC, and M1G (34,
35). The presence of 8-oxodG, a major product of oxidative
damage to DNA, results in mispairing of guanine with adenine
during replication, thus inducing transversions (36). Although 8-
oxodG is believed to be the main cause of this mutation, etheno
adducts formed by lipid peroxidation may also play a signiﬁcant
role in mutagenesis observed in vivo (37).
Fig. S3 shows the mutation spectrum detected in the gpt gene,
of which the following features are noteworthy. In both un-
infected and infected mice, hotspots occurred at nucleotides
C64, G110, G115, and G418; C64, G110, and G115 are CpG sites
and are known hotspots in this assay (38, 39). Hotspots occurring
in infected mice were located at A8, G116, and G143; A8 and
G116 were found predominantly in infected females at both 6
and 12 mo, whereas G143, located at a CpG site, was a hotspot in
infected animals of both sexes. Uninfected mice had hotspots at
G406, G416, and A419, one of which (G416) occurred mainly in
males. Mutations in infected males were concentrated mainly in
hotspots common to both uninfected and infected animals,
whereas in infected females there was an increase in mutations
throughout the gpt gene at non-G:C sites. This result suggests
that the chemistry of DNA damage in mice with a stronger host
response to infection may have differed from that in mice with
mild or minimal gastritis.
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Fig. 4. Twelve-month infection with H. pylori increases the frequency of
point mutations in female mice. The mutation frequency of point mutations
was determined by the gpt assay in uninfected mice (white bars; 6 MPI, n =
13; 12 MPI, n = 15), H. pylori-infected males (light gray bars; 6 MPI, n = 4; 12
MPI, n = 5) and H. pylori-infected females (dark gray bars; 6 MPI, n = 9; 12
MPI, n = 11). Control mice of both sexes were grouped for this analysis. Data
are mean (SEM) of mutation frequency of mice in different treatment
groups. *P < 0.05.
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Mutation analysis using the Spi− assay revealed that the fre-
quency of deletion mutations in gpt of gastric tissue DNA was not
signiﬁcantly affected by H. pylori infection (Fig. 5). Analyses of
57 samples from 32 mice showed that Spi− mutant frequencies in
infected mice (females at 6 MPI, 4.8 ± 2.5 × 10−6, P = 0.09;
females at 12 MPI, 5.0 ± 2.6 × 10−6, P = 0.30; males at 6 MPI,
6.3 ± 2.5 × 10−6, P= 0.87; and males at 12 MPI, 5.2 ± 1.4 × 10−6,
P = 0.17) were not signiﬁcantly different from those of age-
matched controls at either time point (all mice at 6 MPI, 2.9 ±
1.3 × 10−6; all mice at 12 MPI, 3.6 ± 1.8 × 10−6).
Current models of inﬂammation-driven carcinogenesis are
based on chronic inﬂammation inducing mutations that lead to
cancer (40, 41). Female mice at 6 MPI had more hyperplasia,
epithelial defects, and dysplasia than infected males and age-
matched controls, but this increase in pathologic ﬁndings was not
accompanied by increased frequency of mutations. This was
detected only in infected female mice at 12 MPI, which had ex-
perienced more severe gastritis for a longer period, suggesting
that gastritis is necessary but not sufﬁcient to induce mutagenesis.
Similarly, duration of infection in itself was insufﬁcient, as mu-
tation frequency was not increased in male mice at 12MPI. Based
on the GHAI, infected male mice had a weaker response at 6MPI
compared with infected females, whereas by 12 MPI, the level of
pathologic process was similar in both sexes. These data suggest
that the delayed onset of severe gastric lesions in males reduced
the duration of their exposure to chronic gastritis, protecting
them from mutagenesis, highlighting the importance of severity
and duration of the inﬂammatory response.
Our ﬁndings agree with current paradigms for the role of in-
ﬂammation in carcinogenesis (4) and with the more severe pa-
thology induced in female versus male C57BL/6 mice infected
with Helicobacter spp. (42). Our observations in female gpt delta
mice are consistent with previously reported data from female
C57BL/6 Big Blue mice infected withH. felis, which induces more
severe gastritis at earlier time points than H. pylori, effectively
increasing the amount of DNA damage inﬂicted after infection
(23, 43, 44). The higher mutation frequency found at 7 MPI in
H. felis-infected female C57BL/6 Big Blue mice may be compa-
rable to that occurring at 12MPI in female gpt delta mice infected
with H. pylori, based on increased inﬂammation and epithelial
proliferation. In contrast, another study of DNA point mutations
induced byH. pylori in male Big Blue mice reported that, although
mutant frequency was increased at 6 MPI, it returned to control
levels by 12 MPI (22). The decrease between 6 and 12 MPI was
accompanied by loss of iNOS expression and reversion of the
mutation spectrum to one indistinguishable from that of un-
infected mice (22). Two possible explanations for these results are
that (i) the increase in mutations at 6 MPI may have reﬂected
jackpot mutations, because clonal expansion was not assessed or
(ii) loss of infection resulted in absence of iNOS expression and
reversion of the mutation spectrum. An additional factor perti-
nent to comparisons of previous mutagenesis studies involving
gastric infection by Helicobacter spp. is the endogenous Heli-
cobacter status of the mouse colony (45). We recently reported
that concurrent, subclinical infection in C57BL/6 mice with non-
gastric Helicobacter bilis signiﬁcantly reduced H. pylori-associated
premalignant gastric lesions at 6 and 11 MPI (46). This immu-
nomodulatory effect could affect observed mutagenic responses,
Table 1. Twelve months of H. pylori infection increases the mutation frequency of A:T-to-G:C transitions and G:C-to-T:A transversions
in female mice
Effect
6 mo 12 mo
Uninfected all
(n = 6)
Infected male
(n = 4)
Infected female
(n = 8)
Uninfected all
(n = 14)
Infected male
(n = 5)
Infected female
(n = 11)
Transition
G:C to A:T 3.02 (2.07) 2.41 (2.64) 2.74 (1.07) 2.13 (0.87) 2.66 (1.70) 2.69 (0.97)
A:T to G:C 0.27 (0.61) 0.00 0.16 (0.22) 0.23 (0.19) 0.08 (0.16) 0.88 (0.59)*
Transversion
G:C to T:A 1.30 (1.34) 1.64 (1.29) 0.89 (0.68) 0.85 (0.62) 1.69 (2.43) 1.75 (0.54)*
G:C to C:G 0.29 (0.66) 0.36 (0.71) 0.40 (0.60) 0.19 (0.27) 0.84 (1.25) 0.09 (0.14)
A:T to T:A 0.34 (0.47) 0.00 0.37 (0.37) 0.31 (0.41) 0.00 0.53 (0.89)
A:T to C:G 0.00 0.36 (0.71) 0.18 (0.22) 0.05 (0.12) 0.00 0.25 (0.46)
Deletion
1-bp deletion 0.84 (0.94) 2.44 (3.99) 0.66 (0.43) 0.53 (0.35) 0.67 (0.54) 0.88 (0.73)
≥2-bp deletion 0.04 (0.12) 0.00 0.44 (0.57) 0.22 (0.20) 0.18 (0.36) 0.22 (0.34)
Insertion 0.00 0.00 0.08 (0.16) 0.20 (0.23) 0.00 0.11 (0.17)
Complex mutation 0.14 (0.31) 0.00 0.04 (0.08) 0.00 0.18 (0.36) 0.12 (0.29)
Total 6.23 (2.98) 7.20 (2.21) 5.95 (1.54) 4.71 (1.13) 6.29 (5.37) 7.51 (1.91)*
Data are mean (SD) of mutation frequency data from 411 mutants recovered from the gpt assay after excluding 155 mutants considered siblings. Control
mice of both sexes were grouped for this analysis. The mutation frequency of A:T-to-G:C transitions and G:C-to-T:A transversions was signiﬁcantly elevated in
female mice infected with H. pylori for 12 mo.
*P < 0.05.
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Fig. 5. Mutant frequency of deletions was unchanged by H. pylori in-
fection. H. pylori infection did not alter the levels of deletions detected by
the Spi− assay in uninfected mice (white bars; 6 MPI, n = 12; 12 MPI, n = 16),
H. pylori-infected males (light gray bars; 6 MPI, n = 3; 12 MPI, n = 5) and H.
pylori-infected females (dark gray bars; 6 MPI, n = 9; 12 MPI, n = 12). Control
mice of both sexes were grouped for this analysis. Data are mean (SEM) of
mutant frequency of mice in different treatment groups.
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and it is unknown whether Big Blue mice used in previous studies
were free of enteric Helicobacter spp.
Our observed sex-based effects on mutagenesis induced by
H. pylori in mice has not been reported previously, but sex bias
has been found in other responses to infection. In H. pylori–
infected Mongolian gerbils, immune responses and cytokine
production were reported to be affected by sex (47), and H. pylori
preferentially induced cancer in male INS-GAS mice (48).
Greater female susceptibility to gastric Helicobacter infections
has been noted previously in WT C57BL/6 mice (42), whereby
females infected with H. felis experience an earlier onset of
gastric inﬂammation, epithelial hyperplasia, atrophy, and apo-
ptosis (42). Mechanisms responsible for the observed sex-based
effects are incompletely understood, but ﬁndings to date col-
lectively indicate that sex is an important variable, affecting
strength of the host response to H. pylori infection, which in turn
determines disease outcome.
The typical host response to Helicobacter infection is a proin-
ﬂammatory Th1 response that causes chronic gastritis (49, 50).
However, mouse strains such as BALB/c, which mount a strong
antiinﬂammatory Th2 humoral immune response to H. pylori
infection, develop less severe disease (51). We have previously
shown that modulation of the Th1 response by an increased Th2
response reduces pathology associated with concurrent helminth
infections (27). In the current study, the immune response of
females toH. pylori infection was biased toward a greater Th1/Th2
ratio compared with males at both 6 and 12 mo. Higher Th1/Th2
ratios reﬂect a stronger inﬂammatory response to H. pylori in-
fection. Furthermore, proinﬂammatory Th17 cells and regulatory
T cells have been recently shown to modulate host responses to
H. pylori (52, 53). H. pylori-speciﬁc Th17 immunity, mediated by
IL-17 (54), increases inﬂammation unless it is suppressed by reg-
ulatory T cells, which are up-regulated by TGF-β and IL-10 (53).
Higher levels of inﬂammation, epithelial defects, and atrophy
were indeed observed in infected females at 6MPI. At 12MPI, the
level of serum IgG2c was signiﬁcantly elevated in infected females,
reﬂective of increased proinﬂammatory cytokines in the gastric
mucosa, and is consistent with the reduction in H. pylori coloni-
zation levels. The earlier onset of severe pathologic process
caused by the Th1- and Th17-biased response toH. pylori was also
associated with the increase in point mutations seen at 12 MPI.
In summary, we have shown that chronic H. pylori infection
can cause premalignant gastric lesions and induce point muta-
tions consistent with inﬂammatory processes. As our data are
derived from analysis of nontranscribed DNA, it serves as an in-
dicator of unbiased mutations reﬂecting genetic changes during
the early stages of tumor initiation in inﬂamed tissues. At 12 mo,
H. pylori-infected female C57BL/6 mice accumulate more
inﬂammation-mediated point mutations compared with males as
a result of a greater Th1-biased response to infection inducing
earlier and more severe pathology. The sex-biased increase in
premalignant gastric lesions and induction of mutations highlights
the importance of taking into account sex-based effects in future
studies of inﬂammation-driven disease.
Materials and Methods
Bacteria and Animals. H. pylori strain SS1 was grown on blood agar or Bru-
cella broth with 5% FBS as described in SI Materials and Methods. Speciﬁc
pathogen-free (including Helicobacter spp.) male and female C57BL/6 gpt
delta mice (24) were infected by oral gavage with H. pylori SS1 or sham-
dosed. At the indicated times, mice were euthanized, gastric tissue collected
for histopathology and DNA and RNA extraction, and sera were collected for
cytokine and Ig analysis. Gastric lesions were scored for inﬂammation, epi-
thelial defects, atrophy, hyperplasia, mucous metaplasia, hyalinosis, intes-
tinal metaplasia, and dysplasia using previously published criteria (55). The
GHAI is the sum of inﬂammation, epithelial defects, atrophy, hyperplasia,
intestinal metaplasia, and dysplasia scores. A detailed description of the
husbandry, treatment, and histopathology is provided in SI Materials
and Methods.
DNA Isolation and in Vitro Packaging. Genomic DNA was extracted from
gastric tissue using RecoverEase DNA Isolation Kit (Stratagene) following the
manufacturer’s recommendations. λ-EG10 phages were packaged in vitro
from genomic DNA using the Transpack Packaging Extract (Stratagene)
following the instructions.
gpt Assay and Sequencing Analysis. The 6-TG selection assaywas performed as
previously described (24, 56). Brieﬂy, phages rescued from murine genomic
DNA were transfected into E. coli YG6020 expressing Cre recombinase.
Infected cells were cultured on plates containing chloramphenicol (Cm) and
6-TG for 3 d until 6-TG–resistant colonies appeared. To conﬁrm the 6-TG–
resistant phenotype, colonies were restreaked on plates containing Cm and
6-TG. Conﬁrmed 6-TG–resistant colonies were cultured, and a 739-bp DNA
product containing thegptgenewas ampliﬁedbyPCR.DNA sequencingof the
gptgenewasperformedby theBiopolymers Facility atHarvardMedical School
(Boston, MA) with AMPure beads (Agencourt) and a 3730xL DNA Analyzer
(Applied Biosystems). Sequences were aligned with the E. coli gpt gene
(GenBank M13422.1) (57) using Geneious (Biomatters). Mutations were clas-
siﬁed as transitions, transversions, deletions, insertions, or complex (multiple
changes).Duplicatemutations at the same sitewithin an individual tissuewere
excluded to account for clonal expansion of sibling mutations. More in-
formation on primers and methods is provided in SI Materials and Methods.
Spi– Assay. The Spi– assay was performed as described in SI Materials and
Methods. Brieﬂy, phages rescued from murine genomic DNA were trans-
fected into E. coli strains with or without P2 lysogen. Infected cells were
cultured overnight on λ-trypticase agar plates to allow plaque formation.
The inactivation of red and gam genes was conﬁrmed by respotting plaques
on another E. coli strain with P2 lysogen (24).
mRNA Expression. RNA was extracted from gastric tissue and reverse-
transcribed to cDNA.Quantitative real-timePCRwasperformedusingTaqMan
Gene Expression Assays (Applied Biosystems). TaqMan primers and analysis
methods are described in SI Materials and Methods.
H. pylori Detection. H. pylori levels in the gastric mucosa were quantiﬁed by
real-time quantitative PCR assay of gastric DNA as described in SI Materials
and Methods. A threshold of 15 copies of the H. pylori genome was set as
the lower limit for a positive sample.
Serum IgG Isotype Measurement. Sera were analyzed for H. pylori-speciﬁc
IgG2c and IgG1 by ELISA. Additional information on the measurements is
provided in SI Materials and Methods.
Statistical Analysis. Two-way ANOVA followed by Bonferroni posttests were
used to analyze GHAI and mRNA expression values. Student two-tailed t tests
were used to analyze mutant and mutation frequency data and serum IgG
isotypes. Poisson distribution analysis was used to determine hotspots at
a 99% conﬁdence level (58). For some analyses, age-matched controls of
both sexes were grouped when no statistical differences were detected
between sexes. Analyses were done with GraphPad Prism, version 4.0, or
Microsoft Excel 2002. P < 0.05 was considered signiﬁcant.
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